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Abstract 
 
Salamanders such as the red spotted newt Notophthalamus viridescens and 
the  axolotl  Ambystoma  mexicanum  regenerate  a  number  of  anatomical 
structures  following  injury.  Prod1  is  believed  to  guide  patterning  processes 
operating during limb regeneration, however the molecular mechanism through 
which it operates is unclear. Being glycosylphosphatidylinositol (GPI) anchored, 
Prod1 does not make direct contact with the cytoplasm, raising questions as to 
how it functions in the transfer of information across the cell membrane.  
The transmembrane epidermal growth factor receptor was shown to associate 
with Prod1, initiating MAPK signalling and resulting in the induction of matrix 
metalloprotease  9  expression  (MMP9).  MMP9  is  known  to  be  rapidly 
upregulated  in  the  hours  following  amputation  in  the  wound  epithelium,  a 
structure essential for regeneration formed by the migration of epidermal cells 
across the surface of the amputation plane. Patches of newt limb skin explanted 
into culture were used as a model for this process. A sheet of cells expressing 
MMP9 was seen to migrate out from skin patches, and this was shown to be 
sensitive to MMP inhibitors. Further to this, upregulation of MMP9 was seen to 
occur in the dermis of explanted skin patches, a layer of the skin known to be 
instructive to the patterning of the limb. 
The  relationship  of  Prod1s  structure  to  its  MMP9  inducing  function  was 
investigated through the creation of a series of point mutants, and it was shown 
that amino acids located on the α-helix of the protein were essential for this 
function. Axolotl Prod1 lacks a GPI anchor, however despite the requirement of 
newt Prod1 for GPI anchorage in order to induce MMP9 expression in either 
newt  or  axolotl  cells,  axolotl  Prod1  was  fully  functional  in  cells  from  either 
species. There was some indication that amino acids on the α-helix may confer 
this ability to axolotl Prod1.  
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as a member of his research group, for being generous with resources and allowing me to find 
my own way at the bench, and for all of his support and guidance. For these things I shall 
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1.1  Regeneration: A process fundamental to life? 
 
Defined  by  the  Oxford  Dictionary  as  regrowth,  regeneration  operates  on  all 
known levels studied in biology, and is arguably central to the essence of life 
itself.  Scientific  investigation  in  the  21
st  century  has  been  facilitated  by  a 
technological explosion providing opportunities for the study of the nature of all 
things at levels previously unimaginable, practically or conceptually. When put 
in the context of our growing understanding of the truly staggering enormity of 
the  universe,  the  number  of  possible  worlds  on  which  life  could  evolve 
according to the principles formulated by Darwin are so many that it is arguably 
harder  to  accept  that  its  occurrence  be  unique  to  earth  than  that  all  the 
examples we observe have come about as a result of pure chance. Advances 
allowing  the  imaging  of  biological  molecules,  and  the  biochemistry  that  has 
developed alongside has pushed the scope of biology to a level of resolution 
whereby  life  of  all  kinds  can  be  described  at  the  fundamental  level  without 
reference to logic other than that formulated in physics and chemistry. Enquiry 
into topics as diverse as the cause of disease or the manifestation of mind can 
now  be  addressed  in  the  context  of  the  now  seemingly  unquestionable 
established principles describing the mechanics of the operation of the cell, the 
basic unit of any free-living organism. It is at this level, the level of information 
storage by DNA, and the transfer of this information by the cell into the diversity 
of proteins determining the higher order biological processes of an organism 
through their physical and chemical properties, that regeneration can be seen to 
be central to life. Even in the absence of growth and division, a cell requires that 
it  should  be  able  to  replace  proteins  no  longer  fit  for  purpose,  due  to  the 
damage  inevitably  sustained  in  any  environment  capable  of  supporting  the 
chemical  reactions  required  for  life.  In  order  to  accurately  replace  damaged 
proteins, the cell must equally maintain the fidelity of its blueprint. Without such 
mechanisms, any form of life would not exist for long. Even with the ability to 
regenerate damaged proteins and DNA, a cell will eventually die. Although the 
specifics of the basis of cellular mortality are widely debated, limited life-span is 
clearly observed to be a characteristic of all known cells, and it is not hard to 
accept  that  eventually  the  systems  repairing  damage  themselves  become  
  3 
irreparable.  Life  has  found a  strategy  for  overcoming  the  inevitable  eventual 
failure of cellular processes in the form of reproduction. The distribution of a 
DNA blueprint able to support life into independent cells, and mechanisms to 
pass  this  blueprint  on  before  repair  mechanisms  become  overwhelmed, 
ensures  the  potential  for  continued  existence  of  a  life  form,  even  if  each 
individual will eventually cease to be. In order for a life-form to have a chance of 
indefinite existence it must be able to maintain the integrity of the DNA blueprint 
and  all  cellular  processes  associated  with  reproduction  for  long  enough  to 
reproduce the next generation, placing the ability to generate anew essential 
damaged cellular components, even if for only a limited period, at the heart of 
our current conception of what it is to be alive.  
 
1.2  A study of regeneration across phyla 
 
1.2.1  Regenerative capability and reproduction  
This broad definition of regeneration may be better referred to as cellular-repair 
than  regeneration,  however  in  their  essence  the  processes  are 
indistinguishable.  The  field  of  regeneration  research  concerns  itself  with  the 
mechanisms acting to replace tissues lost by an organism, however at this level 
it is still difficult to make clear definitions of what constitutes regeneration. In the 
case  of  some  organisms  capable  of  asexual  reproduction,  detachment  of  a 
section or sections of tissue from the main body results in the generation of new 
organisms.  For  example,  strains  of  planarians,  species  of  the  phylum 
Platyhelminthes (flatworms), are able to detach sections of their body in order to 
reproduce  asexually  whilst  others  reproduce  sexually  (Kobayashi and  Hoshi, 
2002) (Fig.1.1A). Hydra (Fig.1.1 B), species of the phylum Cnidaria studied for 
their  regenerative  abilities,  reproduce  asexually  by  budding,  however  strains 
exist  which  can  reproduce  sexually  (Galliot  and  Schmid,  2002).  These 
organisms posses a pool of stem cells which are constantly proliferating and 
differentiating to replace lost cells, and when cut into two pieces (or more in the 
case of planarians), both planarians and hydra, be they of sexual or asexually 
reproducing strains, regenerate the structures missing from each piece (Galliot 
et al., 2006) (Reddien and Sanchez Alvarado, 2004). The precursor cells for 
this  process  are  located  in  the  body  column  in  hydra  and are  composed  of  
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interstitial  cells,  endodermal  and  ectodermal  epithelial  cells,  each  of  which 
regenerates specific cell lineages (Galliot et al., 2006), whereas the stem cells 
of planaria, the evenly distributed neo-blasts, are considered to be totipotent 
(Reddien and Sanchez Alvarado, 2004). Asexually reproducing planarians can 
be induced to develop sexual characteristics and mate (Kobayashi and Hoshi, 
2002), and the interstitial cells found in hydra produce gametes in the sexually 
reproducing  strain  (Galliot  et  al.,  2006).  That  the  asexual  strains  of  these 
species have the underlying potential to reproduce sexually implies that they 
have  undergone  a  mutation  event  whereby  sexual  reproduction  was  lost  at 
some point in the history of their evolution. Podocoryne, another regenerating 
species  of  Cnidaria,  reproduces  sexually.  The  larvae  metamorphose  into  a 
polyp, similar to hydra, however instead of budding off polyps as in the case of 
hydra,  it  instead  forms  buds  that  differentiate  into  the  sexually  reproducing 
medusa stage of the life cycle. This process of medusa formation requires that 
the polyp cells forming the bud de-differentiate, as the cell types and tissues of 
the medusa are distinct from those of the polyp (Galliot and Schmid, 2002).  
 
We see then from these examples that i) asexually reproducing species such as 
planarians and hydra capable of budding to produce progeny are also highly 
regenerative  ii)  these  regenerative  capabilities  are  also  seen  in  the  sexually 
reproducing strains of these species iii) as sexual reproduction is ancestral, the 
ability  to  reproduce  asexually  may  have  evolved  as  a  consequence  of  an 
acquisition  of  regenerative  ability  iv)  the  process  of  budding  in  Podocoryne 
involves  the  loss  off  differentiated  characteristics  by  cells  followed  by  re-
differentiation whereas in planarians and hydra it does not. 
 
Teleost  fish  such  as  the  zebrafish  Danio  rerio  are  also  studied  for  their 
regenerative abilities. Similar to the planarians and hydra, the tails of teleosts 
grow  continually  over  the  life  of  the  fish,  and  when  amputated  rapidly 
regenerate all the missing structures (Akimenko et al., 2003). Unlike planarians 
and hydra however, a teleost will not regenerate from both pieces when cut in 
half.  This  example  is  put  forward  to  illustrate  that  even  in  species  with  the 
underlying  mechanisms  required  for  regeneration,  regenerative  potential  is 
limited by other factors. In the case of teleost fish, the animal would die from  
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blood-loss long before it stood a chance of initiating the substantial regenerative 
response that would be required to replace all of the structures lost. Even if one 
half of a fish containing both the brain and the heart were able to stay alive, the 
complexity  of  the  anatomy  of  fish  compared  to  flatworms  would  require  the 
replacement of a significantly greater number of tissues, and consequently a 
source of a far greater diversity of cell types in order to completely regenerate. 
The most complex anatomical structure known to regenerate in any animal is 
the limb of urodele amphibians (Fig.1.1C) (Brockes, 1997). Limb regeneration 
requires  the  replacement  of  bone,  cartilage,  muscle,  connective  tissue, 
vasculature,  nerves  and  skin.  Unlike  previously  mentioned  species  however, 
adult urodeles are not continually growing and do not have a large pool of stem 
cells.  
 
Figure 1.1 Regenerative model organisms 
(A)  The  planarians  are  species  of  the  phylum  Platyhelminthes.  Schmidtea 
mediterranea are a commonly studied species and it has been claimed that they can 
regenerate anew from a fragment 1/279
th the size of their body. Picture courtesy of 
A.Aboobaker. (B) The hydra are species of the phylum Cnidaria with a defined body 
axis  and  will  regenerate  from  both  halves  following  bisection.  Hydra  reproduce  by 
asexual budding; A bud is forming in this example. Picture adapted from (Bosch, 2009) 
with  permission  (C)  The  red  spotted  newt  Notophthalmus  viridescens  is  a  urodele 
amphibian of the family salamandridae. N. viridescens and other salamanders are the 
most regenerative adult vertebrates. Picture courtesy of J.Godwin.    
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In  mammals,  regeneration  also  occurs,  albeit  to  a  lesser  extent  than  in  the 
species previously discussed. Precursor cells of limited developmental potential 
are found in the tissues of the body, and are able to regenerate skin (Jones et 
al., 1995), intestinal epithelium (Potten et al., 1997), blood cells (Broxmeyer and 
Williams,  1988),  immune  cells  (McCune  et  al.,  1988),  bone  (Caplan,  1991), 
muscle (Yablonka-Reuveni et al., 1987), liver (Michalopoulos and DeFrances, 
1997) and nerve (Gage, 2000) (Stocum, 2001). These cells are able to replace 
cells  lost  due  to  turnover  associated  with  the  cells  function,  for  example 
repairing damage to skin or gut epithelia which are exposed to environments in 
which some degree of damage is inevitable, or the replacement of muscle cells 
damaged by over exertion, however the extent of regeneration of these tissues 
is limited when compared to the ability of the urodele limb to regenerate. For the 
sake of clarity, the replacement of cell types from existing precursor cells as it 
occurs in mammals may be better termed tissue repair when comparing it with 
the process of regeneration as occurs in the urodele, however as discussed 
shortly,  there  may  be  no  basis  for  drawing  such  a  distinction.  The  most 
regenerative tissue in mammals is the liver, which is able to regenerate through 
a  process  involving  both  the  proliferation  of  differentiated  liver  cells 
(compensatory  hyperplasia)  (Michalopoulos  and  DeFrances,  1997)  and  the 
mobilisation of resident precursor cells (Alison et al., 1996). Here a distinction 
can be drawn which underlies the difference in the regenerative capabilities of 
urodeles compared to mammals. Although urodeles (Morrison et al., 2006) and 
mammals are similar in that both have limited populations of adult precursor 
cells able to proliferate and produce new cells when required and are not in a 
continual state of growth like planarians and hydra of which a high proportion of 
the total cells of the body are proliferative, unlike mammals, urodeles are able 
to  mobilise  many  of  their  existing  differentiated  cell  types  to  become 
proliferating stem cells by a process of de-differentiation (Brockes and Kumar, 
2002)  (discussed  in  greater  detail  below).  The  closest  process  to  de-
differentiation  occuring  in mammals  is  arguably  the  loss  and  subsequent  re-
expression of myelin by Schwann cells as they divide during axon regeneration 
(Harrisingh et al., 2004).  
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1.2.2  Categorising mechanisms of regeneration 
Regeneration  of  missing  structures  can  occur  by  seemingly  distinct 
mechanisms. When hydra are cut into two pieces, regeneration is preceded by 
a  halt  in  the  proliferation  of  its  usually  actively  dividing  population  of  cells 
(Holstein et al., 1991) and results from the re-organisation and differentiation of 
existing precursor cells to produce two regenerates half the size of the original 
(Galliot  and  Schmid,  2002),  a  process  termed  morphallaxis  by  T.H.Morgan 
(Morgan, 1901). During urodele limb regeneration, the stump remains largely 
unchanged  and  a  structure  termed  the  blastema  forms  (discussed  in  more 
detail below) and grows by the proliferation of undifferentiated cells, eventually 
producing  sufficient  new  tissue  to  differentiate  and  replace  the  missing 
structures  (Stocum,  2004),  a  process  termed  epimorphosis  by  T.H.Morgan 
(Morgan, 1901).  
 
Comparisons  between  the  different  regenerative  response  can  therefore  be 
made  on  the  basis  of  i)  whether  proliferation  of  cells  mobilised  from  the 
remaining  stump  tissue  regenerate  the  missing  structures  (epimorphosis)  or 
whether  the  remaining  stump  tissue  becomes  respecified  to  regenerate  the 
missing structures in the absence of proliferation (morphallaxis) ii) whether de-
differentiation  occurs  to  generate  proliferative  precursor  cells,  as  in  the 
formation of the urodele limb blastema (Brockes and Kumar, 2002), Schwann 
cell  de-differentiation  during  axon  regeneration  (Harrisingh  et  al.,  2004)  or 
Podocoryne medusa budding (Galliot and Schmid, 2002), or whether precursor 
cells exist prior to the regenerative response as seen in urodeles (Morrison et 
al.,  2006),  mammals  (Stocum,  2001),  planarians  (Reddien  and  Sanchez 
Alvarado, 2004) or Cnidaria (Galliot et al., 2006). When planaria are cut into 
many pieces, the process of regeneration involves the extensive remodelling of 
the body-plan and also the formation of a blastema. Neoblasts are observed 
immediately to change their differentiation characteristics without dividing, and 
division  of  cells  in  the  blastema  is  also  not  observed  (Agata  et  al.,  2007) 
indicating  morphallaxis  as  a  more  appropriate  classification  of  planarian 
regeneration. Agata et al argue however that as the differentiated tissues of the 
stump  remain  differentiated  long  after  the  blastema  has  formed,  that  the 
process  of  regeneration  is  also  arguably  epimorphic  and  that  these  terms  
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should  therefore  be  abandoned.  They  view  the  blastema  instead  as  an 
organising centre rather than being the source of the regenerating tissue. This 
is a clear example of how analysis of biology at a molecular level, rather than at 
the  gross  level  permitted  at  the  time  that  many  classical  experiments  were 
carried out, can change the way a problem is viewed.  
 
1.2.3  The evolutionary relationship between regenerating species 
Thus  far  we  have  looked at  regeneration  both  in  terms of  its relationship  to 
reproduction,  which  as  argued  at  the  beginning  of  this  essay  is  of  central 
importance when considering the concept of regeneration from an evolutionary 
perspective, and in terms of the origin of the tissue comprising the regenerate. 
Such categorisation of the regenerative attributes of species in an attempt to 
rationalise  the  evolutionary  relationships  of  the  regenerative  responses  does 
not make things much clearer however, as we see from the inability to precisely 
categorise the planarian regenerative response as morphallactic or epimorphic 
whereas for urodeles and hydra it seems clear, or that planarians and hydra 
group  with  mammals  in  that  regeneration  results  from  pre-existing  precursor 
cells, and may in fact be seen as tissue repair rather than ‘regeneration’, whilst 
at the same time being so different in terms of their reproductive cycle. Similarly 
cnidarians,  planarians  and  teleosts  all  exhibit  continual  growth,  however 
teleosts do not posses the ability to reproduce asexually.  
 
It  is  a  long-standing  question  whether  all  metazoans  shared  a  common 
ancestor with the ability to regenerate, which was subsequently lost in some 
species and maintained and elaborated upon in others, or whether the ability to 
regenerate  has  arisen  through  convergent  evolution  in  different  species.  In 
support  of  the  idea  that  at  least  some  regenerating  species  share  a 
regenerating common ancestor is the wide distribution of regeneration across 
phyla  (Sanchez  Alvarado,  2000),  making  it  unlikely  that  the  ability  arose 
independently in all of these cases. An alternative view is that regeneration is 
instead  a  by-product  of  the  processes  maintaining  the  integrity  of  a  given 
structure of an organism. The nematodes are an example of metazoans that 
are  unable  to  carry  out  tissue  repair  or  regeneration.  Nematodes  reproduce 
sexually  and  exhibit  cell  constancy  (Hughes,  1989),  that  is  to  say,  once  
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development has occurred, the number of somatic cells is fixed and cells do not 
turn  over,  consistent  with  the  possibility  that  regeneration,  rather  than  being 
ancestral to all metazoans, is instead a function which has emerged from tissue 
repair mechanisms, which themselves are not present in all phyla (Brockes and 
Kumar,  2008).  Whether  ‘regeneration’  should  really  be  seen as  distinct  from 
tissue repair is debatable as mentioned previously. 
 
If we accept that there is a spectrum of regenerative capabilities ranging from 
that seen in nematodes, to mammals, to urodeles, to hydra to planarians on the 
basis of how much ‘stump’ tissue is required to permit regeneration then we see 
there  is  a  broad  correlation  with  the  degree  of  cell  renewal  (tissue  repair) 
occurring. The underlying mechanisms facilitating tissue repair may represent 
the  evolutionary  relationship  between  regenerating  metazoans  and  help  to 
explain  its  widespread  distribution,  whilst  allowing  for  the  possibility  that  the 
specifics  and  degrees  of  the  different  regenerative  processes  evolved 
independently in different species. Although de-differentiation is not unique to 
urodeles, as exemplified by budding of Podocoryne medusa or Schwann cell 
proliferation,  it  underlies  their  ability  to  regenerate  extensively.  As  discussed 
previously with the teleosts as an example, other features of an animal may 
antagonise  its  regenerative  abilities.  As  the  limb  of  a  urodele  is  highly 
specialised in terms of its structure and contains largely differentiated cell types, 
it can be argued that it requires a different mechanism to regenerate missing 
structures  compared  to,  for  example,  hydra,  as  it  is  unable  to  undergo 
morphallaxis,  whilst  basing  the  process  on  underlying  cellular  mechanisms 
facilitating tissue regeneration. The fact that closely related species exist with 
markedly  different  regenerative  abilities  indicates  that  once  acquired,  the 
mechanisms for regeneration may have subsequently been lost in a number of 
examples (Brockes and Kumar, 2008).  
 
The  widespread  ability  to  regenerate  at  some  level  throughout  metazoans 
opens up the possibility that it may be possible to in some way augment or 
manipulate  existing  biological  systems  in  humans  in  order  to  bring  about 
enhanced  regeneration. The  lifespan  of  hydra  (Bosch,  2009)  and  planarians 
(Newmark and Sanchez Alvarado, 2002) have been argued to be effectively  
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limitless  due  to  their  ability  to  continually  turnover  the  cells  of  their  body. 
Theoretically, regeneration research may then, for better or for worse, produce 
methods  to  drastically  increase  the  life-span  of  human  beings,  or  at  the 
extreme, even put an end to human mortality. It has to be questioned why the 
majority of animals have limited life spans however. It has been suggested that 
evolutionarily, limiting the potential of adult cells to divide may act as a balance 
against cancer (Sharpless and DePinho, 2005), which is perhaps too complex a 
phenomenon to be manifested or cause problems in lower metazoans such as 
platyhelminthes or cnidarians.  
 
1.3  Applying  principles  of  regeneration  in  wider  biological 
contexts  
 
Despite  their  ability  to  de-differentiate  somatic  cells  to  produce  proliferative 
precursor  cells,  the  incidence  of  cancer  in  urodeles  is  low  compared  to 
mammals (Brockes, 1998). The re-entry into the cell cycle of newt myotubes in 
response to serum has been shown to involve the inactivation of the tumour 
suppressor protein Rb, and this can be inhibited by mammalian p16 (Tanaka et 
al., 1997), a cyclin D CDK4 inhibitor (Serrano et al., 1993). Mouse myotubes do 
not re-enter the cell cycle in response to serum unless they lack Rb (Schneider 
et al., 1994), indicating a distinct difference between the ability of newts and 
mice  to  regulate  the  withdrawal  of  cells  from  the  cell  cycle.  The  study  of 
regeneration may therefore shed light on the fundamental processes of the cell 
cycle and their relationship to cancer. The study of regenerative processes in 
model  organisms  may  also  prove  complementary  to  the  field  of  embryonic 
stem-cell (ES cell) research. As argued earlier, links between regeneration and 
reproduction  are  evident,  and  it  is  hoped  that  totipotent  cells  from  the  early 
embryo will prove a useful source of biological material for use in regenerative 
therapies. A number of issues overhang this field of research, both practical and 
ethical in nature. Due to their undifferentiated state, ES cells are capable of 
becoming cancerous when implanted into tissue (Evans and Kaufman, 1981) 
and  therefore  require  accurate  differentiation  prior  to  implantation.  Although 
many  cell-types  have  been  differentiated  in  culture  as  proof-of-principle,  the 
technology  is  still  held  back  by  an  inability  to  produce  absolutely  pure  
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populations (Keller, 2005). The source of ES cells for therapy poses possibly 
the greatest problem for both technical and practical reasons. Firstly, as ES 
cells are derived from an embryo, for them to be widely available for therapeutic 
purposes would require a large, reliable source of human embryos. Whether 
embryo donation on this scale is practical or ethical is debatable. As ES cells 
are  from a  donor and  not  the  patient,  they are  not  genetically  matched and 
therefore  subject  to  immune-rejection.  This  can  in  theory  be  overcome  by 
replacing the nucleus of a donor embryo with one from a patient (Wilmut et al., 
1997). Whether society is prepared to open the door to therapeutic reproductive 
cloning is another matter however.  
 
Whether implanted stem cells will integrate properly into the tissue of a patient 
is likely to depend on a number of factors. Firstly, the extent of differentiation, or 
specific  type  of  the  implanted  cells,  and  secondly,  whether  the  appropriate 
signals exist to appropriately pattern cells in the location of implantation. It is 
these  purely  practical  points  which  may  be  overcome  through  applying 
knowledge of the processes occurring during regeneration in model organisms 
and during normal development to the field of ES cell therapy. 
 
Ideally, ES cells would not be used at all due to the variety of ethical issues they 
pose. Knowledge of the processes occurring in highly regenerative organisms 
may in theory lead to a means of either making use of the resident populations 
of stem cells present in adults, or of manipulating post-mitotic adult cells to de-
differentiate  and  proliferate.  Clearly,  such  interventions  will  still  require  the 
correct cues to produce appropriately patterned regenerated tissue, however 
carrying out these processes in situ may allow the native environment to be 
made use of and reduce the requirement for cues to be provided by external 
sources.  The  urodele  limb  is  an  ideal  model  within  which  to  study  both  the 
processes of de-differentiation and patterning (Brockes and Kumar, 2005), and 
represents the focus of the research conducted in this thesis. 
 
The ability to regenerate limbs varies across a spectrum. Adult urodeles are 
able  to  regenerate  whole  limbs  (Brockes,  1997),  as  are  metamorphosing 
anurans (Stocum, 2004), whilst fetuses of mammals such as humans are able  
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to  regenerate  only  the  tips  of  digits  (Allan  et  al.,  2006).  In  this  sense,  limb 
regeneration in urodeles is distinct from that in anurans and mammals, as in 
urodeles,  differentiated  adult  cells  contribute  to  the  regeneration  by  de-
differentiating  and  proliferating  (Brockes,  1997),  whereas  in  anurans  (Dent, 
1962) and mammals (Allan et al., 2006), it is only whilst cells still exhibit some 
of  the  plasticity  associated  with  the  embryonic  state  that  regeneration  is 
possible. As the nature of the plasticity of de-differentiated newt cells is unlikely 
to be fundamentally different to that observed of embryonic cells, and indeed it 
has been demonstrated earlier that de-differentiation is not unique to urodeles, 
it raises the possibility, at least theoretically, that adult mammalian cells might 
be manipulated to loose some of their differentiated characteristics and then 
drive  regeneration  under  the  guidance  of  the  normal  processes  governing 
development (discussed in detail below). It must be considered however that 
the  length  of  time  it  takes  for  an  adult  human  to  grow  a  fully  sized  limb  is 
significantly longer than that taken by urodeles, making it unlikely to be realistic 
practically, if not in principle, for a human to regenerate an entire limb. Even if 
the regeneration of an entire adult human limb is unrealistic however, there is 
likely much to learn from this fascinating ability of the urodele which may guide 
future therapeutic interventions. 
 
1.4  The process of urodele limb regeneration 
 
The molecular processes governing urodele limb regeneration are beginning to 
be understood, adding much needed detail to the models formulated from the 
observations of classical experiments. Limb regeneration can be considered to 
occur  in  three  distinct  phases  (Endo  et  al.,  2004)  each  of  which  shall  be 
described in detail: 
 
i)  Wound closure and formation of the apical epidermal cap (AEC) 
ii)  Formation of blastema cells 
iii)  Limb growth and morphogenesis 
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1.4.1  Wound healing 
Wound healing in urodeles is distinct from the process occurring in mammals in 
that it is not accompanied by scarring (Roy and Levesque, 2006). In mammals, 
wounding is rapidly accompanied by the formation of a fibrin clot, resulting from 
the release of blood plasma coagulation factors from the vasculature and their 
contact with tissue factor expressed on the surface of stromal cells (Daubie et 
al., 2007). Once this clot is formed, granulation tissue fills in the wound, and 
epidermal epithelial cells migrate through the fibrin clot and over the surface of 
the wound to repair the skin (Singer and Clark, 1999). During these processes, 
fibroblasts  are  continually  depositing  collagen  (Clark  et  al.,  1995)  into  the 
wound site, and as healing progresses, fibres of collagen form (Welch et al., 
1990), giving the repaired tissue tensile strength and contributing to the lasting 
scar  tissue  (Bailey  et  al.,  1975).  The  re-establishment  of  new  and  the  re-
modelling of old extracellular matrix occurring during wound healing requires 
the activity of a variety of matrix metalloproteases (MMPs) (discussed in greater 
detail  below),  which  proteolyse  ECM  proteins  and  allow  the  migration  of 
invading cells into tissue (Bullard et al., 1999) (Pilcher et al., 1997). Collagen 
synthesised by fibroblasts and deposited into the wound can also be degraded 
by MMPs (Pilcher et al., 1997), providing a mechanism by which to regulate the 
level of collagen present in the wound as it heals.  
 
Skin healing in urodeles on the other hand is not accompanied by the formation 
of  a  significant  fibrin  clot,  with  wounds  instead  being  closed  by  the  rapid 
migration of epidermal keratinocytes across their surface. These migrating cells 
do  not  divide  and  have  been  shown to  rapidly  upregulate  the  expression of 
matrix metalloprotease-9 (MMP9) (Satoh et al., 2008). Like mammalian wound 
healing, collagen fibres form beneath the epidermis, however remodelling of the 
matrix restores the original structure of the skin without leaving a scar (Endo et 
al., 2004). When MMPs are inhibited however, a scar-like structure can be seen 
to result which correlates with a complete inhibition of regeneration (Vinarsky et 
al., 2005). MMPs cleave fibrin, fibrinogen and other factors involved in blood 
clot formation as well as matrix proteins (Sternlicht and Werb, 2001), thus the 
regulation  of  MMPs  in  urodeles  may  be  a  factor  in  the  differences  in  clot 
formation and subsequent scarring seen between them and mammals, and this  
  14 
difference  may  in  turn  contribute  to  the  ability  of  urodeles  to  establish  an 
environment able to support the accurate regeneration of tissue by avoiding the 
formation of an inhibitory scar. 
 
That mammals require the formation of a fibrin clot to precede wound healing 
whilst urodeles do not must reflect some difference in the selection they have 
undergone during evolution. The human clotting cascade leading to fibrin clot 
formation is tightly regulated and highly complex. When compared to turtles, 
species which diverged from mammals far back in evolutionary time, a higher 
degree of complexity is observed in the mammalian clotting cascade (Soslau et 
al., 2004), indicating that it has been highly developed by evolution and is of 
significant  importance.  One  possible  explanation  for  the  difference  in 
requirement between humans and urodeles is that urodeles are able to rapidly 
constrict blood vessels to prevent large-scale blood loss (Schmidt, 1968). 
 
1.4.2  The apical epidermal cap 
Amputation of the urodele limb results in the same processes occurring during 
wound  healing,  with  a  sheet  of  MMP9  expressing  epithelial  cells  rapidly 
migrating across the surface of the stump (Satoh et al., 2008). The single layer 
of epithelium covering the wound, known as the wound epidermis, begins to 
thicken by proliferation and forms a structure termed the apical epidermal cap 
(AEC) (Fig.1.2 A) (Christensen and Tassava, 2000). It is beneath this AEC that 
the structure of the blastema (Fig.1.2B) will form. Figures 1.2C and 1.2D show 
the stages of regeneration from amputation, through blastema formation, to full 
digit stage regeneration.  
 
Few molecular markers exist for the AEC, however it is observed that MMP9 
expression persists for 72hrs in epidermal cells fated to form the AEC, whereas 
in skin wounds that will not form blastemas, MMP9 expression is downregulated 
within 24hrs (Satoh et al., 2008). The expression of the transcription factor Sp9, 
a molecule known to be expressed in the apical ectodermal ridge (AER) of the 
developing limb bud involved in limb outgrowth in developing chick, mouse and 
zebrafish  embryos  (Kawakami  et  al.,  2004)  is  also  expressed  by  the  AEC 
(Satoh et al., 2008), indicating some similarity between these structures. Sp9  
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expression is upregulated in the keratinocytes of the AEC by exogenous FGF7/ 
keratinocyte growth factor (KGF) (Satoh et al., 2008). Exogenous KGF has also 
been shown to induce AER formation in chick limb buds (Yonei-Tamura et al., 
1999), further indicating similarity between these structures. Likewise, ectopic 
FGF2  induces  expression  of  the  transcription  factor  Dlx3  in  the  AEC  of 
denervated limbs (Mullen et al., 1996). Dlx genes are homologs of drosophila 
distal-less which are expressed in the AER and regulated by fibroblast growth 
factors  (FGF)  during  limb  development  and  known  to  be  involved  in  the 
outgrowth  of  the  limb  (Pueyo  and  Couso,  2005),  indicating  further  similarity 
between the role of FGFs during development and limb regeneration, and the 
AER and the AEC.  
 
The  early  processes  occurring  to  establish the  AEC  and  the  blastema  have 
been investigated using the ‘accessory limb model’ in which a blastema can be 
initiated  at  a  wound  that  would  usually  regenerate  only  skin  by  deflecting  a 
nerve  to  the  vicinity  (Endo  et  al.,  2004).  A  threshold  level  of  innervation  is 
required  in  order  for  a  blastema to  develop  at  an  amputation  plane  (Singer, 
1952), and as mentioned previously, it has been shown by the accessory limb 
model that the collagen matrix that accumulates below a skin wound does not 
form in the presence of a deflected nerve, the indication of this being that an 
early distinction between blastema formation initiated by the nerve and wound 
healing is the arrangement of the ECM beneath the AEC.  
The AEC has been shown to be essential for the growth of the blastema, as 
when  its  formation  is  prevented  either  by  grafting  a  piece  of  skin  over  the 
amputation  plane  or  inserting  a  freshly  amputated  limb  into  the  body  cavity 
regeneration does not occur (Mescher, 1976) (Goss, 1956a). Removal of the 
AEC at different times during the regeneration process and inserting the limb 
into the body cavity results in truncation of the limb along the proximodistal (PD) 
axis (Goss, 1956b), demonstrating it plays a role in the maintenance of limb 
outgrowth. Denervation after the blastema has begun to grow leads to a halt in 
the proliferation of blastema cells (Maden, 1979). The cells of the blastema are 
able  to  undergo  differentiation  following  denervation,  resulting  in  a  miniature 
limb  being  regenerated  from  the  undersize  blastema  (Singer  and  Craven, 
1948).   
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1.4.3  The origin of blastema cells 
Up until this point the blastema structure has not been considered in greater 
detail than a mound of proliferating cells from which the limb regenerates, which 
requires signals from the nerve and the AEC in order to grow. The origin of 
blastema cells has previously been cited as resulting from the de-differentiation 
of stump cells and this shall be discussed now in greater detail. One question is 
whether the adult stem cells present in the limb also contribute to the blastema 
along with de-differentiated cells. Another important question is whether, once 
de-differentiated, blastema cells are restricted in their potency, or whether they 
can  transdifferentiate  into  cell  types  other  than  those  form  which  they 
originated.  
 
A  study  tracing  the  fate  of  muscle  cells  by  green  fluorescent  protein  (GFP) 
genetic labelling indicated that like muscle, cartilage is also restricted to only 
produce cartilage in the regenerate and that nerve associated Schwann cells 
produce  only  Schwann  cells  (Kragl  et  al.,  2009).  This  highlights  a  general 
principle that blastema cells are not homogenous, and are instead composed of 
a range of cell types, each with restricted potential. It had been demonstrated 
previously that blastema cells are not uniform in their characteristics through the 
identification of a subpopulation of blastema cells derived from Schwann cells 
that express the blastemal marker 22/18 (Kintner and Brockes, 1985), but what 
is now clearer is that different populations of cells have distinct potentials.  
 
Interestingly, cells derived from the dermis (likely to be fibroblasts) are observed 
to  have  wider  potential  to  contribute  to  different  tissues (Kragl  et  al., 2009). 
Following the onset of blastema formation, cells from the dermis are observed 
to  migrate  into  the  blastema  and  become widely  distributed  throughout  it  as 
regeneration proceeds (Gardiner et al., 1986). These cells have been shown to 
regenerate cartilage, connective tissue and tendons. Cells of dermal origin are 
observed within muscle tissue, however they do not contribute to muscle fibres 
or satellite cells (Kragl et al., 2009), indicating that although they become widely 
dispersed throughout the growing blastema, their potential is still limited. To this 
point therefore, no individual totipotent blastema cell type has been identified. 
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Figure 1.2 Urodele limb regeneration 
(A)  Morphology  of  the  apical  epithelial  cap,  AEC  in  relation  to  the  blastema 
mesenchyme, M.  Following  migration of the single layer  of cells forming the  wound 
epithelium,  the  AEC  forms  by  proliferation  of  epithelial  cells.  Image  courtesy  of 
A.Kumar. (B) Limb blastema from N.viridescens. The amputation plane is marked with 
arrows.  Image  from  (Brockes  and  Kumar,  2005).  (C)  The  stages  of  urodele  limb 
regeneration. From (Iten and Bryant, 1973) with permission (D) Regeneration of the 
forelimb of N. viridescens. Distal amputation is shown on the left, proximal on the right. 
Original limbs are shown at the top. Photographs were taken at 7,21,25,28,32,42 and 
70  days  post  amputation.  Note  that  only  structures  distal  to  the  amputation  plane 
regenerate  and  the  similar  length  of  time  required  to  reach  digit  stage  following 
proximal and distal amputation (Goss, 1969).  
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1.4.3.1  Extra-cellular matrix re-modelling and matrix metalloproteases  
MMPs  have  been  mentioned  as  being  involved  in  the  initial  wound  healing 
event of regeneration for their role in permitting cell migration through tissue 
(Bullard et al., 1999) (Pilcher et al., 1997), and MMP9 expression in the cells of 
the  wound  epidermis  is  correlated  with  whether  the  AEC  structure  will  form 
(Satoh et al., 2008). Furthermore, the expression of a number of MMPs is seen 
to be regulated in the mesenchymal cells of the blastema during regeneration 
(Vinarsky et al., 2005). 
 
1.4.3.1.1 Regulation of MMP activity 
Numerous MMPs exist in different species with a range of substrate specificities 
and  they  have  been  shown  to  be  involved  with  a  wide  variety  of  biological 
processes  (Page-McCaw  et  al.,  2007)  (Sternlicht  and  Werb,  2001).  The 
enzymes are synthesised as pro-MMP zymogens (Harper et al., 1971). MMP8 
and MMP9 secretion from neutrophils has been shown to be regulated by their 
release from intracellular granules (Hasty et al., 1990), whereas other MMPs 
are  secreted  in  an  unregulated  way  following  translation.  The  secreted  pro-
enzyme  is  subsequently  activated  by  enzymatic  cleavage,  either  by  other 
MMPs (Kerkela and Saarialho-Kere, 2003), or in the case of some MMPs, by 
other serine proteases associated with wounding such as plasmin (Carmeliet et 
al., 1997) and thrombin (Lafleur et al., 2001), which has itself been implicated in 
the process of de-differentiation preceding regeneration (Tanaka et al., 1999). 
The serine protease elastase is also able to activate MMP9 (Ferry et al., 1997) 
and is seen to be upregulated in the blastema in a similar temporal pattern to 
MMP9 (Vascotto et al., 2006).  
 
MMPs  can  themselves  be  freely  diffusing,  membrane  associated  by  GPI 
anchorage or via a C-terminal transmembrane domain (Sternlicht and Werb, 
2001). Freely diffusing MMPs can also become membrane localised through 
the  interaction  with  specific  receptors.  MMP9  can  be  membrane  localised 
through  interaction  with  the  hyaluronic  acid  receptor  CD44,  facilitating  the 
migration of tumour cells (Bourguignon et al., 1998).  
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Once  activated  by  enzymatic  cleavage,  MMP  activity  is  regulated  by  tissue 
inhibitors of metalloproteases (TIMPs), which interact stoichiometrically with the 
active site of MMPs to reversibly inhibit their catalytic activity. Different TIMPs 
exist,  each  with  a  different  specificity  for  the  various  MMPs  (Gomez  et  al., 
1997). α2-Macroglobulin  which  is  found  in blood  plasma also  inhibits  MMPs 
(Sottrup-Jensen and Birkedal-Hansen, 1989), as do some protein sub-domains 
with homology to TIMPs (Mott et al., 2000). α2-Macroglobulin complexes are 
endocytosed and degraded providing a mechanism for the irreversible removal 
of  MMP  activity  from  the  extracellular environment (Yamashiro  et  al.,  1989). 
Along with their activation, proteolytic cleavage of MMPs can also regulate their 
localisation (Imai et al., 1996) and sensitivity to inhibition by TIMPs (Itoh et al., 
1998). It can therefore be seen that MMP catalytic activity is regulated through 
the  induction  of  its  expression,  however  once  the  protein  is  synthesised,  its 
activity and localisation is also highly regulated and subject to modification. 
 
1.4.3.1.2 MMPs and de-differentiation 
The expression of a number of MMPs becomes widely distributed throughout 
the blastema and if their activity is inhibited using a pharmacological inhibitor, 
hypomorphic limbs are regenerated, consistent with a role for MMPs in the de-
differentiation  or  proliferation  of  blastema  cells.  MMP  inhibition  reduced  the 
length of the regenerated radius/ulna and humerus to a similar extent, but not 
the width of the regenerating bones, indicating that the effect was specific to the 
proximodistal  axis  of  the  limb  (Vinarsky  et  al.,  2005).  In  support  of  the 
hypomorphic  phenotype  resulting  from  defective  de-differentiation  is  the 
observation  that the  level of  de-differentiation  of  blastema  cells  is  correlated 
with  the  level  of  MMP2  and  MMP9  activity.  Retinoic  acid,  which  affects  the 
proximodistal  patterning  of  the  limb  (discussed  in  detail  below),  is  seen  to 
upregulate  these  MMPs  (Park  and  Kim,  1999)  and  increase  the  degree  of 
dedifferentiation (Ju and Kim, 1994), indicating that the initial size of the pool of 
dedifferentiated blastema cells may influence the patterning of the limb along 
the PD axis. 
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It has been shown in hydra that MMP activity is induced in the stump following 
amputation, and inhibition of MMP activity either promotes the de-differentiation 
or  inhibits  the  trans-differentiation  of  stump  cells,  which  blocks  foot 
regeneration. The ECM is in a constant state of turnover in hydra and MMP and 
laminin  expression  is  highest  at  the  extremities  of  the  animal  where  trans-
differentiation is continually taking place during normal growth (Leontovich et 
al., 2000). These observations further link the interaction of cells with the ECM 
and  the  regulation  of  this  by  MMPs  to  the  processes  governing  cell  de-
differentiation. It seems however that in hydra, MMP activity is involved in the 
promoting  the  trans-differentiation  of  stump  cells  or  maintaining  their 
differentiated state, whereas in urodele expression of MMPs is correlated with 
de-differentiation.  MMPs  have  also  been  shown  to  be  involved  in  tissue 
remodelling in flies, worms and sea-urchins (Page-McCaw, 2008), and during 
liver regeneration in rats (Kim et al., 1997). 
 
1.4.3.1.3 Regulation of cell behaviour by MMPs 
That  MMPs  may  influence  de-differentiation  is  not  surprising.  Extracellular 
matrix  proteins  contain  binding  motifs  for  integrin  receptors  (Mould  and 
Humphries,  1991)  (discussed  in  greater  detail  below),  and  the  disruption  of 
integrin  ECM  interactions  as  well  as  the  cleavage  of  adherens  junctions 
between epithelial cells can be catalysed by MMPs (Symowicz et al., 2007), 
and  is  involved  in  the  loss  of  phenotypic  specialisation  seen  in  epithelial-
mesenchymal  transition  (Orlichenko  and  Radisky,  2008).  The  cleavage  of 
matrix proteins exposes otherwise concealed ‘cryptic’ motifs which can activate 
integrins and regulate cellular behaviour (Mott and Werb, 2004). The ECM also 
sequesters  numerous  growth  factors  which  can  be  released  upon  its 
degradation (Mott and Werb, 2004), and a class of MMP domain containing 
enzymes  known  as  adamalysins  are  involved  in  the  shedding  of  membrane 
tethered growth factors such as TNFα (English et al., 2000) and various EGFR 
ligands  (Blobel,  2005)  which  may  influence  the  processes  occurring  in  the 
blastema. MMPs are also able to cleave growth-factor receptors such as the 
FGF receptor type 1 (Levi et al., 1996), which may modulate the sensitivity of 
cells  to  FGFs.  Substance  P,  a  neurotransmitter,  is  also  cleaved  by  MMPs  
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(Diekmann and Tschesche, 1994). It is particularly interesting to note that the 
activity  of  FGF  and  substance  P  may  be  regulated  by  MMPs  as  both  are 
possible mitogens for blastema cells. Reviewed in (Stocum, 2004). Thus MMP 
activity is able to regulate cell signalling through a variety of mechanisms that 
may influence the differentiation state of stump cells.  
 
1.4.4  Patterning the regenerating limb 
Similarities between the AEC and the AER have been demonstrated in terms of 
some of the transcription factors expressed in response to growth factors in the 
two structures and their outgrowth promoting functions. Further similarity exists 
between the limb bud and the blastema in terms of the expression of FGF by 
the AEC and AER and the blastema and limb bud mesenchyme. Reviewed in 
(Stocum,  2004).  Although  not  identical,  the  indication  of  some  similarity 
between  the  blastema  and  the  limb  bud  therefore  makes  it  worthwhile  to 
consider  the  models  of  limb  outgrowth  and  patterning  established  through 
investigation in other model systems in relation to limb regeneration. 
 
1.4.4.1  A study of the developing limb bud 
The  relationship  between  limb  bud  outgrowth  driven  by  the  AER  and 
proximodistal patterning has been the subject of extensive research.  
In a recent review Tabin and Wolpert have proposed a model of limb patterning 
based upon current molecular level information whereby the AER promotes bud 
growth  whilst  a  second  signalling  centre  in  the  flank  is  involved  in  the 
specification of proximal identities (Fig.1.3) (Tabin and Wolpert, 2007), which is 
described below as a framework for considering the process of proximodistal 
patterning of the regenerating urodele limb.  
 
1.4.4.1.1 The role of fibroblast growth factors and retinoic acid 
At the heart of the model is the idea of a proliferating undifferentiated zone of 
cells  maintained  by  FGF  signalling  from  the  AEC  (Globus  and  Vethamany-
Globus, 1976) and a progressively moving ‘differentiation front’. In addition to 
maintaining the pool of dividing progenitors, FGF signalling from the AEC also  
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specifies  distal  fates  (Fallon  et  al.,  1994)  (Niswander  et  al.,  1993).  As  FGF 
signalling has only a limited range, as the limb bud grows, only the distal most 
cells remain under the influence of the AEC, with more proximal cells being free 
to enter differentiation pathways and assume proximal fates, consistent with the 
observed  proximal  to  distal  wave  of  differentiation  that  occurs  during 
development. 
 
 
 
Figure 1.3 The role of retinoic acid and fibroblast growth factors in the 
patterning of the developing limb bud 
(A)  An  undifferentiated  zone  is  maintained  throughout  outgrowth  of  the  limb  bud 
through the activity of FGF from the AER (B) A retinoic acid gradient originating in the 
flank induces Meis expression, which initially overlaps with the undifferentiated zone 
maintained by FGF signals from the flank. Once out of range of distalising AEC signals, 
the  proximal  compartment  of  the  limb  differentiates  under  the  sole  influence  of  the 
proximal  determinant  Meis.  (C)  Meis  and  the  zeugopod  marker  Hoxa11  expression 
initially overlaps, but becomes refined to mutually exclusive compartments as the limb 
bud  develops.  (D)  Hoxa13  expression  becomes  localised  to  the  most  distal 
compartment. Hoxa11 and Hoxa13 expression initially overlap, but become refined to 
mutually exclusive compartments as the limb bud develops. Other signals such as Shh 
may serve to regulate the refinement of markers to mutually exclusive compartments. 
Adapted from (Tabin and Wolpert, 2007).  
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The  model  proposes  that  opposing  gradients  of  retinoic  acid  (RA)  and  FGF 
signalling  (Mercader  et  al.,  2000)  result  in  the  establishment  of  mutually 
exclusive domains of expression of PD determinants timed to occur as cells 
cross the differentiation front, thereby establishing the segments of the limb as it 
develops. Initially RA signalling from the flank and FGF signalling from the AEC 
overlap as the limb bud is small, however as the limb bud grows two zones 
resolve,  the  undifferentiated  zone  under  exclusive  influence  of  AEC  signals 
expressing  distal  determinants,  and  a  zone  under  the  exclusive  influence  of 
flank signals fated to become the proximal regions of the limb. Further growth of 
the limb bud pushes cells out of the range of both signalling centres, which will 
assume distal fates as they are neither under the proximalising influence of the 
flank  nor  maintained  as  undifferentiated  by  signals  from  the  AEC.  FGF 
signalling from the AEC therefore plays a dual role in that in concert with RA it 
is  involved  in  the  establishment  of  clear  boundaries  of  expression  of  PD 
determinants spatially in the limb bud whilst also maintaining a region of the 
limb bud in an undifferentiated state. This mechanism therefore integrates the 
specification of progenitor cell identity with the process of differentiation via FGF 
signalling.  
 
1.4.4.1.2 Markers expressed during limb patterning: The Hox genes 
A  number  of  gene  products  are  seen  to  be  confined  to  specific  limb 
compartments,  providing  markers  that  can  be  followed  during  limb 
development.  Meis1  is  expressed  in  the  proximal  regions  of  the  limb  (the 
humerus  or  stylopod),  upregulated  by  RA  and  downregulated  by  FGF 
(Mercader et al., 2000). Hoxa13 is expressed in distal regions of the limb (the 
hand or autopod) (Yokouchi et al., 1991), upregulated by FGF (Vargesson et 
al., 2001) and downregulated by RA (Mercader et al., 2000). Meis1 and Hoxa13 
also act to repress each other’s expression (Capdevila et al., 1999). Hoxa11 is 
expressed  in  the  radius/ulna  or  zeugopod  (Yokouchi  et  al.,  1991).  RA 
downregulation of Hoxa13 in the autopod extends Hoxa11 expression distally 
(Mercader et al., 2000), however Hoxa11 and Hoxa13 do not appear to regulate 
each other’s expression (Yokouchi et al., 1995). Tabin and Wolpert suggest that  
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Hoxa11  and  Hoxa13  may  respond  reciprocally  to  a  common  signal  such  as 
Shh,  which  may  establish  the  sharp  boundary  between  their  locations  of 
expression. Although good markers for the limb compartments, out of the genes 
mentioned only Meis has been shown to reprogram proximodistal identity when 
overexpressed (Capdevila et al., 1999), although it is not essential for normal 
limb patterning (Azcoitia et al., 2005), indicating some degree of redundancy. In 
the absence of Hox11 gene expression, the zeugopod compartment is formed 
but does not grow correctly (Boulet and Capecchi, 2004), demonstrating that 
although Hox11 genes are involved in the growth of the zeugopod, they are not 
required to establish its initial formation in the limb bud.  
1.4.4.2  Hox gene expression in the regenerating urodele limb 
Studies in axolotls have shown that Hoxa13 expression becomes restricted to 
distal regions of the blastema during regeneration and is downregulated by RA 
(Gardiner et al., 1995) as described previously in the developing limb bud of 
other  model  organisms.  Meis  genes  are  also  upregulated  in  blastemas  and 
developing limbs exposed to RA (Mercader et al., 2005), indicating essentially 
the same underlying mechanisms specifying PD identity may be in place in the 
blastema  as  in  the  developing  limb  bud.  RA  treatment  of  blastemas 
progressively  respecifies  them  to  more  proximal  identities  over  a  range  of 
concentrations,  such  that  at  high  concentrations  a  wrist  level  blastema 
regenerates an entire new limb including the shoulder girdle (Fig.1.4A) (Maden, 
1982).  Overexpression  of  Meis2  is  able  to  re-locate  distal  blastema  cells  to 
more  proximal  locations  and  knockdown  of  Meis  is  able  to  block  the 
proximalising  effects  of  RA  (Mercader  et  al.,  2005),  indicating  that  the 
proximalising  effect  of  RA  on  blastemas  is  indeed  mediated  through  the 
upregulation of the proximal determinant Meis. 
 
1.4.4.3  The autonomy of the blastema 
Developing limb buds can be transplanted to a host limb at the mid-stage and 
develop  normally,  indicating  that  any  requirement  for  RA  in  specifying  the 
progenitor pools of limb segments must occur early (Tabin and Wolpert, 2007). 
Consistent with this, RA is only able to proximalise the blastema during the de- 
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differentiation phase (Thoms and Stocum, 1984). Likewise, a 10 day blastema 
grafted to a remote location will regenerate structures according to its origin 
along  the  limb  axis  (Stocum,  1968)  demonstrating  that  after  this  stage  it  is 
autonomous and requires no instructive cues from the stump or nerve in order 
to pattern its tissues or grow. Whether RA plays any role in regulating the PD 
identity of regenerating blastemas is unclear. In the developing limb bud, all 
cells are initially in the range of signalling from the flank however in the case of 
a distal blastema it is significantly remote from the flank to not realistically be 
under significant influence of such a morphogen gradient. In the regenerating 
limb  however,  the  stump  tissues  are  already  specified  to proximal  identities, 
thus it is conceivable that only the distal AEC signalling centre is necessary to 
direct  the  process.  It  has  been  suggested  that  regeneration  is  distinct  from 
development  in  that  a  distal  boundary  is  established  by  the  AEC  and  that 
missing structures are ‘filled in’ or intercalated between the proximal and distal 
boundaries (Stocum, 1984). If cells are maintained in an undifferentiated pool 
beneath the AEC and progressively differentiate into ever more distal structures 
as  they  cross  the  ‘differentiation  front’  as  in  the  model  of  limb  development 
proposed by Tabin and Wolpert, then the specification of the first blastema cells 
to  differentiate  to appropriate  PD  values  could  be  achieved  if  the  progenitor 
cells had some form of ‘memory’ of their origin along the PD axis. This has 
been proposed to be mediated by a mechanism involving a graded expression 
of  a  cell-surface  determinant  of  PD  identity  expressed  by  progenitor  cells 
(Stocum,  1984).  Arguments  against  a  mode  of  fate  specification  whereby 
structures differentiate in a proximal to distal wave exist however due to the 
observation that the most distal cells of the blastema are fated to form the most 
distal  structures  of  the  limb  very  early  after  the  blastema  is  established 
(Echeverri and Tanaka, 2005) (discussed in greater detail below). 
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1.4.4.4  A cell-surface determinant of proximodistal identity? 
1.4.4.4.1 Classical experiments: Engulfment, affinophoresis and 
intercalation 
Arguments  for  a  surface  determinant  of  PD  identity  come  from  a number of 
classical experiments. When a proximal and a distal blastema are cultured in 
contact with one another, the proximal blastema will tend to engulf the distal 
blastema (Fig.1.4Ba) (Nardi and Stocum, 1983) and this has been interpreted 
as  being  due  to  a  difference  in  adhesiveness  of  the  surface  of  proximal 
compared to distal blastema cells. If a distal blastema is grafted onto the dorsal 
surface of a proximal blastema it will remain undifferentiated and translocate 
distally as the regenerating limb grows, until it reaches the level of its origin 
along the PD axis, at which point it will differentiate hand structures (Fig.1.4Bb) 
(Crawford and Stocum, 1988a), a phenomenon termed affinophoresis. Similar 
to this, if a distal blastema is labelled and grafted onto a proximal stump, the 
stump tissue will intercalate the missing tissue between itself and the blastema 
(Fig.1.4C). If a proximal blastema is grafted onto a proximal stump however, 
regeneration occurs by growth of the blastema without mobilising stump tissue 
(Pescitelli and Stocum, 1980). If distal blastemas are treated with RA prior to 
grafting onto a proximal stump, they behave as if they were proximal blastemas, 
with no intercalation from the stump occurring and regeneration being driven 
purely from cells of the blastema. Likewise, if an RA treated distal blastema is 
grafted onto the dorsal surface of a regenerating limb, it does not translocate 
distally  and  differentiates  at  the  proximal  position  at  which  it  was  grafted 
(Crawford  and  Stocum,  1988b).  These  observations  argue  that  the  surface 
determinant of PD identity is regulated by RA. The authors of these studies 
have suggested that distal blastema cells may be more adhesive than proximal 
cells, providing a means by which cells can sort themselves according to PD 
identity. 
 
It is observed that a distal blastema takes the same length of time to reach the 
digit stage as a proximal blastema (Iten and Bryant, 1973). Although the reason 
for this is unclear, this observation taken together with the autonomous nature 
of blastemas help to explain why a grafted blastema completes regeneration  
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co-ordinately with the blastema of the amputated limb onto which it was grafted. 
As the blastema is autonomous at this point, the interaction with the host limb 
relates only to its translocation along the axis until it reaches its level of origin, 
suggested to be mediated by the affinity of cells for others of like PD identity. 
 
1.4.4.4.2 Sensing disparity between cells of different proximodistal origin 
Some mechanism of sensing local disparity in PD values between neighbouring 
cells is proposed to drive intercalation to restore the missing positional values 
(Stocum, 1996). The positional value of cells of the stump could be sensed in 
this  way,  ensuring  that  only  the  missing  distal  structures  are  intercalated 
between  it  and  the  AEC.  This  observation  that  a  stump  will  produce  only 
missing distal structures has been termed the rule of distal transformation. It 
has been shown that labelled distal blastema cells implanted into a proximal 
region of an upper arm blastema translocate distally (Echeverri and Tanaka, 
2005),  in  similarity  to  distal  blastemas  grafted  onto  the  dorsal  surface  of  a 
regenerating  limb.  Experiments  with  dissociated  chick  wing  bud  cells  have 
indicated that distal cells express higher N-cadherin than proximal cells and that 
this expression correlates with a tendency to associate with other distal cells 
(Yajima et al., 2002). The authors suggest that this may play a role in patterning 
along the PD axis of the limb. 
 
1.4.4.5  The role of Prod1 in proximodistal patterning 
1.4.4.5.1 The identification of Prod1 
RA has been used to screen for potential surface determinants of PD identity 
regulated  by  it  with  a  pattern  of  expression  consistent  with  its  proximalising 
effect.  The  expression  of  genes  encoding  cell-surface  expressed  molecules 
was compared between RA treated and normal blastemas, and selected on the 
basis of them either being upregulated by RA and expressed at a higher level in 
proximal limbs and blastemas compared to distal or downregulated by RA and 
expressed at a lower level in proximal limbs and blastemas compared to distal. 
A  single  molecule  was  identified  on  this  basis  and  named  Prod1.  Prod1  is 
expressed to a higher level in proximal blastemas and sections of the limb and  
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is upregulated by RA, making it a possible candidate for marking the relative 
extent of proximal identity of stump or blastema cells (da Silva et al., 2002).  
 
1.4.4.5.2 What does Prod1 do? 
Prod1  antibodies  block  the  engulfment  of  distal  blastemas  by  proximal 
blastemas  (da  Silva  et  al.,  2002)  indicating  it  may  mediate  the  differential 
adhesiveness  proposed  by  Nardi  and  Stocum.  When  Prod1  is  focally 
electroporated  into  the  most  distal  cells  of  a  distal  blastema,  which  would 
usually  differentiate  to  form  the  hand  structures,  cells  are  found  at  more 
proximal locations in the regenerating limb (Fig1.4C) (Echeverri and Tanaka, 
2005), similar to results seen with Meis2 electroporation (Mercader et al., 2005) 
and RA receptor activation in individual blastema cells (Pecorino et al., 1996).  
 
1.4.4.5.3 A link between Prod1, retinoic acid and Meis? 
As  noted  previously,  Meis  is  a  determinant  of  proximal  identity  positively 
regulated by RA. Prod1 is also positively regulated by RA, and there is some 
indication that the Prod1 promoter may have Meis response elements within it 
(N. Shaikh, P.Gates unpublished), raising the possibility that Meis may regulate 
its expression. Unlike Prod1, Meis expression is not graded along the PD axis 
of  the  limb,  however  it  is  expressed  more  highly  in  proximal  blastemas 
(Mercader et al., 2005). That Meis expression is not higher proximally in the 
intact limb is not inconsistent with it regulating PD identity via Prod1 expression 
during regeneration, as it is higher in proximal blastemas, and this is when its 
PD specifying activity is required. It will be interesting to understand further the 
relationship  between  the  proximal  determinant  of  development  Meis,  and 
Prod1, a potential determinant of PD identity of the regenerating blastema. 
 
1.4.4.5.4 Prod1 as the cell-surface determinant of proximodistal identity 
A model to explain the replacement of missing distal structures based upon the 
level  of  cell  surface  Prod1  expression  as  the  PD  determinant  has  been 
proposed such that when stump cells first de-differentiate, Prod1 expression is   
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Figure 1.4 Proximodistal patterning of the regenerating urodele limb 
(A) Distal blastemas treated with increasing concentrations of RA show duplications of 
increasingly proximal limb structures as they regenerate. Adapted from (Thoms and 
Stocum,  1984).  (B)  Classical  experiments  with  blastemas.  a)  When  juxtaposed  in 
culture,  proximal  blastemas  engulf  distal  blastemas.  b)  When  a  distal  blastema  is 
grafted  onto  the  dorsal  surface  of  a  proximally  amputated  limb,  the  blastema 
translocates to its level of origin before differentiating, a process termed affinophoresis. 
c)  When  a  distal  blastema  is  grafted  onto  the  amputation  surface  of  a  proximally 
amputated limb, the stump regenerates the majority of the limb by intercalation, with 
the  grafted  distal blastema contributing predominantly to  distal structures.  (Brockes, 
1997) (C) Prod1 expression proximalises distal blastema cells. a) Distal blastema cells 
electroporated with DS Red are localised distally in the regenerated limb, b). c) Distal 
blastema cells electroporated with GFP and Prod1 become more proximally located 
than  those  in  b)  in  the  regenerated  limb  d).  Adapted  from  (Echeverri  and  Tanaka, 
2005).  
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lost, producing a disparity between the initial blastema cells to de-differentiate 
and the stump cells, which will have a Prod1 encoded PD value corresponding 
to their position along the limb axis. Intercalation then fills in the missing values 
between  these  two  boundaries  by  progressive  respecification  of  the  level  of 
Prod1 expression of blastema cells as they divide, which then determines the 
fate of cells once they differentiate (Echeverri and Tanaka, 2005). 
 
1.4.4.6  Specification of blastema cell-fate 
Labelling experiments with early blastemas indicate that PD identity of blastema 
cells is specified very early, as distal cells are not respecified by moving them to 
more proximal positions in the blastema, and labelling of the most distal cells of 
an  early  blastema  indicates  that  these  cells  always  contribute  to  the  hand 
(Echeverri  and  Tanaka,  2005).  The  authors  suggest  that  this  rules  out  the 
possibility of models whereby the blastema grows at the distal tip with proximal 
structures  are  specified  first  as  they  exit  the  undifferentiated  zone  as  in  the 
model of limb development proposed by Tabin and Wolpert. They suggest that 
either populations of cells corresponding to the three limb compartments are 
established very early on, with each expanding and eventually differentiating, or 
that  the  early  blastema  is  divided  into  proximal  and  distal  regions,  with  the 
stump continually providing cells to the blastema during the de-differentiation 
phase  of  regeneration  with  progressively  more  proximal  identities,  producing 
progenitors with the appropriate identities to intercalate the structures missing 
between  the  distally  specified  region  of  the  blastema  and  the  stump.  Any 
contribution by the stump must none the less be complete by the time at which 
a grafted blastema will develop autonomously. Even if specification of positional 
identity is not coupled to outgrowth, there must be some mechanism by which 
the  blastema  regulates  the  differentiation  of  the  specified  progenitors.  It  is 
possible  that  once  pools  of  progenitors  are  established  they  regulate  their 
development  through  entry  into  cell  autonomous  differentiation  programs, 
interactions between neighbouring  cells,  the  establishment  of  local  signalling 
centres or a combination the three.  
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Consistent  with  a  difference  in  the  specification  of  distal  cells  between 
development and regeneration is that the distal marker HoxA13 is not observed 
in the initial stages of limb bud development in the axolotl, however is seen to 
be expressed after only 24hrs in the blastema (Gardiner et al., 1995). Nuclear 
localised Meis2 protein was seen to be expressed throughout the early limb bud 
and  subsequently  refined  to  a  clear  proximal  domain  as  the  bud  developed 
(Mercader et  al.,  2005)  consistent  with  observations  in  other  models  of  limb 
development  (Tabin  and  Wolpert,  2007).  As  mentioned  previously,  Meis 
expression is not observed to be graded along the PD axis of the limb, however 
it is expressed more highly in proximal compared to distal and in RA treated 
blastemas. These observations are consistent with the proposal that distal fates 
are established early in all blastemas, as shown by the Hoxa13 marker, and 
that it is the degree of proximal identities that are regulated by some means, as 
shown by differential Meis expression between proximal and distal blastemas. 
Although  growth  of  the  blastema  is  unlikely  to  occur  by  proliferation  of  an 
unspecified distal zone of cells that subsequently differentiate in a proximal to 
distal  wave,  the  data  is  not  inconsistent  with  the  involvement  of  the  AEC  in 
setting up the pools of progenitors that will form the discrete limb compartments 
early on.  
 
Some caution must be exercised in interpreting data from axolotl regeneration 
due to their paedomorphic character, as the recapitulation during regeneration 
of  gene  expression  seen  during  development  may  be  misleading  when 
interpreted with data from newts, which are true adults. It is possible that axolotl 
limb  regeneration  is  comparable  to  limb  regeneration  by  metamorphosing 
anurans (Dent, 1962) in which tissues have not fully differentiated. Classical 
experiments  with  grafted  blastemas  show  the  same  results  with  newts  and 
axolotls, however it has not been ruled out that different patterning mechanisms 
may exist between the different species. The similarity observed between the 
AER and limb bud in models of limb development and the AEC and blastema 
suggests that any difference between axolotls and newts is likely to be subtle 
though. 
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1.4.4.6.1 Retinoic acid in the regenerating blastema 
Proximal  blastemas  are  observed  to  have  higher  RA  activity  than  distal 
blastemas  (Scadding  and  Maden,  1994),  consistent  with  a  role  for  it  in 
conferring  proximal  identity  to  blastemas.  The  basis  for  this  is  unknown  but 
must reflect some underlying difference encoded by the stump cells contributing 
to either the AEC or the blastemal mesenchyme. An alternative model to one 
based  on  the  stable  expression  of  a  graded  cell-surface  determinant  of  PD 
identity by limb cells based on this difference in RA between proximal and distal 
blastemas  and  the  observation  that  RA  treated  blastemas  show  a  greater 
degree of de-differentiation (Ju and Kim, 1994) would be that the size of the 
pool of de-differentiated cells in some way determines their response to signals 
from  the  AEC.  A  small  pool  may  produce  only  the  distal  most  structures 
whereas  increasingly  larger  pools  of  progenitors  may  adopt  increasingly 
proximal  fates  upon  specification  to  distinct  limb  compartments  due  to 
increased  distance  from  distalising  AEC  signals,  which  subsequently  expand 
and differentiate according to their PD identity. In proximal blastemas where 
there  is  greater  de-differentiation,  the  stump  would  produce  progenitors  of 
increasingly proximal values as they come in ‘at the back’ of the blastema out of 
range  of  the  AEC.  Consistent  with  this  is  the  observation  that  RA  only  acts 
during de-differentiation (Thoms and Stocum, 1984). If RA is involved in the 
extent of de-differentiation of the stump and this is a primary determinant of the 
fates that populations of blastema cells will adopt, it seems logical that RA be 
unable to respecify the blastema after de-differentiation has occurred. Also, RA 
does not have the same proximalising effects during development, during which 
patterning occurs by processes distinct from those tied to the process of de-
differentiation occurring during regeneration (Scadding and Maden, 1986).  
 
1.4.4.6.1.1  Retinoic acid and matrix metalloprotease expression 
The increased de-differentiation in RA treated blastemas is also correlated with 
increased MMP production (Park and Kim, 1999). Inhibition of MMPs produces 
hypomorphic limbs rather than proximal truncations however (Vinarsky et al., 
2005),  which  is  hard  to  reconcile  with  a  model  in  which  the  degree  of  de-
differentiation determines the PD compartmentalisation of the early blastema, if  
  33 
it is indeed MMP activity regulating this de-differentiation. The indication from 
this  data  is  that  MMPs  determine  the  size  of  the  compartments,  possibly 
through  the  regulation  of  precursor  pool  size,  rather  than  the  number  of 
compartments.  Due  to  the  exponential  nature  of  cell  division,  even  small 
differences in size of the early pools of de-differentiated cells fated to different 
compartments  could  have  a  large  effect  on  the  eventual  size  of  those  limb 
segments  once  proliferation  is  halted  and  differentiation  is  initiated.  If  MMP 
activity is behind the increased de-differentiation seen in RA treated blastemas, 
the  fact  that  it  does  not  affect  patterning  per  se  suggests  that  RA  may 
coordinate both the production of extra de-differentiated cells in order to provide 
a  sufficiently  large  pool  of  precursor  cells  to  differentiate  into  the  extra 
structures  whilst  independently  regulating  the  number  of  limb  compartments 
formed.  It  would  be  interesting  to  address  this  question  either  by 
overexpression of MMPs in the blastema, to see if either extra limb segments 
are  produced  or  larger  than  ordinary  limb  segments  are  produced.  The 
combination of MMP inhibition and RA administration may also provide some 
insight into the problem. 
 
Late  denervation  of  the  blastema  results  in  a  miniature  limb  (Singer  and 
Craven, 1948) similar to the effect of MMP inhibition, indicating that the nerve 
regulates growth rather than patterning. On the other hand, late removal of the 
AEC results in distal truncation of the regenerate (Goss, 1956b). This could be 
interpreted as indicating that the AEC is required for maintaining distal fates as 
the  blastema  grows,  however  evidence  from  AER  removal  from  limb  buds 
indicates that this may be due to the death of underlying mesenchyme (Rowe et 
al., 1982). As distal cells are specified early and retain their distal character 
when grafted proximally (Echeverri and Tanaka, 2005) it seems unlikely that 
AEC  signals  are  required  to  maintain  distal  cell  fate  and  therefore  likely 
represents the death of the most distal precursors (Rowe et al., 1982), which 
cannot be reestablished from the more proximally determined cells. 
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1.4.4.6.1.2  Retinoic acid and Meis expression 
Meis itself has been shown to be regulated by RA directly (Mercader et al., 
2005), however its regulation in the blastema is likely to be different from in the 
limb  bud  due  to  the  presumed  lack  of  an  RA  gradient  from  the  flank.  It  is 
possible  that  Meis  expression  is  induced  by  RA  in  the  blastema  and  that 
opposing  signals  from  the  AEC  define  the distal  boundary of  its  expression, 
providing  a  means  of  establishing  early  proximal  and  distal  zones  in  the 
blastema. It is conceivable that only in blastemas with a sufficiently large pool of 
de-differentiated cells is Meis stably induced by RA. This model puts RA in a 
dual role, in both inducing Meis expression and determining the size of the pool 
of  progenitors  which  will  in  turn  determine  whether  any  cells  are  sufficiently 
distant  from  the  AEC  to  stably  express  Meis  and  form  the  proximal  most 
compartment of the limb. There is some indication that Meis activity in axolotls 
is regulated through its nuclear localisation (Mercader et al., 2005), raising the 
possibility that this may also play a role in the mechanism specifying PD identity 
of blastema cells. 
 
1.4.4.6.2 Prod1, Meis, and cell sorting in the blastema 
Proximal respecification by Meis is limited at later stages of the blastema and 
the  authors  suggest  that  this  may  be  because  cells  are  ‘trapped’  in  their 
compartment at this point (Mercader et al., 2005). Perhaps by this point cell 
associations  have  been  developed  that  do  not  permit  movement  to  more 
proximal regions of the blastema. It is also conceivable that by later stages of 
blastema development, cells become refractory to Meis upregulation. In support 
of  this,  RA  is  unable  to  proximalise  blastemas  after  de-differentiation  has 
occurred (Thoms and Stocum, 1984). That distally localised cells do become 
more  proximally  localised  by  early  Meis  (Mercader  et  al.,  2005)  or  Prod1 
expression and relocate distally when grafted more proximally (Echeverri and 
Tanaka, 2005) does suggest that some degree of cell migration or sorting can 
occur within the early blastema. Unless de-differentiating cells are specified to 
random proximal and distal identities and subsequently sort into compartments 
it is unclear whether cell sorting would be necessary during the normal situation 
in the blastema. Perhaps the affinity of cells for others with the same PD identity  
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represents  a  mechanism  to  ensure  robust  compartment  formation  early  in 
regeneration in order to prevent specified cells from becoming mislocated.  
 
One  interesting  point  is  that  evidence  from  affinophoresis  and  cell  grafting 
suggests that it is distal cells which tend to desire to make contact with other 
distal cells (Echeverri and Tanaka, 2005), whereas proximal blastemas have 
higher  Prod1  (da  Silva  et  al.,  2002)  and  Prod1  causes  cells  to  relocate 
proximally (Echeverri and Tanaka, 2005), indicating that high Prod1 reduces a 
cell’s  affinity  for  other  distal  cells.  The  interpretation  of  engulfment  of  distal 
blastemas by proximal blastemas has also been interpreted as being due to the 
higher adhesiveness of distal blastema cells (Nardi and Stocum, 1983), and if 
this is taken as being adequate explanation then the block of this process with 
Prod1  antibodies  (da  Silva  et  al.,  2002)  is  again  consistent  with  high  Prod1 
expression  reducing  the  adhesiveness  of  proximal  blastemas.  Nardi  and 
Stocum suggests that the process is analogous to placing a drop of liquid on 
another with which it is immiscible, however in this process gravity act on the 
drop being placed to ‘pull’ it over the surface of the other (Nardi and Stocum, 
1983).  With  blastema  confrontation,  although  distal  cells  may  have  a  higher 
tendency for self-association and therefore maintain the integrity of the distal 
blastema to a greater extent than the cells of the proximal blastema, none the 
less it is unclear what causes the proximal blastema to spread over it unless 
active cell migration is occurring. It is conceivable that proximal cells are more 
migratory due to looser association with either each other or blastema ECM 
proteins.   
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1.5  Signal transduction 
 
In this section, a number of well-characterised signal transduction pathways will 
be examined as a prelude to a final investigation of how Prod1 may function at 
the molecular level to control cell behaviour.  
 
1.5.1  Transmembrane receptors 
1.5.1.1  Heterotrimeric G-protein coupled receptors  
Heterotrimeric  G-protein  coupled  receptors  (GPCRs)  are  a  large  family  of 
transmembrane receptors with a diverse array of ligands (Hauser et al., 2006). 
The  structure  of  GPCRs  are  composed  of  seven  transmembrane  spanning 
domains  linked  by  cytoplasmic  and  extracellular  loops,  with  the  extracellular 
regions  being  responsible  for  ligand  binding  and  the  intracellular  domain 
mediating  the  interaction  with,  and  activation  of  the  GTPase  activity  of  their 
associated heterotrimeric G-protein (Rosenbaum et al., 2009). Ligand binding to 
the  extracellular  region  of  GPCRs  leads  to  a  conformational  change  in  the 
cytoplasmic loops, stimulating the exchange of GDP for GTP by the α subunit of 
the associated G-protein, leading to its dissociation for the βγ subunit (Morris 
and Malbon, 1999). 
 
G-proteins  come  in  a  number  of  flavours.  All  are  composed  of  α,  β  and  γ 
subunits, however the activity of the dissociated α and βγ subunits depend upon 
their type. Two classes of α subunits, αs and αi, stimulate or inhibit the activity of 
the  enzyme  adenylate  cyclase  respectively,  which  produces  the  second 
messenger  cyclic  adenosine  monophosphate  (cAMP)  (Malbon,  2005).  Many 
possible β and γ subunits exist, and depending upon the subunit composition of 
the dimer they are also able to activate adenylate cyclase along with a large 
array of other downstream signalling pathways components including subtypes 
of phospholipase C (PLC), phosphatidylinositol 3-kinase (PI3K) and Src kinases 
(Schwindinger  and  Robishaw,  2001).  Activated  heterotrimeric  G-proteins  are 
also able to activate other small G-proteins of the Ras family through either 
direct activation of their regulatory guanine nucleotide exchange factors (GEF) 
as  in  the  case  of  Rho  GTPases  (Whitehead  et  al.,  2001),  or,  most  likely,  
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through the activation of non-receptor tyrosine kinases (NRTK) such as Src in 
the  case  of  Ras  (Kranenburg  and  Moolenaar,  2001).  Src  activation  by  G-
proteins  is  also responsible  for  their  ability to  activate  signal  transducer  and 
activator of transcription 3 (STAT3) (Ram and Iyengar, 2001), a regulator of 
gene  expression  also  activated  by  the  epidermal  growth  factor  receptor 
(EGFR). 
  
1.5.1.2  Integrins 
Integrins  are  heterodimeric  transmembrane  receptors  composed  of  various 
combinations of α and β subunits, each with different preferences for binding 
ECM proteins, providing both a means of anchoring a cell and also sensing the 
ECM  environment  (Hynes,  2002).  Although  the  cytoplasmic  domains  of 
integrins  do  not  posses  intrinsic  kinase  activity,  ECM  protein  binding  to  the 
extracellular regions of the receptor leads to activation of kinases associated 
with  the  cytoplasmic  tails  of  the  α  and  β  subunits  (Giancotti  and  Ruoslahti, 
1999).  Focal  adhesion  kinase  (FAK)  is  commonly  activated  by  integrin 
signalling (Miyamoto et al., 1995) (Schaller et al., 1995) leading to Src activation 
(Schaller  et  al.,  1994)  and  the  activation  of  PI3K  (King  et  al.,  1997)  and 
extracellular  signal-regulated  kinases  1  and  2  (ERK1/2)  mitogen  activated 
protein  kinase  (MAPK)  signalling  by  recruitment  of  the  Grb2-SOS  complex 
(Schlaepfer et al., 1994) (discussed in greater detail below). Some integrins are 
also able to interact directly with Src kinases, either via their α or β subunits. 
α6β4 integrin is phosphorylated on the β4 subunit by Src kinases, leading to the 
recruitment  of  the  adaptor  protein  Shc  (Mainiero  et  al.,  1997).  Downstream 
pathways and adaptors are discussed in greater detail below.  
 
ECM protein activation of downstream signalling from integrins promotes cell 
survival via the PI3K pathway (Khwaja et al., 1997), and is linked, via Src and 
SHC as mentioned, to receptor tyrosine kinase (RTK) signalling (Roovers et al., 
1999).  The  integration  of  integrin  signalling  with  RTK  signalling  provides  a 
means by which the ECM encountered by a cell can influence the response of a 
cell  to  other  growth  factors,  determining  whether  a  given  growth  factor  will 
stimulate  cell  proliferation  (Roovers  et  al.,  1999)  (Oktay  et  al.,  1999)  or  
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migration via the remodelling of the cytoskeleton (Cary et al., 1998) (Sieg et al., 
2000).  
 
1.5.1.3  Epidermal growth factor receptor signalling 
The EGFR has great potential for mediating and integrating signalling events. It 
provides sites for the activation of both kinases and adaptor proteins through 
which it is able to regulate the activation of a number of signalling pathways. 
The EGFR is activated by ligands such as epidermal growth factor (EGF) and 
transforming growth factor (TGF), which are initially synthesised as membrane 
anchored precursors (Schneider and Wolf, 2009). Four EGFR family members 
exist  denoted  ErbB1-4  with  different  downstream  targets  and  ligand  binding 
potential  (Yarden  and  Sliwkowski,  2001).  Of  these  only  ErbB1,  commonly 
referred  to  as  EGFR,  binds  EGF,  whereas  only  ErbB4  binds  neuregulin  4 
(NRG4) (Jones et al., 1999). Ligand binding to the extra cellular domains of 
ErbB  monomers  exposes  dimerisation  interfaces,  leading  to  the  formation  of 
homo- or hetero-dimers (Schlessinger, 2002). The ErbB2 extracellular domain 
adopts a conformation primed for dimerisation without the ability to bind ligand 
(Klapper  et  al.,  1999)  and  is  the  preferred  partner  of  the  other  ErbB  family 
members  (Tzahar  et  al.,  1996)  and  binds  a  greater  number  of  downstream 
signalling components than the other monomers (Jones et al., 2006), whereas 
ErbB3 does not have a functional kinase domain (Guy et al., 1994). When in a 
monomeric  state  the  kinase  activity  of  EGFR,  ErbB  2  and  ErbB4  is  auto-
inhibited  by  self-association  of  regions  of  the  cytoplasmic  domains,  with 
activation resulting from a phosphorylation independent, asymmetric interaction 
between the two members of a dimer (Zhang et al., 2006). Once activated, the 
kinase  domain  can  phosphorylate  residues  on  the  C-terminal  domain  of  the 
receptor,  producing  docking  sites  for  components  of  downstream  signalling 
pathways  (Yarden  and  Schlessinger,  1987).  See  Figure  1.5  for  a  cartoon 
depicting major components of the EGFR pathway. 
 
Along  with  regulation  of  kinase  activation, EGFR  activity  is  controlled  at  the 
level  of  receptor  internalisation  and  degradation,  a  process  which  occurs 
through regulated endocytosis following activation, with different heterodimers  
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having  different  propensities  for  endocytosis  due  to  their  different  abilities  to 
interact  with  regulatory  proteins  (Baulida  et  al.,  1996).  Endocytosis  of  the 
activated  EGFR  is  thought  to  occur  largely  through  the  clathrin-dynamin 
mediated pathway as inhibition of its phosphorylation prevents its accumulation 
in clathrin coated pits (Sorkina et al., 2002) and clathrin or dynamin knock-down 
has  been  shown  to  inhibit  its  internalisation  (Huang  et  al.,  2004).  Following 
receptor activation and phosphorylation of the C-terminal domain, the ubiquitin 
ligase Cbl marks the receptor for internalisation and subsequent degradation 
(Levkowitz et al., 1998) (Dikic, 2003) (Marmor and Yarden, 2004), although it is 
of note that the phosphorylated C-terminal of the activated EGFR is exposed to 
the  cytoplasm  whilst  in  the  endocytic  pathway  and  is  likely  to  be  able  to 
continue signalling whilst in endosomes (Wiley, 2003). Inactive EGFRs are also 
slowly internalised at a rate comparable to bulk membrane and recycled back to 
the cell membrane (Wiley et al., 1991); some examples also exist of pinocytic 
endocytosis  of  the  activated  EGFR  by  A431  carcinoma  cells  (Haigler  et  al., 
1979), though the physiological relevance of these results is debated due to the 
extremely  high  level  of  EGFR  expressed  by  this  cell  line  (Sorkin  and  Goh, 
2008).  
 
1.5.1.4  Attenuation of receptor activation 
The inactivation of receptor signalling has not been examined in detail here. 
Activated G-proteins hydrolyse GTP (Kleuss et al., 1994), leading to their re-
association  with  βγ  subunits  and  inactivation  (Meij,  1996),  whereas  receptor 
tyrosine kinases such as the EGFR can be inactivated by dephosphorylation 
catalysed by the regulated activity of phosphatases (Tiganis, 2002). Prolonged 
activation  of  GPCRs  can  also  lead  to  their  desensitization  via  their 
phosphorylation  by  activated  downstream  kinases  such  as  protein  kinase  A 
(PKA), leading to their endocytosis (Ferguson, 2001).  
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.   
Figure  1.5  The  epidermal  growth  factor  receptor:  A  paradigm  for 
transmembrane receptor signalling  
Ligand  binding  to  the  EGFR  leads  to  the  activation  of  a  number  of  downstream 
signalling pathways. Black arrows denote phosphorylation (p). Tan arrows represent all 
other interactions. Shc and Grb2/SOS link EGFR activation to the MAPK pathways via 
Ras. Activated ERK1/2  and JNK1/2 translocate  to the nucleus and phosphorylate  a 
number  of  transcription  factors,  including  c-fos  and  c-jun.  STATs  can  be 
phosphorylated  by  EGFR  activated  JAKs,  Src  or  by  the  EGFR  itself  (not  shown), 
leading to their dimerisation and translocation to the nucleus where they regulate gene 
expression. PLCγ can be activated directly by ErbB3, or via Ras activation (not shown), 
leading  to  cleavage  of  phosphatidylinositol  4,5-bisphosphate  (PIP2)  to  diacylglycerol 
(DAG)  and  inositol  triphosphate  (IP3).  IP3  releases  Ca
2+  from  the  endoplasmic 
reticulum (ER), which acts as a co-factor with DAG in the activation of protein kinase C 
(PKC). PIP2 phosphorylation by PI3K produces PIP3, which activates AKT. Activated 
AKT and PKC regulate gene expression by phosphorylating transcription factors such 
as the cyclic-AMP response element binding protein (CREB).  
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1.5.1.5  General principles of receptor signalling 
The  examples  presented  here  of  three  distinct  types  of  transmembrane 
receptors illustrate the diverse mechanisms through which extracellular signals 
can  be  transmitted  across  the  cell  membrane.  Although  the  mechanisms  of 
those described are of course not representative of all known receptors, and of 
those  mentioned,  description  of  all  their  known  mechanistic  details  is 
incomplete, they do serve to illustrate some fundamental aspects of receptor 
signalling.  The  EGFR  is  either  a  hetero-  or  homo-dimer  with  intrinsic  kinase 
activity, integrins are hetero dimers and require associated cytoplasmic kinases 
for  signalling  activity,  whereas  signals  from  GPCRs  are  transduced  by  the 
exchange of guanine nucleotides by their associated heterotrimeric G-proteins. 
 
1.5.2  Adaptor  proteins,  non-receptor  tyrosine  kinases  and  small  G-
proteins 
In many cases adaptor or scaffolding proteins form a link between receptors 
and downstream signalling pathways by providing a means by which to bring 
proteins  together  into  functional  signalling  complexes.  Individual  NRTKs  and 
small  G-proteins  are  activated  following  the  activation  of  a  number  of 
transmembrane receptors. As these classes of proteins can both be activated 
by  various  inputs  and  lead  to  the  activation  of  a  variety  of  downstream 
pathways, they serve to integrate the effects of receptor activation. Figure 1.6 
shows the involvement of some of the proteins described below in relation to 
EGFR signalling.  
 
1.5.2.1  SH2, PTB and SH3 domains 
The adaptor proteins Shc (Pelicci et al., 1992) and Grb2 (Lowenstein et al., 
1992)  contain  the  Src  homology  2  (SH2)  domain,  which  mediates  their 
interaction with phosphorylated tyrosine residues (Mayer and Baltimore, 1993). 
Shc  can  also  contains  a  second  phosphotyrosine  interacting  domain,  the 
phosphotyrosine  binding  (PTB)  domain  (Blaikie  et  al.,  1994)  whereas  Grb2 
contains two Src homology 3 (SH3) domains (Lowenstein et al., 1992), which 
facilitate its interaction with both proline-rich motifs on other proteins (Sparks et 
al.,  1996)  and  other  sequence  motifs  (Lewitzky  et  al.,  2001).  Shc  binds  to  
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phosphorylated tyrosines on many proteins including the EGFR (Pelicci et al., 
1992),  the  T-cell  receptor  (Ravichandran  et  al.,  1993),  the  platelet  derived 
growth factor receptor (PDGFR) (Yokote et al., 1994) via its SH2 domain, and 
the neurotrophin receptor TrkA (Zhou et al., 1995) via its PTB domain, leading 
to  its  phosphorylation.  As  mentioned  previously,  Shc  also  interacts  with  Src 
phosphorylated integrins (Mainiero et al., 1997). Phosphorylated Shc provides a 
docking site for Grb2 (Sasaoka et al., 1994), though it has been shown that 
Grb2  can  also  become  localised  to  the  EGFR  directly  via  its  SH2  domain 
(Batzer  et  al.,  1994).  These  proteins  containing  multiple  different  interaction 
domains  therefore  facilitate  the  regulation  of  protein  complex  formation  in 
response to receptor stimulation, linking the activated receptor to downstream 
components in the signalling pathway. 
 
1.5.2.2  Ras, Rho and Src 
Grb2  is  constitutively  associated  with  the  Sos  GEF  in  the  cytoplasm.  Upon 
recruitment to a transmembrane receptor, Sos initiates the exchange of bound 
GDP  for  GTP  by  the  small  G-protein  Ras  (Olivier  et  al.,  1993),  which  is 
anchored to the inner leaflet of the cell membrane by covalently attached prenyl 
and palmitoyl groups (Pechlivanis and Kuhlmann, 2006). Targets of Ras include 
upstream  components  of  the  MAPK  pathways  Raf  (Hallberg  et  al.,  1994; 
Hamilton and Wolfman, 1998) and MEKK-1 (Lange-Carter and Johnson, 1994), 
PI3K  (Rodriguez-Viciana et  al.,  1994)  and protein  kinase  C  ζ  (PKCζ)  (Diaz-
Meco et al., 1994), all of which are described below in greater detail. 
 
The Rho GTPases, of which Rac, Cdc42 and the Rho sub-categories are family 
members, are a sub-family of the Ras super-family of molecules responsive to 
growth factor receptor (Schiller, 2006) and integrin stimulated signals (Keely et 
al.,  1997)  (Ren  et  al.,  1999)  (Shaw  et  al.,  1997).  Like  Ras,  their  activation 
requires the catalysed exchange of bound GDP for GTP by GEFs (Rossman et 
al., 2005). This sub-family has been shown to regulate cell shape and motility 
through their ability to interact with cytoskeletal associated proteins, modulating 
the dynamics of the turnover of the cytoskeleton (Heasman and Ridley, 2008) ,  
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as  well  as  functioning  in  the  activation  of other  signalling  pathways  such  as 
MAPK (Joneson et al., 1996). 
 
The NRTK Src contains an SH2 and an SH3 domain. In its inactive state it is 
auto-inhibited  through  the  binding  of  its  SH2  domain  to  an  inhibitory 
phosphorylated tyrosine (Liu et al., 1993), leading to the association of the SH3 
domain with a stretch of proline residues (Xu et al., 1999), disrupting its kinase 
activity (Young et al., 2001). 
 
Thus  Src  can  be  activated  by  de-phosphorylation  of  the  inhibitory  tyrosine 
bound by the SH2 domain, association with phosphorylated tyrosines residues 
on  proteins  such as  the  EGFR  (Stover  et  al.,  1995)  and  integrin  associated 
focal adhesion kinase (FAK) (Schaller et al., 1994), which compete for binding 
of  its  SH2  domain,  or  similarly,  association  with  proline  residues  on  other 
proteins which compete for binding with its SH3 domain (Gonfloni et al., 2000). 
When  associated  with  the  EGFR,  activated  Src  phosphorylates  tyrosine 
residues on the receptor, providing new binding sites for proteins (Biscardi et 
al., 1999) whilst also phosphorylating other EGFR associated proteins such as 
STATs (Quesnelle et al., 2007). 
 
1.5.3  Feedback and crosstalk: An added level of complexity to receptor 
signalling 
The  activation  of  a  cell-surface  receptor  can  transactivate  other  pathways 
through either direct or indirect production of other ligands. For example, GPCR 
activation can lead to elevated MMP activity, which in turn leads to an increase 
in available EGFR ligand and EGFR activity through cleavage and release of 
cell-membrane anchored heparin-binding EGF (HB-EGF) precursor (Prenzel et 
al., 1999). A similar mechanism operates following the activation of the uPAR 
receptor by its ligand uPA (Guerrero et al., 2004).The MMP involved may be of 
the ADAM (a disintegrin and metalloprotease) family, known to regulate EGFR 
activity in a number of contexts through the release of membrane tethered HB-
EGF  (Blobel,  2005).  EGFR  activation  can  lead  to  the  production  of  its  own 
ligands  (Schulze  et  al.,  2001),  providing  a  positive  feedback  loop  through 
autocrine signalling. In addition, NRTKs such as the Src family can be activated  
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by integrins leading to phosphorylation of tyrosine residues on the EGFR (Moro 
et  al.,  2002),  providing  an  example  of  how  activation  of  one  receptor  can 
modulate the activity of another. 
 
Src family NRTKs are activated by a number of receptors, such as the EGFR 
(Stover et al., 1995) and integrins (Schaller et al., 1994), and have been shown 
to participate in down-stream signalling from both of them (Leu and Maa, 2003) 
(Playford  and  Schaller,  2004).  Such  crosstalk  between  pathways  originally 
thought of as independent is emerging as the rule rather than the exception. In 
light of the fact that compared to the possible cellular outcomes of signalling the 
number  of  receptors  involved  is  small,  that  they  are  able  to  interact  and 
modulate each other explains the observed complexity they generate. Figure 
1.6 illustrates some of the crosstalk between EGFR and integrin signalling as 
an example. 
 
1.5.4  Signal transduction pathways 
1.5.4.1  Mitogen activated protein kinase pathways 
The  MAPK  pathways  provide  a  clear  illustration  of  the  principles  of  cell 
signalling via kinase cascades. Three or more tiers of kinases are activated by 
phosphorylation,  with  each  kinase  phosphorylating  the  next  leading  to  the 
eventual activation of one or more MAPKs (Pearson et al., 2001). Figure 1.7 
illustrates some of the points described below in the text. 
 
1.5.4.1.1 MAPK kinase kinases 
At the top of the cascade are MAPK kinase kinases (MAPKKK), which can be 
activated by signals originating from G-protein coupled receptors (Kranenburg 
and Moolenaar, 2001), RTKs (English et al., 1999) and integrins (Giancotti and 
Ruoslahti,  1999).  Of  these,  Raf  is  specific  for  the  ERK1/2  MAPK  pathway 
(Kyriakis et al., 1992), whilst MEKKs 1-4 are able to activate multiple MAPK 
pathways  (Hagemann  and  Blank,  2001).  MEKK1  can  be  activated  by  Ras 
(Lange-Carter  and  Johnson,  1994),  which  is  a  target  of  EGFR  activation  
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(Lowenstein  et  al.,  1992),  providing  a  link  between  the  EGFR  and  multiple 
MAPK pathways.  
 
 
 
Figure  1.6  Crosstalk  between  epidermal  growth  factor  receptor  and 
integrin signalling 
Ligand  activated  EGFR  recruits  the  Grb2/SOS  complex  directly  or via  Shc. Integrin 
contact  with  the  ECM  activates  FAK,  leading  to  the  recruitment  of  the  Grb2/SOS 
complex. FAK also activates Src, which can phosphorylate FAK, providing a docking 
site for components leading to Rac activation, some integrin β subunits, providing a 
docking  site  for  Shc,  or  tyrosine  residues  on  the  C-terminal  domain  of  the  EGFR, 
modulating its activity. FAK activation also activates PI3K, either directly or via Ras. 
Black arrows denote phosphorylation (p). Tan arrows represent all other interactions 
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1.5.4.1.2 MAPK kinases 
MAPKKKs activate MAPK kinases (MAPKK) (Hagemann and Blank, 2001). The 
specificity of Raf for ERK1/2 lies in its own specificity for the ERK1/2 MAPKKs 
MEK1  and  MEK2  (Kyriakis  et  al.,  1992),  whereas  MEKKs  1-4  are  able  to 
phosphorylate  and  activate  MEK4/7,  the  MAPKK  of  c-Jun  N-terminal  kinase 
(JNK) MAPK, MEK3/6, the MAPKK of p38 MAPK as well as MEK1 and MEK2 
(Hagemann and Blank, 2001). In addition to their activation by Ras, MEKKs1 
and 4 can be activated by Rho family kinases (Fanger et al., 1997) (Gerwins et 
al., 1997), providing a means of integrating these signals into the ERK1/2, JNK 
and  p38  pathways.  As  well  as  performing an  integrating  function,  the  tiered 
kinase cascade provides a means of signal amplification as in many cases the 
number  of  target  kinases  at  one  level  in  the  pathway  greatly  exceeds  the 
number of effector kinases (Pearson et al., 2001). 
 
1.5.4.1.3 Extracellular signal regulated kinase: An example of the MAPKs  
MEKs  are  activated  by  serine/threonine  phosphorylations  (Zheng  and  Guan, 
1994).  ERK1/2  activation  by  MEK1  and  MEK2  involves  an  initial  tyrosine 
phosphorylation  followed  by  a  threonine  phosphorylation  (Ferrell  and  Bhatt, 
1997) (Pearson et al., 2001). Tyrosine phosphorylation does not itself activate 
ERK1/2 and a threshold level of tyrosine phosphorylated molecules must be 
reached before phosphorylation of the activating threonine can occur (Ferrell, 
1997).  Activated  ERK1/2  can  be  inactivated  by  tyrosine,  serine/threonine,  or 
dual  specificity  phosphatases  which  can  themselves  be  activated  by  MAPK 
phosphorylation, providing a negative feedback loop regulating the duration of 
MAPK activation (Keyse, 2000). The expression of other phosphatases can be 
induced by extracellular stimuli, (Guan et al., 1992) providing further means of 
regulating MAPK pathway activity. 
 
1.5.4.1.4 Achieving specificity in the MAPK pathways 
The promiscuity of MEKKs 1-4 illustrates a puzzle central to the study of cell 
signalling, as although in principle their activation by different inputs would be 
expected to lead to the same downstream effects this is of course not the case.  
  47 
Specificity of downstream effects in response to different stimuli is proposed to 
be achieved through scaffolding proteins that regulate the ability of MEKs to 
engage with their MAPKs or through proteins which inhibit kinases in specific 
MAPK  pathways  (Hagemann  and  Blank,  2001).  For  example,  the  activity  of 
MEKs can also be regulated by Rho family G-proteins, which may affect their 
ability  to  participate  in  protein  complexes  (Frost  et  al.,  1997).  The  ability  of 
MAPKs  to  engage  their  targets  or  to  themselves  become  activated  is  also 
regulated  through  their  subcellular  localisation  (Pouyssegur  and  Lenormand, 
2003). 
 
1.5.4.1.5 Targets of the MAPKs 
Targets  of  MAPKs  include  other  cytoplasmic  effector  kinases,  cytoskeletal 
components,  phospholipase  A2  (PLA2),  and  nuclear  transcription  factors 
(Pearson et al., 2001). Mnk1 and Mnk2 are kinases that are phosphorylated by 
ERK1/2  and  p38,  but  not  JNK,  and  function  to  stimulate  translation  via 
activation  of  eukaryotic  elongation  factor  eIF-4E  (Waskiewicz  et  al.,  1997). 
MAPKAP kinase 2 is also a target of both p38 and ERK1/2 (Stokoe et al., 1992) 
which phosphorylates the F-actin binding proteins hsp27 (Larsen et al., 1997) 
and LSP1 (Huang et al., 1997) and the transcription factors CREB (Xing et al., 
1998) and ATF-1 (Tan et al., 1996), as are Msk1 and Msk2 (Deak et al., 1998) 
which can phosphorylate histone H3 (Thomson et al., 1999) and cyclic AMP 
response-element binding protein (CREB).  
Translocation of MAPKs to the nucleus allows them to directly phosphorylate 
transcription factors. The AP-1 transcription factors c-fos (Chen et al., 1993) 
and c-jun (Hibi et al., 1993) are phosphorylated directly by ERK1/2. ERK1/2 
phosphorylation  of  c-jun  inhibits  its  activity  whilst  phosphorylation  by  JNK 
stimulates it (Hibi et al., 1993). The transcription factor Elk-1 is phosphorylated 
by ERK, JNK and possibly p38 (Janknecht et al., 1993), whilst SAP-1 and SAP-
2 are phosphorylated only by ERK1/2 and p38 (Strahl et al., 1996). Thus it can 
be seen at both the level of MAPK activation and the downstream targets of the 
MAPKs  that  some  components  of  the  pathways  are  specific  to  one  MAPK, 
whereas others may be integrated into two or more.  
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Figure 1.7 The MAPK pathways 
A number of MAPKKKs exist with overlapping substrate specificity, each of which has 
different specificity for MAPKKs. The MAPKKs on the other hand are more specific for 
their  respective  kinases;  Regulation  of  MAPKK  activation  via  their  interaction  with 
scaffolding proteins (not shown) facilitates the activation of specific MAPKs in response 
to stimuli such as receptor activation. The MAPKs themselves also have overlapping 
substrate  specificity  and  regulate  transcription  via  the  direct  phosphorylation  of 
transcription  factors  or  via  other  kinases  such  as  MSK1/2  and  MAPKAP  kinase  2. 
MSK1/2  also  regulates  gene  expression  by  remodelling  chromatin  structure  via  the 
phosphorylation  of  histone  H3.  MAPKAP  kinase  2  regulates  actin  structure  via  the 
phosphorylation  of  cytoskeleton  associated  proteins  hsp27  and  LSP1.  Black  arrows 
denote  phosphorylation (p). See (Hagemann  and Blank,  2001)  and (Pearson  et al., 
2001) for detailed reviews of the MAPK signalling cascades.   
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1.5.4.2  Janus  kinase/  signal  transducer  and  activator  of  transcription 
pathway 
A number of STATs are activated by phosphorylation through the binding of 
their  SH2  domains  to  phosphorylated  tyrosines  on  receptor  tyrosine  kinases 
such  as  EGFR  (Silvennoinen  et  al.,  1993),  or  through  activation  of  cytokine 
receptors and GPCRs via NRTKs such as Src (Ram and Iyengar, 2001) (Silva, 
2004), leading to their dimerisation and translocation to the nucleus where they 
regulate gene expression. EGFR signalling can regulate STAT mediated gene 
expression  through  the  direct  phosphorylation  of  STATs,  via  Src  or  via  the 
activation of janus kinases (JAKs), which phosphorylate and activate a number 
of STAT proteins (Quesnelle et al., 2007). In addition to the activation of the 
STAT pathway through different routes originating from the EGFR, JAKs and 
the ERK1/2 MAPK pathway converge in the regulation of STAT transcriptional 
activity (Chung et al., 1997).  
 
1.5.4.3  Phosphatidylinositol 3-kinase pathway 
PI3K can be activated by receptor tyrosine kinases such as the EGFR. Unlike 
ErbB3 (Ram and Ethier, 1996), EGFR does not directly activate PI3K, however 
it is able to do so via Ras activation (Marte et al., 1997). This ability of ErbB3 to 
activate PI3K directly and via Ras highlights the non-linearity of cellular signal-
transduction pathways. The PI3K pathway can also be activated via G-protein 
coupled receptors (Murga et al., 1998) and integrins (Clark et al., 1998).  
 
The target of PI3K is the lipid phosphatidylinositol (PI) in the inner leaflet of the 
cell  membrane.  Multiple  phosphorylations  of  PI  lead  to  the  production  of 
phosphatidylinositol  4,5-bisphosphate  (PIP2)  and  phosphatidylinositol  3,4,5-
triphosphate (PIP3). PIP2 serves as a docking site at the membrane for the 
kinase  Akt,  localising  it  appropriately  for  its  activation  by  phosphoinositide 
dependent kinase 1 (PDK1) (Chan et al., 1999). Akt is involved in the regulation 
of  a  wide  diversity  of  cellular  processes  including  proliferation,  survival, 
inhibition  of  apoptosis  through  a  variety  of  effector  molecules  (Chan  et  al., 
1999),  and  the  stimulation  of  translation  through  the  mammalian  target  of 
rapamycin  (mTor)  pathway  (Mamane  et  al.,  2006).  Akt  also  phosphorylates  
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transcription  factors  including  CREB  (Du  and  Montminy,  1998).  The  PI3K 
pathway illustrates how signalling pathways can involve the phosphorylation of 
lipids as an intermediate step between the activation of two kinases. Akt can 
also phosphorylate and inactivate Raf in the ERK1/2 MAPK pathway (Lee et al., 
2008). 
 
1.5.4.4  Phospholipases, protein kinase A and protein kinase C 
The  activation  of  phospholipases  is  another  mechanism  through  which  the 
membrane lipid phosphatidylinositol can act as a signal-transducing molecule. 
PLCγ can be activated by the EGFR (Margolis et al., 1989) and cleaves PIP2 to 
yield  IP3  and  diacylglycerol  (DAG)  (Kamat  and  Carpenter,  1997).  DAG 
functions as a co-factor for the activation of PKC, whereas IP3 releases Ca
2+ 
from the endoplasmic reticulum, another co-factor in the activation of PKC, from 
intra-cellular stores (Pettitt et al., 1997) (Weiss et al., 1991). A subclass of PKCs 
named  the  atypical  PKCs  also  exist  which  do  not  require  Ca
2+  for  their 
activation  (Spitaler  and  Cantrell,  2004).  As  mentioned,  PI3K  catalyses  the 
phosphorylation of PI to PIP2 and PIP3, providing a link between PI3K and IP3 
signalling  (Chan  et  al.,  1999).  As  with  many  of  the  pathways  discussed, 
activated PKC leads to phosphorylation of transcription factors such as CREB 
(Yamamoto  et  al.,  1988),  thereby  regulating  gene  expression.  PLCγ  is  also 
involved  in  the  re-organisation  of  the  cytoskeleton  in  response  to  EGFR 
activation, and has been shown to do so via interaction with the Rho GTPases 
(Li et al., 2009).  
PLA2  is  Ca
2+  dependent  (Burke  and  Dennis,  2009)  and  becomes  activated 
following  phosphorylation  by  MAPKs  and  PKC  (Nemenoff  et  al.,  1993). 
Activated PLA2 translocates to the cytoplasmic surface of the cell membrane 
where it catalyses the cleavage of phospholipids to produce arachidonic acid 
(Burke and Dennis, 2009), which subsequently becomes modified into active 
compounds  such  as  prostaglandins  and  leukotrienes  which  regulate  cell 
behaviour  via  the  activation  of  GPCRs,  and  may  also  regulate  gene 
transcription via nuclear hormone receptors (Funk, 2001). 
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PKA is activated by intracellular cAMP produced in response to activated GS-
protein coupled receptor mediated stimulation of adenylate cyclase (Meinkoth et 
al.,  1993).  PKA  has  a  number  of  targets,  amongst  which  are  transcription 
factors such as CREB (Thomson et al., 2008). 
 
1.5.4.5  General principles of signal transduction pathways 
The signal transduction pathways described, although by no means complete in 
terms of those that exist in the eukaryotic cell, illustrate many of the general 
principles  of  signal  transduction.  Phosphorylation  of  tyrosine,  serine  and 
threonine  occurs  widely  throughout  the  various  pathways,  leading  to  either 
activation or inhibition of a given molecule’s activity. Components of different 
pathways can interact, providing the cross-talk necessary to establish specific 
outcomes  from  pathways  with  many  potential  outputs.  Signalling  can  be 
initiated  via  phosphorylation  events  originating  from  receptor  or  non-receptor 
tyrosine kinases or through mechanisms that do not require kinase activity such 
as in the case of heterotrimeric G-protein coupled receptors. Following receptor 
activation, signal transduction can also be mediated either via further kinase 
activity,  the  exchange  of  phosphorylated  guanine  nucleotides  by  small  G-
proteins, or through distinct mechanisms involving second messengers such as 
DAG,  Ca
2+  or  cAMP,  which  in  many  cases  results  in  signal  amplification  at 
some stage of the pathway. The end points of many pathways are the activation 
by phosphorylation of transcription factors controlling gene expression, many of 
which are the targets of multiple pathways. As well as regulating transcription, 
receptor mediated signalling is also able to control translation and cell growth, 
the balance of cell survival and apoptosis and cell motility via the modification of 
cytoskeletal components.  
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1.6  Glycosylphosphatidylinositol anchored proteins 
 
Prod1 is a glycosylphosphatidylinositol (GPI) anchored cell-membrane localised 
protein (da Silva et al., 2002). GPI anchored proteins are synthesised with an 
N-terminal signal peptide shared by all secreted proteins which is cleaved co-
translationally,  targeting  the  molecule  into  the  endoplasmic  reticulum  (ER) 
(Rapoport, 1991), and a C-terminal peptide which is a recognition sequence for 
the GPI anchor attachment machinery (Eisenhaber et al., 1998).  
 
1.6.1  GPI anchor attachment 
The consensus C-terminal peptide has been defined in terms of the biochemical 
properties  of  the  amino  acids  rather  than  specific  residues  and  can  be 
described as a region of 4 small amino acids followed by a moderately polar 
spacer  region  of  7  amino  acids  and  a  mostly  hydrophobic  tail  region 
(Eisenhaber et al., 1998). The GPI anchor is covalently attached to the second 
small amino acid in the recognition sequence in a concerted reaction occurring 
on the inner surface of the ER membrane, during which the C-terminal peptide 
is cleaved (Eisenhaber et al., 2003). The C-terminal peptide of Prod1 conforms 
moderately  to  the  consensus  and  it  has  been  demonstrated  that  Prod1 
mediated  effects  on  blastema  engulfment  can  be  blocked  by 
phosphatidylinositol-phospholipase  C  (PIPL-C)  (da  Silva  et  al.,  2002), 
demonstrating its attachment to the cell membrane via a GPI anchor is required 
for its biological activity.  
 
1.6.2  Trafficking of GPI anchored proteins 
After GPI anchor attachment, proteins are linked to the inner leaflet of the ER 
membrane (Eisenhaber et al., 2003). The GPI anchor itself is composed of a 
highly  conserved  glycan  core  modified  with  a  number  of  side-chains  and 
attached to a phospholipid anchor (Fig.1.8) (Paulick and Bertozzi, 2008). The 
primary lipid anchor is modified subsequent to GPI anchor attachment yielding 
an  anchor  of  variable  lipid  composition.  In  yeast,  lipid  anchor  modification 
occurs in the ER (Fujita and Jigami, 2008), and it has been proposed that GPI 
anchored  proteins  become  concentrated  at  specific  regions  of  the  ER  
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membrane through association with these lipid anchor remodelling enzymes. 
These regions then bud  to  produce  vesicles  that  are  trafficked  to  the Golgi. 
Transmembrane  proteins  are  concentrated  at  regions  of  the  ER  membrane 
distinct from where GPI anchored proteins tend to accumulate, and tend to be 
trafficked to the Golgi in separate vesicles from those carrying GPI anchored 
proteins, though sorting is not absolutely efficient as a population of vesicles are 
observed containing both GPI anchored and transmembrane proteins (Castillon 
et al., 2009). In mammals it is not until proteins reach the Golgi that the lipid 
anchor is modified (Kinoshita et al., 2008) and thus it is likely that this will be the 
location of GPI anchored protein sorting if it occurs . 
GPI anchored proteins are internalised by a pathway independent of clathrin or 
caveolin  mediated  endocytosis.  Internalisation  of  GPI  anchored  proteins  is 
instead mediated by pinocytosis, delivering them to recycling endosomes rather 
than the Golgi (Sabharanjak et al., 2002). 
 
 
 
Figure 1.8 The glycosylphosphatidylinositol anchor 
The GPI anchor is composed of a glycan core, which can be decorated with a variety 
of side groups and a phospholipid tail of variable composition. Proteins are linked to 
the GPI anchor via a phosphoethanolamine linker.  
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1.7  ‘Lipid rafts’, or detergent insoluble microdomains 
 
1.7.1  Cell membrane localisation of GPI anchored proteins 
Once trafficked to the cell membrane by exocytosis, the GPI anchor becomes 
inserted into the outer leaflet of the lipid bilayer (Eisenhaber et al., 2003). Thus 
GPI  anchored  proteins  do  not  make  direct  contact  with  the  proteins  in  the 
cytoplasm, posing questions as to how they function in a signal transducing 
capacity. It has been proposed that the sequence of the C-terminal peptide can 
determine the specific composition of the GPI anchor and thereby regulate the 
localisation  of  a  molecule  on  the  cell  membrane  (Nicholson  and  Stanners, 
2006). It has also been indicated that the activity of molecules may rely on their 
GPI  anchorage,  as  when  they  are  instead  anchored  proteinaceously,  their 
activity is altered (Robinson et al., 1989). These results tend to be explained in 
the  context  of  detergent  insoluble  membrane  microdomains  or  ‘lipid  rafts’ 
(Helms and Zurzolo, 2004).  
 
Cholesterol alters the biophysical properties of lipid bilayers by causing the acyl 
chains of lipids to become more closely packed and ordered. This ordered state 
of  the  membrane  is  further  enhanced  by  sphingolipids  (Brown  and  London, 
2000)  and  it  has  been  proposed  that  stable  local  regions,  or  ‘rafts’,  rich  in 
cholesterol and sphingolipids exist within the membrane, which as a whole is 
less  ordered  (Pike,  2004).  These  rafts  are  proposed  to  concentrate  GPI 
anchored proteins in the outer leaflet of the membrane (Brown and Rose, 1992) 
and  lipid  anchored  NRTKs  and  G-proteins  in  the  inner  leaflet  (Resh,  1999). 
Transmembrane  proteins  such  as  receptors  are  proposed  to  be  included  or 
excluded from rafts depending on their identity (Simons and Toomre, 2000). 
Although GPI anchor modification has been proposed to be a mechanism for 
sorting  of  proteins  into  detergent  resistant  microdomains  (Brown  and  Rose, 
1992), it has been shown with the GPI anchored prion protein PrP that deletion 
of  the  C-terminal  GPI  anchor  attachment  sequence  does  not  affect  its 
localisation (Walmsley et al., 2003).   
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1.7.2  Lipid rafts and signal transduction 
The localisation of GPI anchored proteins to microdomains in the outer leaflet of 
the cell membrane and NRTKs and G-proteins to the inner leaflet has been 
proposed as a means of facilitating signal transduction (Simons and Toomre, 
2000). It is observed that antibodies against GPI anchored proteins can activate 
downstream signalling, and this is interpreted as being the result of GPI protein 
clustering  (Murray  and  Robbins,  1998).  This  clustering  is  then  proposed  to 
result in the transduction of a signal across the cell membrane to NRTKs and 
G-proteins  localised  to  the  inner  membrane  surface  (Simons  and  Toomre, 
2000).  This  can  be  explained  with  reference  to  the  participation  of  a 
transmembrane adaptor protein in the process, however it has been suggested 
that in the case of some molecules, rather than the protein itself, it is instead the 
anchor that mediates biological effects (Nicholson and Stanners, 2006). Such a 
mode  of  signal  transduction  suggests  that  the  protein  domain  acts  only  to 
facilitate clustering of anchors, leading to the activation of molecules localised 
to the inner surface of the membrane by the interaction of lipids between the 
two  leaflets.  Thus  a  ‘soft’  interpretation  of  lipid  rafts  would  be  that  the 
localisation of proteins to the inner leaflet of the cell membrane positions them 
appropriately to maximise their potential to be activated by events involving GPI 
anchored  proteins  occurring  in  an  adjacent  region  of  the  outer  membrane, 
transduced across it by transmembrane proteins. A ‘hard’ interpretation of the 
function of lipid rafts would be that without the co-ordination of the composition 
of  adjacent  regions  of  the  inner  and  outer  leaflets  of  the  membrane,  signal 
transduction  across  the  cell  membrane  initiated  by  events  involving  GPI 
anchored proteins could not occur due to the requirement for the interaction 
between the lipid anchor of the GPI anchored protein and some the signalling 
proteins involved. 
 
1.7.3  A continuous model of the cell membrane 
In contrast to the microdomain organisation of the cell membrane, a continuous 
model  proposes  that  cholesterol  and  sphingolipids  are  evenly  distributed 
throughout the membrane. See Figure 1.9 for a comparison between lipid raft 
containing cell membranes and continuous membranes. The observation that 
an  insoluble  fraction  enriched  in  GPI  anchored  proteins,  NRTKs,  G-proteins,  
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cholesterol  and  sphingolipids  is  seen  after  centrifugation  of  cell  membranes 
lysed in Triton X-100 at 4°C in a density gradient (Yu et al., 1973) has been 
taken  as evidence  for  lipid  rafts.  As  evidence  for the  existence of  rafts,  this 
observation is not sufficient however as it is open to alternative interpretations. 
Detergent solubilisation of the membrane occurs as a result of the insertion of 
individual detergent molecules into the membrane until holes form, causing its 
fragmentation (le Maire et al., 2000), during which membrane components may 
become re-arranged in various ways (Munro, 2003) giving a false impression of 
its  natural  composition.  Likewise,  the  effects  of  depleting  cholesterol  from 
membranes  on  cell  signalling  taken  as  supporting  the  lipid  raft  model  of 
signalling  (Tansey  et  al.,  2000)  can  be  interpreted  as  being  the  result  of 
interfering  with  the  permeability  and  physical  state  of  the  membrane  without 
definitively implicating the existence of lipid rafts (Munro, 2003). The dynamics 
of lateral diffusion in the cell-membrane of the GPI anchored protein CD59 has 
also been seen to be very similar to a non-raft phospholipid (Subczynski and 
Kusumi,  2003),  in  contrast  to  expectations  were  it  raft  localised  and  adding 
further cause for scepticism of the model.  
 
Even  if  lipid  rafts  do  not  truly  exist,  the  concentration  of  GPI  proteins  into 
regions of either the ER or Golgi membrane during their synthesis, and their 
sorting into specific vesicles prior to trafficking to the cell membrane (Castillon 
et  al.,  2009)  may play  a role  in  determining  potential  molecular  interactions. 
Membrane proteins linked to the cytoskeleton may concentrate other proteins in 
membrane microdomains by limiting lipid lateral diffusion (Fujiwara et al., 2002), 
thus if multi-protein complexes are formed at specific locations on membranes 
within the cell, trafficked in specific vesicles and subsequently become situated 
in regions of the cell membrane with limited diffusion, proteins may still become 
localised to microdomains.  
 
In light of current evidence, it seems unwise to place rigid constraints based on 
the GPI anchored nature of Prod1 on the potential molecular interactions it may 
participate in. As no molecular level information exists on Prod1 other than its 
structure, this investigation of its signal transducing activity has remained open-
minded to the possibility that it may or may not be localised to specific domains  
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of the cell membrane, that its GPI anchor may or may not play a functional role 
in the mechanism of its action and that it may or may not interact with other 
transmembrane proteins.  
 
 
 
Figure 1.9 Lipid rafts or a continuous membrane? 
It has been proposed that cholesterol and sphingolipids form micro-domains in the cell 
membrane termed ‘lipid rafts’ enriched in GPI anchored proteins in the outer leaflet, 
lipid  anchored  signalling  molecules  in  the  inner  leaflet  and  specific  transmembrane 
receptors.  Alternatively,  cholesterol  and  sphingolipids  may  be  uniformly  distributed 
throughout the membrane. In this case, if GPI anchored proteins are localised to micro-
domains it is due to factors other than the membrane composition. Phosphatidylcholine 
(PtdCho),  phosphatidylserine  (PtdSer),  phosphatidylethanolamine  (PtdEth).  Image 
adapted from (Munro, 2003). 
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1.8  How does Prod1 function at the molecular level? Insights 
from Prod1 homologs 
 
Prod1 is a member of the large three-fingered family of proteins (TFPs) and is 
structurally most similar in structure to CD59 and domain 3 of the urokinase 
plasminogen activator receptor (uPAR), both of which are also GPI anchored 
proteins  (Garza-Garcia  et  al.,  2009).  Structural  similarity  between  TFPs  is 
shown in Figure 1.10. 
 
1.8.1  CD59 
CD59 is expressed on the surface of a wide variety of cells and functions to 
protect cells from the innate immune system by disrupting the formation of the 
membrane attack complex (MAC) and thereby inhibiting cell lysis (Rollins and 
Sims, 1990). In addition to physically disrupting the formation of the MAC, CD59 
has been shown to initiate downstream signalling in response to complement 
factor binding and antibody cross-linking (Murray and Robbins, 1998).  
CD59  has  also  been  shown  to  immunoprecipitate  with  the  α  subunit  of 
heterotrimeric  G-proteins,  which  are  known  to  be  associated  with  detergent 
resistant  microdomains  (Resh,  1999),  though  the  signalling  events  resulting 
from this are uncharacterised (Solomon et al., 1996). 
 
In  haematopoietic  cells,  cross-linking  of  CD59  with  antibodies  or  binding  of 
complement  factor  8  leads  to  phosphorylation  of  Shc  (Murray  and  Robbins, 
1998). When activated by phosphorylation, Shc dimerises with the Grb2-SOS 
complex leading to the activation of Ras and the ERK1/2 MAPK pathway as 
described previously. CD59 cross linking also led to Src phosphorylation and 
Src  kinase  activity  dependent  phosphorylation  of  other  cytoplasmic  kinases 
(Murray and Robbins, 1998). As described previously, Src family kinases are 
associated with phosphorylated tyrosine residues on other proteins such as the 
EGFR  (Stover  et  al.,  1995)  and  are  able  to  phosphorylate  an  number  of 
downstream  targets  including  Shc  (van  der Geer  et  al.,  1996).  An  unbiased 
screen for potential EGFR interacting proteins indicated a physical interaction 
between CD59 and the EGFR (Blagoev et al., 2003). Shc and Src are known to   
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be involved in EGFR signalling as described previously, thus the EGFR may 
represent the link between phosphorylation of Shc, Src, and CD59 dimerisation. 
 
 
 
Figure 1.10 The three fingered family of proteins 
Three-fingered proteins can be categorised into groups A-D based upon their protein 
structure.  Structural  comparison  groups  Prod1  most  closely  with  2OFS  (CD59)  and 
2FD6-3 (domain 3 of the urokinase-like plasminogen activator receptor) (Garza-Garcia 
et al., 2009). Image courtesy of A. Garza-Garcia. 
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1.8.2  The urokinase-type plasminogen activator receptor 
uPAR  is  another  member  of  the  three-fingered  family  of  proteins  structurally 
similar to CD59 and Prod1 (Garza-Garcia et al., 2009) with a significantly more 
detailed body of literature surrounding its participation in cell-signalling. High 
expression of uPAR leads to ligand-independent phosphorylation of the EGFR 
in response to fibronectin binding α5β1 integrin, via the activity of cytoplasmic 
FAK, leading to cell proliferation (Liu et al., 2002). Likewise, activation of uPAR 
by its ligand uPA has been shown to result in the phosphorylation of EGFR by 
Src,  leading  to  increased  fibronectin  secretion  by  fibroblasts  (Monaghan-
Benson and McKeown-Longo, 2006). The phosphorylation of sites on EGFR by 
uPAR dependent Src activity has also been shown to modulate the response of 
cells to EGF. In this example EGF activates ERK1/2, but does not stimulate cell 
proliferation in the absence of uPAR. Interactions between uPAR and integrins 
mediate Src dependent phosphorylation of sites on the EGFR in response to 
EGF that result in STAT5b activation in addition to ERK activation, leading to a 
stimulation of proliferation (Jo et al., 2007). As well as activating downstream 
signalling pathways via integrins and the EGFR, uPAR has also been shown to 
initiate  signalling  via  interaction  with  a  GPCR,  leading  to  the  activation  of 
tyrosine kinases and cell migration (Resnati et al., 2002). 
 
1.8.2.1  A link between Prod1 and MMP9? 
uPAR integrin interactions leading to Src dependent activation of ERK1/2 have 
also been shown to regulate the activity of MMP9 (Wei et al., 2007), which as 
discussed previously, is highly regulated during blastema formation (Vinarsky et 
al., 2005) and may contribute to cell de-differentiation (Park and Kim, 1999) and 
the establishment of the wound epidermis (Satoh et al., 2008). The similarities 
between the structures of Prod1 and uPAR (Garza-Garcia et al., 2009) and the 
demonstrated  involvement  of  MMPs  with  the  processes  of  regeneration 
(Vinarsky et al., 2005), taken together with the observations that RA increases 
the level of de-differentiation of a blastema (Ju and Kim, 1994) and upregulates 
both Prod1 (da Silva et al., 2002) and MMP9 (Park and Kim, 1999) discussed 
previously make the investigation of a role for Prod1 in the regulation of MMPs  
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a seemingly worthy point at which to begin the investigation of the molecular 
mechanisms through which this little studied protein regulates cell behaviour.  
 
1.8.2.2  A role for the EGFR in Prod1 signal transduction? 
The observed interaction of CD59 (Blagoev et al., 2003) and uPAR (Mazzieri et 
al., 2006) with the EGFR warrants investigation of the possibility that it may 
serve as a transmembrane signal transducing protein able to relay a signal from 
Prod1 across the cell membrane. In cancer biology, upregulation of uPAR and 
MMPs  is  prognostic  of  a  metastatic  phenotype  (Inuzuka  et  al.,  2000).  As 
discussed above, previous studies of Prod1 may indicate it as having a role in 
cell migration, a process with clear analogy to metastasis. Due to its similarities 
with uPAR, in addition to the relevance of this investigation to understanding the 
processes regulating regeneration, study of the potential regulation of MMP9 by 
Prod1 may yield insights with wider implications in the field of cancer biology.  
  62 
 
 
 
 
 
 
 
 
 
 
 
 
2  Materials and methods  
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2.1  Constructs 
 
2.1.1  EGFR and β1 integrin 
Notophthalmus viridescens Prod1 was cloned previously (da Silva et al., 2002). 
Notophthalmus  viridescens  EGFR  and  β1  integrin  were  cloned  by  rapid 
amplification of cDNA ends (RACE) from blastemal cDNA, as were Ambystoma 
mexicanum and Ambystoma maculatum Prod1 (P. Gates). 
 
2.1.2  Epitope tagging 
Epitope  tags  were  added  by  polymerase  chain  reaction  (PCR)  with  primers 
containing a tag sequence and restriction sites to produce fragments that were 
subsequently cloned back into the PCI-Neo vector. 
 
2.1.3  Prod1 Flag deletion constructs 
Prod1 Flag deletion constructs were cloned by PCR of the original Prod1 Flag 
construct with restriction site containing primers to produce truncated fragments 
that were subsequently cloned back into the PCI-Neo vector.  
 
2.1.4  Prod1 Flag site-directed mutagenesis 
Computer  algorithms  were  used  to  select  residues  for  mutation  following 
inspection of the three-dimensional structure of Prod1 and the alignment of its 
amino acid sequence with other TFPs. Care was taken to ensure that mutation 
sites were distributed across the whole protein surface to sample all possible 
interaction surfaces. A residue was selected as a candidate for mutation if: 
 
a) more than 30% of the side chain is solvent accessible 
b)  by  inspection  of  the  structure  it  does  not  appear  to  fulfil  a  role  in  the 
attainment of the Prod1 three-dimensional fold 
c) it is not conserved across the TFP superfamily. 
 
Point  mutations  were  generated  using  the  Stratagene  Quick  Change  site-
directed mutagenesis kit (Stratagene 200519) according to the manufacturer’s  
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instructions. Prod1-Flag, Prod1-Flag LFA and Axolotl Prod1 cloned into the N2 
vector were PCR amplified with Pfu turbo enzyme using mis-matched primers 
at the site of mutation and subsequently degraded using Dpn1 prior to cloning 
the mutated product. 
 
2.2  Cloning 
 
2.2.1  Fragment purification 
PCR fragments were electrophoresed on an agarose gel, bands of appropriate 
size were cut from the gel and DNA was purified using a Quiagen gel extraction 
kit.  After  restriction  digestion  of  insert/  vector,  DNA  was  purified  by  organic 
phase  separation.  Equal  volumes  of  phenol  chloroform  isoamyl  alcohol 
(25:24:1)  were  mixed  with  DNA  in  TE  buffer  (see  below)  and  spun  for  5 
minutes.  The  aqueous  phase  was  then  collected  and  mixed  with  an  equal 
volume of chloroform isoamyl alcohol (24:1) and spun for 10 minutes to pellet 
the DNA. Pellets were washed in 70% ethanol and re-suspended in TE. 
 
2.2.2  Ligation/transformation 
Ligations were performed for 1hr at 11°C with T4 DNA ligase in 10ul reactions 
using a 20:1 ratio of fragment to vector. XL2 Blue E.coli (Stratagene 200150) 
were  transformed  according  to  manufacturer’s  instructions  and  plated  under 
antibiotic  selection.  Although  not  confirmed  extensively,  there  was  some 
indication  that  constructs  cloned  with  RecA-  XL2  Blue  E.coli  gave  better 
expression in B1H1 cells than when cloned in RecA+ SURE E.coli (Stratagene). 
Cultures were grown from single transformed colonies and DNA was prepared 
by Quiagen Maxi-prep according to the manufacturer’s instructions. 
 
See  Appendix  for  construct  sequences,  primers  used  for  site-directed 
mutagenesis and a more detailed discussion of the different constructs. 
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2.3  Cell culture 
 
2.3.1  Conditions 
B1H1 cells were grown in tissue culture plastic flasks coated with gelatin.  
B1H1 cells were cultured in 70% minimal essential medium (MEM) + Earles 
(21090 GIBCO), 30% H2O (hereafter referred to as AMEM), supplemented with 
10%  FBS,  100U-100U/ml  penicillin-streptomycin  (15140  GIBCO),  2mM 
glutamine (25030 GIBCO) and 10ug/ml insulin (Sigma I-5500). 
 
HEK293T cells were grown in uncoated tissue culture plastic flasks. 
HEK293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
+  4.5g/L  glucose,  +  580mg/L  L-glutamine,  -pyruvate  (41965  GIBCO) 
supplemented  with  10%  foetal  calf  serum  and  100U-100U/ml  penicillin-
streptomycin (15140 GIBCO) 
 
2.3.2  Passage 
B1H1  cells  (Ferretti  and  Brockes,  1988)  were  rinsed  twice  using  70% 
Dulbecco’s phosphate buffered saline (DPBS) 30% H2O (hereafter referred to 
as APBS) and incubated at room temperature in trypsin (15090 GIBCO) diluted 
to  1x  concentration  (0.25%)  in  APBS  until  cells  detached.  Trypsin  was  then 
neutralised  using  growth  media and  cells  were  spun  down  in  conical-bottom 
tubes  at  1000rpm  for  3  minutes.  Media  were  aspirated,  pellets  were  re-
suspended and cells were either plated onto tissue culture dishes or into tissue 
culture flasks pre-coated with gelatin. B1H1 cells were split at no greater than 
1:3 and were passaged after 7-14 days. 
 
HEK 293T cells were rinsed twice using PBS and incubated at 37°C in trypsin 
(15090 GIBCO) diluted to 1x concentration in PBS until cells detached. Trypsin 
was then neutralised using growth media and cells were spun down in conical-
bottom  tubes  at  1000rpm  for  3  minutes.  Media  were  aspirated,  pellets  were 
resuspended and cells were either plated onto ‘Primera’ tissue culture dishes 
(Falcon) or into tissue culture flasks. HEK 293T cells were passaged routinely 
every 3-4 days. 
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2.3.3  Incubation 
HEK 293T cells were incubated at 37°C in 7% CO2. 
B1H1 cells and explanted skin patches were incubated at 25°C in 2% CO2. 
 
2.4  Transfection 
 
2.4.1  B1H1 cells  
Cells were plated on gelatin 7 days prior to transfection. Confluent dishes of 
cells were transfected for 18hr using a 1:2 ratio of DNA to Lipofectamine 2000 
(11668-019  Invitrogen)  according  to  manufacturer’s  instructions  in  AMEM 
without penicillin/streptomycin. 35mm dishes were transfected in 2ml medium 
plus 4ug DNA. 60mm dishes were transfected in 5ml medium with 10ug DNA. 
 
2.4.2  HEK 293T cells 
Cells were plated 24hr prior to transfection on ‘Primera’ dishes (Falcon). Cells 
were  transfected  at  a  density  of  30%  for  7hr  using  a  1:2  ratio  of  DNA  to 
Lipofectamine  2000  (11668-019  Invitrogen)  according  to  manufacturers 
instructions  in  DMEM  without  penicillin/streptomycin.  60mm  dishes  were 
transfected in 5ml medium with 6ug DNA. 
 
2.4.3  Transgenic HEK 293T cells 
HEK  293T  cells  were  infected  with  a  lentiviral  vector  containing  the  coding 
region for Prod1-Flag or Prod1-Flag Q59A and a puromycin resistance gene. 
Cells were grown at clonal density in the presence of puromycin and transgenic 
strains were derived from individual colonies (A.Janmohamed)  
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2.5  RNA preparation 
 
2.5.1  Tissue culture cells 
Cells were collected in conical-bottom tubes as described under ‘cell passage’, 
resuspended in cold APBS and then pelleted in 1.5ml tubes at 4°C. Cells were 
lysed on ice in appropriate volumes of cold Ambion Lysis Buffer (Ambion Cells-
to-cDNA II Kit AM1723), samples were heated to 75°C for 10 minutes, cooled 
on ice and then treated with deoxyribonuclease (DNAse) (Ambion) at 37°C for 
15  minutes.  DNAse  was  inactivated  at  75°C  for  5  minutes  prior  to  cDNA 
synthesis. 
 
2.5.2  Tissue samples  
Skin  and  other  tissue  samples  were  mechanically  dissociated  in  Tri  reagent 
(Sigma  T9424)  and  RNA  was  extracted  by  phase  separation  according  to 
manufacturers instructions. RNA samples were treated with DNAse in Ambion 
Lysis Buffer (Ambion Cells-to-cDNA II Kit AM1723) prior to cDNA synthesis. 
 
2.6  cDNA synthesis 
 
Complementary DNA (cDNA) was synthesised in 20ul reactions including 1ul 
Superscript  II  Reverse  Transcriptase  (Invitrogen  18064-014),  1ul  RNAse  out 
RNAse  inhibitor  (Invitrogen  10777-019),  5uM  random  hexamers  (Invitrogen 
N8080127),  1uM  dNTP’s  (Invitrogen18427-013)  and  <500ng  RNA  in  Ambion 
Lysis Buffer (Ambion Cells-to-cDNA II Kit AM1723). 
 
2.7  Quantitative real-time PCR 
 
Quantitative real-time PCR (qRT-PCR) was used to assay gene expression in 
cultured cells and explanted skin-patches. mRNA was reverse transcribed using 
random  primers  to  produce  cDNA  representative  of  the  transcriptome  under 
investigation. Genes of interest were amplified from cDNA using gene specific 
primers  and  the  accumulation  of  product  measured  over  the  course  of  the 
reaction. The intercalation of SYBR Green into double-stranded DNA produces  
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fluorescence, which was used to quantify the accumulation of PCR product for 
all target genes other than Prod1. As Prod1 is expressed at low levels in most 
tissues,  the  more  sensitive  TaqMan  PCR  approach  was  employed,  during 
which  a  fluorescent  dye  attached  to  a  gene  specific  primer  becomes  un-
quenched as the primer becomes incorporated into product. 
 
The PCR cycle at which product begins to accumulate exponentially is denoted 
the cT value. As at this point in the PCR product is doubling each cycle, cT 
values can be compared to calculate the relative number of target sequences 
between samples based upon the premise that a difference in cT value of 1 
represents a two-fold difference in the number of target sequences, which holds 
true under optimal PCR conditions with efficient primers. cT values were used 
to  calculate  the  relative  difference  in  expression  of  a  gene  between  two 
samples using the equation: 
 
Relative difference = 2
ΔcT 
 
In order to take into account unequal amounts of total cDNA in samples either 
due  to  their  being  synthesised  from  unequal  amounts  of  RNA  or  slight 
differences in efficiency of cDNA synthesis, the level of a housekeeping gene 
was determined and taken to bear the same relationship to the total cDNA in 
each  sample  to  serve  as  a  normalisation  factor.  The  normalised  relative 
difference of expression of gene X between sample 1 and sample 2 is: 
 
2
(cT Sample 1- cT Sample 2)
Gene X/ 2
(cT Sample 1- cT Sample 2)
 Gene Normaliser 
 
cDNA was amplified using a two-step protocol. A melting temperature of 95 °C 
was used in all reactions. Primer-pairs were characterised by determining the 
temperature that gave the lowest cT value whilst also producing a clear, sharp 
peak on the melt-curve. This temperature was used for annealing/ extension. 
 
All  quantitative  real-time  PCR  was  performed  using  the  Biorad  Chromo  4 
detector and analysed using Biorad Opticon Monitor software. iQ Supermix with  
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SYBR  green  (Biorad  170-8882)  was  used  for  all  PCR  reactions  with 
conventional  primers.  iQ  Supermix  (Biorad 170-8862)  was  used  for  TaqMan 
PCR reactions. 
 
In initial experiments results were verified using two independent normalising 
genes,  GAPDH  plus  either  L27,  Actin  or  EF1a.  Subsequent  repeats  were 
carried out using GAPDH only. In cultured cells, two normalising genes were 
used to ensure that drug treatments truly affected MMP9 expression and not 
the  expression  of  the  normalising  housekeeping  gene.  When  comparing 
between different limb tissues, the use of multiple normalising genes was of 
particular  importance,  as  the  level  of  expression  of  housekeeping  genes 
compared to the total messenger RNA (mRNA) in a cell cannot be assumed to 
be the same between different cell types (Vandesompele et al., 2002). 
 
RNA used for cDNA synthesis was included as a control in all experiments to 
ensure  that  signal  from  cDNA  samples  did  not  result  from  contaminating 
genomic DNA that had evaded DNAse degradation prior to cDNA synthesis. If 
RNA controls generated traces emerging at cT values within 4 cycles of cDNA, 
therefore representing 1/16  (2
4=16) of total signal, RNA was further treated 
with DNA and cDNA was re-synthesised for a repeat PCR reaction, or samples 
were discarded. 
 
2.8  Western-blotting 
 
Western-blotting  was  used  for  detecting  overexpressed  proteins  and  protein 
phosphorylation  in  cultured  cells.  Cultured  cells  were  washed  with  PBS  and 
lysed by scraping in ice-cold cell lysis buffer (see below). 35mm dishes were 
lysed in 100ul and 60mm dishes in 200ul. Lysates were incubated on ice for 30 
minutes prior to clearing debris by spinning at 5,000g for 10 minutes at 4°C. For 
analysis of EGFR phosphorylation, cells were lysed in ice-cold RIPA buffer (see 
below) with protease inhibitors (Roche 04906837001). 
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Protein  concentration  was  determined  by  bicinchoninic-acid  assay  using  a 
Dynex Technologies MRX spectrophotometer to read absorbance. Samples of 
equal  total  protein  were  prepared  by  heating  lysates  with  SDS-buffer  (see 
below) and reducing agent (Invitrogen NP0009) at 90°C for 10 minutes. 
 
Protein samples were run on appropriate NuPage Bis-Tris pre-cast SDS gels 
according to manufacturer’s instructions in MES buffer (Invitrogen NP0002) with 
antioxidant  (Invitrogen  NP0005).  12%  Gels  (NP0341BOX)  were  used  for 
analysing  Prod1  Flag  expression  and  ERK1/2  phosphorylation.  4-12%  gels 
(NP0321BOX)  were  used  for analysing  EGFR-Myc  and  β1-Integrin-Myc  pull-
down  and  3-8%  gels  (EA03755BOX)  were  used  for  analysing  EGFR 
phosphorylation. 
 
Protein  was  blotted  from  gels  onto  nitrocellulose  membrane  (1041191- 
Whatman) for 3hr at 150mA constant current immersed in transfer buffer (see 
below). Membranes were then rinsed in TBS (see below), blocked in Odyssey 
Block (Li-Cor 927-40000) for 10 minutes and incubated with primary antibody at 
4°C  overnight  in  Odyssey  Block  or  TBST  (see  below).  Unbound  primary 
antibody was removed by washing membranes three times for 10 minutes in 
TBST. Membranes were then incubated for 1hr at room temperature with infra-
red labelled secondary antibodies diluted 1:10,000 in TBST 0.005% SDS, and 
unbound secondary was removed by washing three times for ten minutes in 
TBST followed by two washes for two minutes in TBS.  
 
2.9  Zymography 
 
Zymography was used to quantify the level of matrix metalloprotease enzyme 
activity secreted by cells into culture medium. Conditioned serum-free medium 
was collected from cells, debris was pelleted at 5,000rpm for 10min at 4°C and 
SDS sample buffer was added (see above). Enzyme-containing samples were 
electrophoresed  on  pre-cast  NuPage  polyacrylamide  zymography  gels 
impregnated with either 10% gelatin (Invitrogen-EC6175BOX) or 12% caesin 
(Invitrogen  EC6405BOX)  using  NuPage  Tris-Glyceine  buffer  (Invitrogen- 
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LC2675)  for  2hr  at  125V.  After  electrophoresis,  enzymes  in  the  gels  were 
renatured (Invitrogen-LC2670) and developed overnight at room temperature in 
the presence of metal ion co-factors (Invitrogen-LC2671), allowing enzymatic 
degradation  of  the  substrate  at  positions  on  the  gel  determined  by  the 
electrophoretic  mobility  of  enzymes  present  in  the  sample.  Gels  were  then 
stained  for  3hr  using  Coomassie  Blue  Safe  Stain  (Invitrogen-LC6065)  then 
washed overnight in H20, staining the substrate protein impregnated in the gel 
uniformly and producing reverse stained bands at positions on the gel to which 
an MMP had migrated, proportional in intensity to its level of enzymatic activity. 
Gels were scanned at 700nm on a Li-Cor Odyssey scanner.  
 
2.10 Band quantitation 
 
Western-blot  membranes  and  zymogram  gels  were  imaged  using  a  Li-Cor 
Odyssey scanner and software. Scanning intensity was set at a level to produce 
a  visible  band  compared  to  background  fluorescence  whilst  avoiding  over-
exposing pixels of images.  
Band intensities were quantified using Fuji ImageGauge software. Pixel values 
were  summed  along  a  line  perpendicular  to  the  width  of  the  band  and 
background pixel intensities above and below the band were subtracted. To be 
able to compare between experiments, arbitrary relative values for each band 
were normalised against a chosen band in each experiment, the value of which 
was set at unity. 
 
2.11 Co-immunoprecipitation 
 
Protein-G  Dynabeads  (Invitrogen-10003D)  were  loaded  with mouse  anti-Flag 
antibody  as  instructed  by  manufacturer  at  a  ratio  of  5ug  antibody  per  75ul 
beads. 60mm dishes of HEK 293T cells were transfected for 7hr and split 1:2 
the following day. 48hr post transfection two 60mm dishes of HEK 293T cells 
were lysed in 200ul of ice-cold IP lysis buffer (see below) and incubated on ice 
for 30 minutes. Lysates were spun at 5,000g for 10 minutes at 4°C to pellet 
debris. 200ul volumes of cleared lysates were incubated with rotation with 75ul  
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of antibody-loaded beads for 45 minutes at 4°C after which beads were washed 
3 times with 200ul of ice-cold PBS. Captured protein was eluted from beads by 
heating 75ul beads in 15ul H2O, 15ul SDS-Sample buffer (see below) and 3ul 
Reducing  Agent  (Invitrogen  NP0009)  to  90°C  for  ten  minutes  after  which 
samples were analysed by Western-blotting.  
 
2.12 Skin patch preparation 
 
Before preparation of skin patches for culture, animals were anaesthetised in 
0.1%  tricane  (Sigma  A5040),  bathed  in  0.01%  Virkon  for  30  seconds,  then 
washed three times in sterile water. Limb skin was dissected from amputated 
limbs under a Leica MZ8 stereo microscope by removing the hand, making an 
incision along the length of the limb then peeling the skin away from the muscle. 
Patches were then plated onto type1 collagen coated plastic dishes with 200ul 
Skin  culture  medium  (70%  MEM  +  Earles  (21090  GIBCO),  30%  H20,  10% 
serum,  2mM  glutamine  (25030  GIBCO),10ug/ml  insulin  (Sigma  I-5500), 
antibiotic-antimycotic  solution  (Sigma  A5955),  50ug/ml  gentamycin.  A  further 
200ul was added the following day after attachment to the substrate. 
 
Upper epidermal layers were removed by incubating patches in 0.025% trypsin 
in 70% L15 medium (Gibco 21083), 30% H20, 2mM glutamine (25030 GIBCO) 
10ug/ml insulin (Sigma I-5500), antibiotic-antimycotic solution (Sigma A5955), 
50ug/ml  gentamycin  for  1hr,  followed  by  mechanical  separation  of  the  two 
layers under a Leica MZ8 stereo microscope. 
 
2.13 In-situ hybridisation 
 
In situ hybridisation was used to analyse the expression pattern of MMP9 in 
cells migrating from skin patches. All reagents were RNAse free and solutions 
prepared with diethylpyrocarbonate (DEPC) treated water. 
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2.13.1 Cloning region of gene for use as probe 
Probes were prepared by first cloning a region of the gene of interest from newt 
cDNA  by  performing  PCR  with  the  gene-specific  primers 
ACTACGATACAGACAGGAAG and CGTCACAGCTGGGTATAGCA. A second 
PCR  was  then  performed  on  the  initial  PCR  product  using  primers 
TGAATTCGGGCACGCCATTGGCCT  and  AGAGGAGCGTTGATTGTCCCA. 
pBluescript SK vector (Stratagene) was cut with Sma1, the fragment was blunt 
ligated  into  it  and  transformed  into  E.coli  as  described  previously.  Insert 
containing colonies were identified by blue-white selection on X-gal coated agar 
plates and PCR was performed to identify inserts of correct size. Colonies were 
then sequenced and an appropriate clone identified.  
 
2.13.2 Probe synthesis 
The vector containing the probe fragment was cut either side of the insert in 
separate  reactions  to  create  a  template  for  anti-sense  and  sense  strand 
synthesis,  and  DNA  was  purified  by  organic  phase  separation  as  described 
previously. Precipitated DNA pellet was resuspended in DEPC water for use as 
a  template  for  probe  synthesis.  Dioxigenin  (DIG)  labelled  RNA  probe  was 
synthesised for 3hr at 37°C using T3 (Stratagene 600111-51) or T7 polymerase 
(Stratagene  600123-51)  and  DIG  labelled  deoxynucleotide  triphosphates 
(dNTP’s) (Roche 1277073),  and  then  DNA was  degraded  using  RNAse  free 
DNAse (Stratagene 600031-51). DIG labelled RNA probe was then precipitated 
in  cold  ethanol,  50mM  EDTA,  80uM  LiCl,  and  0.1mg/ml  yeast  transfer  RNA 
(tRNA). The pellet was then washed in 75% ethanol, resuspended in TE and 
precipitated again in 80uM LiCl and ethanol at -30°C. The pellet was once again 
washed  in  ethanol,  dried  and  resuspended  in  TE  with  RNAse  Inhibitor 
(Invitrogen  10777-019).  The  RNA  concentration  was  determined  and  an 
appropriate volume was added to hybridisation solution (see below) to give a 
probe concentration of 1ug/ml. 
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2.13.3 Sample preparation 
Skin  patches  prepared  as  described  previously  were  cultured  for  a  defined 
period,  rinsed  with  PBS  and  then  fixed  for  15  minutes  with  fresh  4% 
paraformaldehyde (PFA). Samples were then rinsed twice with PBT, digested 
for 10 minutes at 37°C with 10ug/ml proteinase K (Roche 03115887001) and 
fixed again with 4% PFA for  5 minutes. A PBS rinse was followed by two 10 
minutes washes with 2mg/ml glycine solution, a further PBT rinse and a PBS 
rinse.  
 
2.13.4 Hybridisation 
Samples were then rinsed with hybridisation solution pre-heated to 45°C, and 
after  a  further  1hr  incubation  in  hybridisation  solution  (see  below)  at  45°C 
incubated  overnight  at  45°C  with  DIG  labelled  probe  denatured  at  80°C  for      
10 minutes then cooled to 45°C. 
 
2.13.5 Washing 
Unbound probe was washed off at 45°C for 20 minutes with wash buffer 1 (see 
below), 20 minutes with wash buffer 2 (see below) and a further 10 minutes with 
wash buffers 1 and 2 mixed in equal quantities. All buffers were pre-heated to 
45°C. 
 
2.13.6 Antibody 
Samples  were  blocked  for  40  minutes  in  blocking  solution  (Roche 
11096176001)  then  incubated  at  4°C  overnight  with  1:500  sheep  anti-DIG 
antibody (Roche 11093274910) in blocking solution. 
 
2.13.7 Colour Development 
The sample was washed 5 times for 10 minutes in 100mM Tris 150mM NaCl 
pH  7.5  to  remove  unbound  antibody,  rinsed  in  alkaline  phosphatase  (AP) 
substrate buffer (see below) and incubated with AP developing reagents BCIP 
and NBT (Promega S771) in AP buffer with 10% polyvinyl alcohol (Mw 31,000- 
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50,000) until colour was visible. The reaction was stopped by washing in 1% 
Triton PBS for 1hr, rinsing with PBS three times and then post-fixing with 4% 
PFA. Samples were then mounted in VectaMount AQ (Vector laboratories H-
5501).  
 
2.14 Immunofluorescence 
Tyramide signal amplification (TSA) used to visualise Prod1 expression on cell 
membranes was performed using the TSA-Plus Cyanine 3 System Kit (Perkin 
Elmer NEL744) according to manufacturers instructions by J. Brockes. Mouse 
α-Flag  (Sigma  F  3165)  was  used  for  the  first  layer  antibody  and  biotin-
conjugated rabbit α-mouse (Zymed 61-0140) for the second layer. 
Migrating cells were analysed for markers of epidermal and dermal character by 
A. Kumar. In all cases, 10% goat serum APBS was used to block samples prior 
to and when reacting with primary antibody. 
For keratin identification, explants were fixed with ice cold methanol/acetic acid 
(95:5) for 5 minutes, washed with PBT and reacted overnight at 4°C with 1:100 
LP34 mouse α-pan-keratin IgG (Abcam ab17153). The next day samples were 
washed with PBS and reacted for 1hr with 1:500 Cy3-conjugated goat α-mouse 
(Jackson Laboratories 115-163-03). 
For vimentin identification, explants were fixed with PFA, reacted overnight at 
4°C with 1:100 13.2 mouse IgM α-vimentin (Sigma V5255), and reacted for 1hr 
with  1:500  texas  red-conjugated  class  specific  goat  α-mouse  (Southern 
Biotechnology) the following day. 
B1H1  cells  were  reacted  in  parallel  as  a  negative  control,  and  for  both 
antibodies, no staining was observed (not shown). 
 
Longitudinal limb sections were analysed for Prod1 expression by A.Kumar.  
Whole limbs were fixed with 0.5% PFA in APBS containing 0.1% glutaraldehyde 
overnight at 4 °C. Limbs were washed in APBS, embedded in TissueTEK OCT 
compound (Sakura FineTEK 4583) and 12uM longitudinal sections were cut in 
a  Leica  CM1850  cryostat.  Air  dried  sections  were  rehydrated  in  PBS  for            
3 minutes then washed for 6 minutes in freshly prepared PBS 0.1% NaBH4 
(Sigma 21346-2) and then rinsed in PBS. Sections were reacted overnight with  
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1:200  683  affinity  purified  rabbit  α-Prod1  antibody  (custom  peptide  antibody 
produced by Eurogentec) (da Silva et al., 2002) then reacted with 1:1000 goat 
α-rabbit Alexa 488 (Invitrogen) for 1hr the following day. 
 
2.15 Microscopy  
 
2.15.1 Fluorescence microscopy 
Live cell imaging was carried out using a Carl Zeiss Axiovert 200M microscope 
and Cascade 2 camera (Photometrics). Stage movement, objective selection, 
filter  selection  and  shutters  were  controlled  automatically  via  Axiovision 
software, which was also used for image manipulation and analysis. 
Fixed samples were imaged using a Carl Zeiss Axioskop 2 microscope and a 
Hamamatsu C4742-95 camera. Image manipulation and analysis was carried 
out using Improvision Openlab software. 
 
2.15.2 Bright field microscopy 
Fixed samples were imaged using a Carl Zeiss Axiophot 2 microscope and an 
Axiocam HRc camera. Image manipulation and analysis was carried out using 
Axiovision software.  
  77 
2.16 Reagents 
 
2.16.1 Buffers 
TE 
10mM Tris, 1mM EDTA pH 8.0 
 
Cell Lysis Buffer (Western-blot) 
1% NP40,150mM NaCl, 50mM Tris HCl pH 7.5, 1mM sodium orthovanadate, 
2mM AEBSF, 1.6uM aprotinin, 40uM leupeptin, 80uM bestatin ,  
30uM pepstatin A, 28uM E-64 
  
RIPA buffer (Western-Blot) 
100mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP40, 1% NaDoc,  
0.1% SDS 
 
Sample Buffer (Western blot/ Zymography) 
100mM Tris pH 8.0, 4% SDS, 0.02% Bromophenol Blue, 20% Glycerol   
 
Western Transfer Buffer 
40mM glycine, 50mM Tris base, 0.07% SDS, 20% methanol 
TBS 
25mM Tris pH 8.0, 0.1M NaCl 
 
TBST 
2mM Tris HCl pH 8.0, 0.1M NaCl, 0.1% Tween 20 
 
IP Lysis Buffer 
1% Triton X-100, 150mM NaCl, 50mM Tris, 2mM MgCl2, 2mM EGTA, 1mM 
NaVO4, 10% glycerol, 2mM AEBSF, 1.6uM aprotinin, 40uM leupeptin,  
80uM bestatin, 30uM pepstatin A, 28uM E-64 
 
PBS 
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4 pH 7.4  
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PBT 
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.4mM KH2PO4 pH 7.4 
0.3% Triton X-100 
 
Wash Buffer 1 
50% deionised formamide, 5X SSC, 1% SDS 
 
Wash Buffer 2 
50% deionised formamide, 2X SSC, 1% SDS 
 
Hybridisation Buffer 
50%  deionised  formamide,  5X  SSC,  1mg/ml  tRNA,  0.1mg/ml  heparin,              
1x Denhardts solution, 0.2% Tween 20, 5mM EDTA 
 
Alkaline Phsophatase (AP) Buffer 
100mM Tris pH 9.5, 100mM NaCl, 50mM MgCl2, 0.1% Tween 20 
 
Post Hybridisation Wash (Tris-NaCl) Buffer 
100mM Tris pH 7.5, 150mM NaCl 
 
2.16.2  Western-blotting antibodies 
•  Mouse a-Flag, M2 monoclonal (Sigma F 3165) 
•  Rabbit a-Flag, affinity purified (Sigma F7425) 
•  Rabbit a-Myc, affinity purified (Cell-Signalling 2272) 
•  Mouse a-Myc, 9E10 monoclonal (Sigma M4493) 
•  Mouse 4G10 a-pY (gift from Ivan Gout) 
•  Rabbit a-pERK, affinity purified IgG (Upstate 07-467) 
•  Mouse a-pERK (Sigma M 9692) 
•  Rabbit a-ERK (Gift from J. Ladbury) 
•  Rabbit a-pJNK, affinity purified (Cell-Signalling 9251) 
•  Rabbit a-Y845, affinity purified (Cell-Signalling 2231) 
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2.16.3 Inhibitors 
•  AG1478 (Invitrogen PHZ1034) 
•  AG879 (Calbiochem 658460) 
•  PD153035 (Calbiochem 234490) 
•  U0126 (Calbiochem 662005) 
•  JNK Inhibitor II (Calbiochem 420119) 
•  P38 Inhibitor (Calbiochem 506126) 
•  PP2 (Calbiochem 529573) 
•  AG490 (Calbiochem 658401) 
•  GM6001 (Biomol El-300) 
•  MMP9 Inhibitor I (Calbiochem 444278) 
•  Recombinant mouse DKK-1 (R&D Systems 1765-DK) 
 
2.16.4 Primers 
2.16.4.1  RT PCR primers 
EGFR 
GATTCAGGATCAAGAATCCCA 
TCCTTAATGGCTACAGGGAT 
 
Prod1 
TTCCCTAGAATTTGGGAACG 
GGCAGCTAGTTCACGTGTTG 
TGACTGGTGTCCTCACACAACCACC Fam labelled probe 
 
GAPDH 
TGTGGCGTGACGGCAGAGGTG 
TCCAAGCGGCAGGTCAGGTCAAC 
 
Actin 
CCACTGCTGCTTCTTCATCCTCTC 
GGGCACCTGAACCGCTCATTG 
 
L27  
TACAACCACTTGATGCCA 
CAGTCTTGTATCGTTCCTCA 
 
EF1α 
TAGAGTGCAGGTGACGATCC 
AGTCACCAAGTCTGCCATCA 
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MMP9 newt 
CATCGTAGGATTCACCATCG 
ACCACGACCGACTATGACAA 
 
MMP9 axolotl 
GCATCGTAGGATTCTCCATCA 
ACCAGTGAAGGCCGTTCCGAT 
 
2.16.4.2 Site-directed mutagenesis primers  
(mismatches are marked in bold) 
 
D28A 
CACCAGAAACGGAGCCGACAGGACTGTG 
CACAGTCCTGTCGGCTCCGTTTCTGGTG 
T33A 
GGAGACGACAGGACTGTGGCCACCTGCGCCG 
CGGCGCAGGTGGCCACAGTCCTGTCGTCTCC 
E37A 
GTGACCACCTGCGCCGCGGAACAGACTCG 
CGAGTCTGTTCCGCGGCGCAGGTGGTCAC 
Y49A 
GCCTCTTCGTACAACTGCCAGCTTCTGAGATACAAGAATG 
CATTCTTGTATCTCAGAAGCTGGCAGTTGTACGAAGAGGC 
E54A 
CTGAGATACAAGCATGCAAGACGGTGCAACAGTG 
CACTGTTGCACCGTCTTGCATGCTTGTATCTCAG 
Q59A 
GAATGCAAGACGGTGGCACAGTGTGCTGAGGTGT 
ACACCTCAGCACACTGTGCCACCGTCTTGCATTC 
E66A 
GTGTGCTGAGGTGTTAGCGGAAGTCACTGCC 
GGCAGTGACTTCCGCTAACACCTCAGCACA 
Y73A 
GTCACTGCCATTGGAGCTCCAGCAAAGTGCTGCTGCG 
CGCAGCAGCACTTTGCTGGAGCTCCAATGGCAGTGAC 
K76A  
GGATATCCAGCAGCGTGCTGCTGCGAGGAT 
GATCCTCGCAGCAGCACGCTGCTGGATATCC 
C79S 
CCAGCAAAGTGCTGCAGCGAGGATCTCTGCAAC 
GTTGCAGAGATCCTCGCTGCAGCACTTTGCTGG  
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R85A 
GCTGCGAGGATCTCTGCAACGCGAGTGAGCAAG 
CTTGCTCACTCGCGTTGCAGAGATCCTCGCAGC 
 
2.16.5 Expression constructs 
2.16.5.1  A discussion of vector choice for amphibian cell expression 
constructs 
All Prod1 constructs are derived from the original Prod1 construct 70/71, which 
was  cloned  from  cDNA  (da  Silva  et  al.,  2002)  complete  with  5’  and  3’ 
untranslated region (UTR) into PCI-Neo. The entire 70/71 insert was subcloned 
into a vector driven by the cytoskeletal actin (CSKA) promoter. All other Prod1 
constructs lack the 5’ and 3’ UTR sequences of 70/71 and express only vector 
UTR.  
Both  the  70/71  and  the  CSKA  constructs  showed  only  very  weak  MMP9 
induction,  possibly  due  to  the  newt  5’  UTR,  whereas  the  N2  and  PCI-Neo 
constructs contained only vector UTR. It is unclear why this was the case but a 
number of possible explanations exist. The N2 5’ UTR sequence may be more 
favourable than that in PCI-Neo or from the Prod1 gene for promoting message 
stability or protein translation in B1H1’s. The 5’ UTR in the Prod1 gene may 
suppress its expression either constitutively or in a regulated fashion. Also, PCI-
Neo contains intronic sequence in the 5’ UTR designed to enhance the correct 
processing of mRNA’s in mammalian cells and this may perturb expression in 
newt cells, as both N2 and CSKA vectors, which do not contain an intron, were 
seen  to  drive expression  of  other  genes  to  a  significantly  higher  degree,  as 
seen by Western-blotting (J.Godwin, not shown).  
 
2.16.5.2  A discussion of the origin of constructs used 
Expression cassettes are shown below with 5’ and 3’ restriction sites used for 
cloning.  Prod1-Flag,  Prod1-Flag  ΔC-terminal  anchor,  Prod1-Flag  ΔN-terminal 
signal and Axolotl CD59-Flag were originally cloned into the PCI-Neo vector 
(Promega E1841, GenBank Acc # U47120) with N-terminal Flag tags; however 
poor expression of PCI-Neo constructs was seen in B1H1 cells and expression  
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cassettes  were  subsequently  subcloned  into  the peGFP-N2  vector  (Clontech 
6081-1,  GenBank  Acc  #U57608)  replacing  the  GFP  sequence.  As  a  non-
specific  GPI  anchored  protein  negative  control,  GPI  anchored  GFP  was 
employed (GPI GFP). The construct contains an enhanced green fluorescent 
protein  (eGFP)  with  the  C-terminal  GPI  anchor  attachment  sequence  from 
lymphocyte  function  associated  antigen  3  (LFA3)  and  the  N-terminal  signal 
peptide  of  lactase  phlorizin  hydrolase  (Keller  et  al.,  2001).  Prod1-Flag  LFA 
anchor was cloned by replacing the GFP sequence of GPI GFP with Prod1-
Flag, producing a Prod1-Flag construct with both N- and C-terminal peptides 
from  original  the  GPI  GFP  construct.  Point mutations at  Q59  and  E66  were 
generated  in  Prod1-Flag  LFA  in  order  to  express  detectable  levels  of  the 
proteins on the cell membrane. 
Fragments of newt EGFR and newt β1 integrin were both cloned from newt 
genomic DNA by P.Gates and assembled in pTL-1 vector with a C-terminal Myc 
tag. pTL-1 is a pSG5 plasmid (Stratagene 216201) with an extended polylinker. 
For technical reasons, it was not possible to subclone these constructs into the 
N2 vector. 
 
2.16.5.3  Constructs used  
 
•  Newt Prod1-Flag (WT) 
•  Newt Prod1-Flag ΔC-terminal anchor sequence (NA) 
•  Newt Prod1-Flag ΔN-terminal secretory sequence (NS) 
•  Newt Prod1-Flag LFA anchor (LFA) 
•  Axolotl Prod1-Flag (Axo) 
•  Axolotl CD59-Flag (CD59) 
•  Newt EGFR-Myc (EGFR-Myc) 
•  Newt β1 integrin-Myc   
•  GFP anchored with LFA3 GPI anchor (GPI GFP) (Keller et al., 2001) 
 
Sequences are found in the Appendix at the end of the thesis 
 
  
  83 
 
 
 
 
 
 
 
 
 
 
 
 
3  Prod1  regulates  MMP9  expression  and 
ERK1/2 activation 
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3.1  Introduction 
 
Since Prod1 is GPI-anchored (da Silva et al., 2002), and thus unable to make 
direct  contact  with  the  cytoplasm  of  the  cell  in  which  it  is  expressed,  it  is 
hypothesised that a transmembrane protein binding partner may facilitate signal 
transduction.  Prod1  exhibits  structural  similarities  with  uPAR  and  CD59  (da 
Silva et al., 2002) (Garza-Garcia et al., 2009) both of which have been shown to 
interact with the EGFR (Blagoev et al., 2003) (Mazzieri et al., 2006), prompting 
an investigation to determine whether Prod1 also interacts functionally with the 
EGFR.  uPAR  activates  the  ERK1/2  pathway  via  its  ligand-independent 
activation  of  the  EGFR  (Liu  et  al.,  2002),  however  little  is  known  of  the 
downstream effects of CD59 EGFR interaction. uPAR is also known to regulate 
the expression of MMP9 via the ERK1/2 MAPK pathway activation (Wei et al., 
2007).  
 
MMP9 is highly up-regulated in the wound epidermis in a temporally defined 
manner during early blastema formation (Satoh et al., 2007) and its expression 
is seen to be spread throughout the blastema as it grows, with MMP activity 
being essential for normal regeneration to take place (Vinarsky et al., 2005). 
The  involvement  of  Prod1  in  this  process  could  provide  a  basis  for  the 
mechanisms contributing to patterning of the limb during regeneration. It was 
hypothesised  therefore  that  Prod1  might  regulate  the  expression  of  MMP9 
through a mechanism involving the EGFR. 
 
In order to establish a suitable experimental system within which to study the 
mechanism of action of Prod1, a number of alternatives were considered. The 
types of experiments under consideration required a simple system that lent 
itself to genetic manipulation and allowed appropriate controls to be built in. 
Due to the lack of genetic tools and the complexity of working with animals, 
experiments with salamanders were ruled out at an early stage. During the time 
of this thesis a protocol was developed by A. Kumar and J. Godwin in which 
primary blastemal cells could be derived and maintained temporarily in culture 
(Kumar et al., 2007b). The availability of these cells was limited due to the time  
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required to derive them from limb blastemas and the heavy requirements they 
placed on the animal stocks, as they were not expandable in culture. Two cell 
lines, B1H1 and A1, derived from newt limb and capable of extensive passage 
and expansion were available (Ferretti and Brockes, 1988). B1H1 cells were 
favoured, as a protocol for effective transfection had been developed previously 
by J. Godwin, providing a genetically manipulatable, and fast growing model 
system.  B1H1  cells  had  been  shown  by  P.  Gates  not  to  express  Prod1  as 
assayed by RNAse protection. This indicated their potential as a suitable model 
system  within  which  to  investigate  the  hypothesised  functional  interaction 
between  Prod1  and  the  EGFR,  providing  the  opportunity  to  compare  the 
characteristics of cells in the presence and absence of Prod1 expression.  
 
3.2  Results 
 
3.2.1   Characterising Prod1 and EGFR expression in B1H1 cells 
In B1H1 cells, no Prod1 signal could be detected after 40 PCR cycles. This 
represents a level of expression at least 4.5*10
5 fold lower than that observed in 
the skin (Table 3.1) and indicates that Prod1 is not expressed in B1H1’s, thus 
confirming previous observations. 
 
In  view  of  the  potential  interest  in  the  newt  EGFR  for  the  study  of  the 
mechanism of action of Prod1, this cDNA was cloned by P. Gates. Sequence 
alignment showed it to be the newt ortholog of ErbB1, the stereotypical EGFR 
(Fig. 3.1). Alignment with mouse and human ErbB1 is shown in Supplementary 
Figure 1. Expression of EGFR mRNA in B1H1 cells was confirmed by qRT-PCR 
(Fig.  3.2)  and  their  ability  to  respond  to  EGF  was  demonstrated  in  order  to 
confirm  the  expression  of  the  EGFR  protein  on  the  cell  surface.  A  well-
established  down-stream  target  of  EGFR  signalling  is  the  ERK1/2  MAPK 
(Jorissen  et  al.,  2003).  ERK1/2  phosphorylation  was  analysed  by  Western-
blotting the proteins extracted from B1H1 cells incubated in the presence and 
absence of recombinant human EGF with phospho-ERK1/2 specific antibodies. 
Serum-starvation conditions were optimised and it was found that a 24hr  
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  B1H1 
cT 
Skin 
cT 
Relative difference 
Expression  Skin  vs. 
B1H1 
Prod1  >40  24.2  >5.7*10
4 
GAPDH  15.76  18.73  0.13 
Normalised  relative  difference 
Prod1 expression Skin vs. B1H1 
    >4.5*10
5 
Table 3.1 Prod1 expression in B1H1 Cells  
cT values of a representative qRT-PCR analysis of cDNA prepared from B1H1 cells 
and newt limb skin. Comparison of cT values allows the determination of the relative 
difference  between  the  number  of  target  sequences  in  two  samples,  and  can  be 
normalised to the level of expression of a housekeeping gene. The relative difference 
in expression of Prod1 between skin and B1H1 cells is normalised to GAPDH in this 
example.  For  details  of  cDNA  synthesis,  qRT-PCR  and  quantitation  of  relative 
differences in gene expression from cT values, see Material and Methods. 
 
 
Figure  3.1  Comparison  of  human  and  newt  epidermal  growth  factor 
receptors 
Schematic representations of the human and newt EGFRs based upon alignment of 
amino-acid sequences. Selected phosphorylation sites and boundaries of domains are 
shown for comparison, indicating a high degree of similarity between the two proteins, 
with  no  major  insertions  or  deletions.  For  detailed  comparison  of  sequences  see 
Supplementary Figure 1.  
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Figure 3.2 EGFR expression in B1H1 cells 
qRT PCR traces of EGFR and GAPDH signal in cDNA and RNA prepared from B1H1 
cells.  Traces  for  cDNA  are  the  average  of  three  samples  with  bars  showing  the 
standard  deviation.  Traces  for  RNA  are  single  samples,  shown  without  bars.  The 
fluorescence signal for cDNA traces can be seen above the background signal of the 
RNA  control,  demonstrating  the  expression  of  EGFR  and  GAPDH  mRNA  in  B1H1 
cells. Note that the GAPDH fluorescence signal increases exponentially significantly 
earlier than the EGFR signal, suggesting that GAPDH expression is higher in B1H1 
cells, however direct comparisons between signals from different primer pairs cannot 
be made. For an explanation of qRT-PCR data output, see Materials and Methods. 
 
starvation period gave the largest and most reproducible EGF response in EGF 
treated cells compared to untreated controls (Fig. 3.3a.). The ERK1/2 response 
to EGF was seen to be dose-dependent and the optimal concentration of EGF 
was determined (Fig. 3.3b). The ability to respond to EGF confirmed not only 
the presence of the EGFR on the surface of B1H1 cells but also demonstrated 
that  the  EGFR/  ERK1/2  pathway  in  newt  cells  is  similar  to  the  well-
characterised mammalian pathway. 
   
  88 
Commercial  antibodies  generally  give  little  indication  of  whether  they  will  be 
cross-reactive  with  salamander  proteins,  and  as  little  genomic  information  is 
available for N.viridescens in order to make comparisons with the antigen to 
which antibodies were raised, antibodies require validation experimentally. The 
ability  to  detect  ERK1/2  phosphorylation  in  response  to  EGF  validated  the 
phospho-ERK1/2 antibodies used. An attempt to detect the phosphorylation of 
the EGFR in response to EGF using an anti-phosphotyrosine was unsuccessful 
in B1H1 cells, (Fig. 3.3c.) compared to in high EGFR expressing A431 human 
tumour cells, where a good response was seen. 
 
3.2.2  Investigating the effect of Prod1 expression on MMP9 secretion 
Having  established  a  suitable  system  in  which  the  EGFR  is  expressed  and 
Prod1 is not, investigation of the effects of Prod1 expression and its relationship 
to the EGFR could begin. As the Prod1 antibody used in the laboratory was in 
limited supply, and it was anticipated that large amounts of antibody would be 
used over the course of the project, all experiments were carried out using Flag-
tagged  Prod1  constructs  in  order  to  allow  their  immuno-detection  using 
commercially available anti-Flag antibodies. GPI anchored GFP (GPI GFP) was 
used  as  a  general  non-specific  GPI  anchored  protein  control  throughout  the 
experiments  in  order  to  control  both  for  effects  of  transfection  and 
overexpression of a GPI anchored molecule.  
 
The ability of Prod1 to regulate the expression of MMP9 was investigated by 
analysing culture medium from Prod1 and GPI GFP expressing B1H1 cells by 
gelatin zymography, a standard method of analysing MMP enzyme activity (see 
Materials and Methods for a detailed description of the technique). The linearity 
and range of detection of gelatin zymograms was first established by running a 
dilution  series  of  conditioned  medium  collected  from  B1H1  cells  (Fig.  3.4) 
demonstrating their linearity and ability to detect small differences in enzyme 
activity.  
 
The requirement for serum in culture medium was investigated, as experiments 
would  ideally  be  conducted  under  serum-free  conditions  in  order  to  simplify 
interpretation of results. Analysis of conditioned medium by gelatin zymography    
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Figure 3.3 EGF response of B1H1 cells  
(A)  B1H1  cells  were  serum  starved  for  the  indicated  duration  and  stimulated  with 
50ng/ml  EGF  or  (B)  serum  starved  for  24hr  and  stimulated  with  the  indicated 
concentration of EGF for 20min. Cell lysates were Western-blotted using anti phospho-
ERK1/2  antibody.  (C)  B1H1  cells  were  serum  starved  for  24hr  and  stimulated  with 
200ng/ml EGF for 5min. A431 cells were serum starved for 8hr and stimulated with 
100ng/ml  EGF  for  5min.  Cell  lysates  were  Western-blotted  with  an  anti- 
phosphotyrosine antibody. Note increased phosphorylation of the 170kD EGFR in EGF 
stimulated A431 cells. Note that despite activating ERK1/2 phosphorylation, no EGFR 
phosphorylation was detectable in response to EGF in B1H1 cells. ERK1/2 response to 
EGF was observed to diminish after extended starvation periods.   
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Figure 3.4 Establishing the linearity of gelatin zymography 
(A) Cell-culture medium was collected from B1H1 cells and a range of dilutions was run 
on a gelatin zymogram. (B) Band intensity was quantitated as detailed in Materials and 
Methods,  and  plotted  as  a  function  of  the  dilution  factor,  revealing  a  good  linear 
relationship between the actual level of gelatinase activity in a sample and the level of 
gelatinase activity as determined by zymography. 
 
revealed that expression of Prod1 led to an increased gelatinase activity in cell 
culture medium (Fig. 3.5) both in presence and absence of serum. Inclusion of 
serum appeared to raise both the level of MMP9 secretion in GPI GFP and 
Prod1 expressing cells.  
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A  number  of  considerations  were  taken  into  account  in  light  of  the  known 
functions of MMP9 and the uPAR paradigm. uPAR regulates the expression of 
MMP9 in response to RGD motifs through interplay with the fibronectin receptor 
α5β1 integrin (Wei et al., 2007), and as MMP9 is involved in re-modelling the 
ECM,  preliminary  investigations  were  mindful  of  the  possibility  that  any 
mechanism involving MMP9 regulation by Prod1 may also involve extracellular 
matrix  (ECM)  proteins.  Standard  culture  conditions  for  B1H1  cells  involve 
growth  on  gelatin  also  raising  the  question  of  whether  the  experimental 
conditions  should  include  such  substrates.  It  was  observed  that  Prod1 
expressing cells cultured in the absence of substrate exhibited the same pattern 
of enhanced gelatinase secretion compared to the GPI GFP control as when 
cultured  on  gelatin  (Fig.  3.5a)  or  fibronectin  (Fig.  3.5b),  though  a  mild 
enhancement in MMP9 secretion in both Prod1 and GPI GFP expressing cells 
was observed when cells were cultured on these ECM substrates. In light of the 
lack of requirement for either serum or ECM substrate, neither was included in 
future experiments in favour of simplifying experimental conditions and aiding 
ease of interpretation.  
 
Culture medium was analysed on gelatin and casein gels so as to identify the 
gelatinase  activity  increasing  in  response  to  Prod1  expression.  The 
approximately  80Kd  molecular  weight  in  combination  with  an  inability  to 
degrade  casein  indicated  it  to  be  newt  MMP9  based  upon  previous 
characterisation (Vinarsky et al., 2005) (Fig. 3.6a). Gelatinase activity was also 
inhibited by the broad-spectrum MMP inhibitor GM6001 and an MMP9 specific 
inhibitor (Fig.3.6b), indicating it genuinely to be MMP9.  
 
MMP9 was also seen to be secreted by cultured blastema cells along with a 
second  unidentified  MMP  of  roughly  55Kd able  to  degrade  both  gelatin  and 
casein  (Fig.  3.6c).  This  55Kd  enzyme  was  also  observed  in  B1H1  cell 
conditioned medium (Fig. 3.5a, marked *), however its activity was not seen to 
increase  in  response  to  Prod1  expression,  indicating  the  effect  of  Prod1 
expression is acting through a pathway specific to MMP9 and not a result of a 
non-specific up-regulation of MMPs or secreted proteins in general. 
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Figure  3.5  Gelatinase 
regulation by Prod1  
The  effect  of  culturing 
B1H1  cells  expressing 
Prod1  or  GPI  GFP  on 
gelatin  (A)  and  fibronectin 
(B) compared to culture on 
plastic was assessed in the 
presence  and  absence  of 
serum.  Cells  were  serum 
starved  for  24hr  then 
culture  medium  was 
replaced  for  either  serum 
free  or  serum-containing 
medium.  Culture  medium 
was collected after 48hr of 
conditioning  and  analysed 
by  gelatin  zymography  as 
described in  Materials and 
Methods.  Note  that 
gelatinase  activity  was 
upregulated  by  Prod1 
expression  in  the  absence 
of  serum,  gelatin  or 
fibronectin,  and  that 
fibronectin  and  gelatin 
increase  the  level  of 
gelatinase  expression  in 
control  GPI  GFP 
expressing cells and Prod1 
expressing cells in both the 
presence  and  absence  of 
serum. 
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Figure 3.6 Characterisation of the gelatinase regulated by Prod1 
(A) Culture medium from B1H1 cells expressing Prod1 was analysed by gelatin and 
casein zymography. A faint band is marked *, however the secretion of this enzyme is 
not regulated by Prod1 expression. (B) Equal volumes of culture medium from B1H1 
cells expressing Prod1 were run on a gelatin zymogram and developed in the presence 
of either  DMSO vehicle,  MMP inhibitor  GM6001 or an  MMP9 specific inhibitor.  The 
gelatinase activity is seen to be sensitive to both inhibitors. (C) Culture medium from 
cultured blastema cells was analysed by gelatin and casein zymography, revealing the 
expression of two distinct enzymes, one of which degrades both substrates. 
 
3.2.3  The effect of Prod1 expression on MMP9 transcription 
In  order  to  determine  if  the  increase  in  extracellular  MMP9  activity  brought 
about  by  Prod1  expression  was  a  consequence  of  increased  MMP9  gene 
expression, cDNA was prepared from cultured cells and analysed by qRT-PCR 
as detailed in Materials and Methods. Prod1 constructs cloned into a variety of 
vectors were tested in order to compare MMP9 gene induction relative to the 
GPI GFP control (Fig. 3.7a). Construct N2 gave a level of MMP9 gene induction 
at least 6 times greater than any of the other constructs, and was adopted for 
use in all further experiments. For further discussion of constructs see Materials 
and Methods. The effect of the Flag-tag expressed at the N-terminal of Prod1  
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constructs on MMP9 gene induction was investigated by comparison of Flag-
tagged N2 Prod1 to a construct derived from it lacking the tag, showing it to 
have  no  detectable  effect  on  the  process  and  validating  its  use  in  future 
experiments (Fig. 3.7b).  
 
 
Figure 3.7 MMP9 gene regulation by Prod1 
B1H1 cells were transfected with (A) Prod1 constructs N2, PCI, CSKA and 70/71, and 
GPI GFP, and (B) Prod1+Flag tag (WT), Prod1 -Flag tag (-Flag) and GPI GFP. cDNA 
was prepared from transfected cells after 72hrs serum starvation and expression of 
MMP9  was  analysed  by  qRT-PCR.  MMP9  expression  in  individual  experiments  is 
relative to N2 and WT in (A) and (B) respectively. Values for relative MMP9 expression 
are normalised to GAPDH in all experiments. Note that Prod1 was most able to induce 
MMP9 expression when itself expressed from the N2 vector, and that the Flag tag did 
not affect this activity. 
 
Having determined that Prod1 expression in B1H1 cells results in an increase in 
both MMP9 secretion and transcription when compared to a non-specific GPI 
anchored protein, more rigorous controls were introduced. The hypothesis was 
that Prod1 would be bringing about this effect through its expression on the cell 
membrane,  and  to  test  this  Prod1  constructs  unable  to  localise  to  the  cell 
surface membrane were employed. Prod1 is synthesised as a polypeptide with 
both N- and C- terminal peptides that are cleaved post-translationally (da Silva 
et  al.,  2002),  the  N-terminal  peptide  being  a  hydrophobic  sequence  which 
targets proteins into the secretory pathway (Rapoport, 1992) and the C-terminal  
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peptide being a recognition sequence for GPI-anchor attachment (Eisenhaber 
et al., 1998). The lack of a C-terminal sequence would be expected to produce 
a protein that entered the secretory pathway and was secreted because of the 
absence of a GPI anchor, whilst the lack of an N-terminal peptide would prevent 
a  protein  from  entering  the  secretory  pathway  resulting  in  its  accumulation 
within cells. Expression of these two constructs resulted in enzyme secretion 
(Fig. 3.8a,b) and gene expression (Fig. 3.8c) equal to that seen for the non-
specific GPI anchored protein control, consistent with a requirement that Prod1 
must indeed be expressed at the cell membrane in order to regulate MMP9 
expression.  Expression  of  Prod1-Flag  and Prod1-Flag  lacking  the  C-terminal 
anchor attachment sequence was shown by Western-blotting samples of cell 
lysate  and  conditioned  medium  (Fig.  3.8d),  and  cell-surface  expression  of 
Prod1-Flag  was  confirmed  by  immunofluorescence  (Fig.  3.8e).  A  significant 
proportion of expressed Prod1-Flag was observed in conditioned medium, with 
a  higher  molecular  weight  than  that  seen  in  cell  lysates.  This  may  be  an 
unanchored species retaining the C-terminal anchor attachment sequence. The 
higher apparent molecular weight of Prod1-Flag in cell lysates compared to the 
construct  lacking  a  C-terminal  anchor  sequence  is  taken  to  be  due  to  a 
retardation of mobility resulting from the attachment of a GPI anchor.  
 
3.2.4  The effect of Prod1 expression on ERK1/2 activation 
As  demonstrated,  ERK1/2  MAPK  is  a  downstream  effector  of  newt  EGFR 
(nEGFR), and due to the lack of availability of an antibody to directly detect 
activated  nEGFR,  the  effect  of  Prod1  expression  on  ERK1/2  activation  was 
investigated. uPAR is known to regulate MMP9 expression via ERK1/2 (Wei et 
al., 2007) and it was shown that expression of Prod1 on the cell surface of 
B1H1  cells  raised  the  level  of  ERK1/2  phosphorylation  when  compared  to 
control constructs in serum starved cells. The largest and most reproducible 
ERK1/2  response  to  Prod1 expression  compared  to  controls  was  seen  after 
starvation for 24hrs (Fig. 3.9). 
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Figure 3.8 Requirement of membrane localisation of Prod1 for MMP9 
induction 
B1H1 cells were transfected with Prod1 (WT), Prod1 ΔN-terminal signal peptide (NS), 
Prod1  ΔC-terminal  anchor  attachment  peptide  (NA)  and  GPI  anchored  GFP  (GPI). 
Cells  were  serum  starved  for  72hr  and  MMP9  activity  in  conditioned  medium  was 
assayed by zymography (A). Secreted MMP9 enzyme activity was quantitated relative 
to Prod1 in 6 independent experiments. Bars represent SEM (B). Cells were serum 
starved for 72hr and MMP9 gene expression was quantitated relative to Prod1 by qRT-
PCR.  MMP9  expression  is  normalised  to  GAPDH  and  bars  represent  SEM  (C). 
Expression of Prod1 and Prod1 ΔC-terminal anchor attachment peptide in cell lysate 
relative  to  cell  culture  medium  was  analysed  by  Western-blotting  with  anti-Flag 
antibodies  (D).  Expression  of  Prod1-Flag  on  the  membrane  of  B1H1  cells  was 
confirmed by immunofluorescence (E). 
Note that MMP9 secretion and gene induction occurred only when Prod1 was localised 
to the cell membrane by a GPI anchor.   
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Figure 3.9 Prod1 activation of ERK1/2  
B1H1 cells were transfected with Prod1 (WT) Prod1 ΔN-terminal signal peptide (NS), 
Prod1  ΔC-terminal  anchor  attachment  peptide  (NA)  and  GPI  anchored  GFP  (GPI). 
Cells  were  serum  starved  for  the  indicated  duration  and  cell  lysates  were  western 
blotted  with  anti  phospho-ERK1/2  antibodies.  Note  that  ERK1/2  activation  occurred 
only when Prod1 was localised to the cell membrane by a GPI anchor and that ERK1/2 
background was seen to rise in controls after extended serum starvation. 
 
3.3  Discussion  
 
3.3.1  Implications of ERK1/2 activation 
The  observation  that  Prod1  expression  on  the  cell  membrane  both  induces 
MMP9  gene  expression  and  activates  ERK1/2  MAPK  invites  further 
investigation  of  whether  a  link  exists  between  the  two  in  light  of  the  known 
requirement for ERK1/2 signalling in the regulation of MMP9 by uPAR (Wei et 
al., 2007). Activation of the ERK1/2 pathway is a pre-requisite of a number of 
cellular  effects  originating  from  uPAR  signalling  including  cell  migration  and 
proliferation (Pulukuri et al., 2005) (Jo et al., 2003) (Aguirre-Ghiso et al., 2001)  
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(Jo et al., 2005) (Liu et al., 2002) (Tarui et al., 2003) (Wei et al., 2007) and 
given  that  ERK1/2  regulates  the  activity  of  a  variety  of  transcription  factors 
(Pearson et al., 2001) it is highly probable that Prod1 regulates a variety of 
other target genes and processes.  
 
3.3.2  MMP9 induction in the absence of extracellular matrix proteins 
The lack of a requirement for serum raises the possibility that the mechanism 
by  which  Prod1  regulates  the  expression  of  MMP9  may  be  EGFR  ligand 
independent,  and  this  is  in  agreement  with  the  known  mechanism  of  uPAR 
activation of EGFR signalling (Liu et al., 2002). It was observed when optimising 
conditions for detecting differences in ERK1/2 phosphorylation in response to 
both  Prod1  and  EGF  however  that  shorter  incubation  periods  in  serum-free 
medium  generally  saw  lower  background  ERK1/2  phosphorylation.  This 
indicated  that  after  an  initial  decrease,  phosphorylation  levels  rose  again, 
pointing  to  either  a  cellular  response  to  prolonged  serum  starvation  or  the 
accumulation of growth factors in culture medium over time. 
 
Fibronectin  and  gelatin  are  not  required  for  Prod1  to  induce  MMP9  gene 
expression, and although this does not rule out the involvement of integrins in 
the mechanism, it is in contrast to some previous observations with uPAR (Wei 
et al., 2007) (Liu et al., 2002) (Madsen and Sidenius, 2008), which co-operates 
in  processes  requiring  the  binding  of  ECM  proteins  to  integrins  in  order  to 
regulate  downstream  signalling.  uPAR,  integrins  and  the  EGFR  have  been 
shown to form a dynamic complex (Mazzieri et al., 2006), and the EGFR has 
been  shown  to  transduce  uPAR  dependent  signals  originating  from  α5β1 
integrin  binding  to  fibronectin  (Liu  et  al.,  2002).  It  cannot  be  ruled  out  that 
integrins  may  still  be  being  activated  by  binding  to  motifs  on  the  coating  of 
culture dishes or ECM substrate laid down by the cells themselves, however. A 
mild enhancement in MMP9 secretion was observed both in control and Prod1 
transfected cells plated on either gelatin or fibronectin. Cells plated on these 
substrates  have  a  more  ‘spread’  morphology  compared  to  those  plated  on 
plastic  (not  shown),  and  as  B1H1  cells  do  express  MMP9  even  in  control 
transfected  cells,  this  enhancement  in  MMP9  secretion  may  simply  reflect  a  
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more general effect of cells being healthier, or exhibiting a general increase in 
gene  expression  or  protein  secretion.  As  this  effect  was  observed  not  to be 
specific  to  Prod1  expressing  cells  however,  it  was  not  investigated  further. 
Similarly,  the  general  increase  in  MMP9  secretion  seen  in  the  presence  of 
serum may be due to a general increase in protein synthesis or secretion. This 
was investigated further in Chapter 4 when addressing the role of the EGFR 
and its ligand dependence in the process of MMP9 gene regulation.   
 
3.3.3  MMP9 in the blastema 
Why would Prod1 be involved in regulating MMP9 expression and how does 
this relate to proximodistal patterning in the regenerating limb? These questions 
are not easy to address other than at a superficial level. MMPs are known to be 
involved in tissue re-modelling (Page-McCaw, 2008) and cell-migration during 
metastasis (Liotta et al., 1980) and wound healing (Pilcher et al., 1997), both 
specific processes inevitably contributing to the broader process of ‘patterning’. 
Whether  MMP9  is  more  highly  expressed  in  proximal  blastemas  than  distal 
blastemas  may  shed  some  light  on  this  question.  Perhaps  higher  MMP9 
expression  in  proximal  blastemas  produces  a  more  plastic  environment  to 
facilitate  the  regeneration  of  a  greater  amount  of  tissue.  Over-expression  of 
Prod1 in cells of distal blastemas re-specifies them to more proximal identities 
in the regenerate (Echeverri and Tanaka, 2005) raising the possibility that cell 
migration within the early blastema may be playing a role in the mechanism by 
which Prod1 directs patterning during limb regeneration. 
 
It was observed that cultured blastema cells express two MMP’s, MMP9 and 
another  unidentified  enzyme.  B1H1  cells  also  express  a  low  level  of  this 
enzyme, however Prod1 expression and the other experimental manipulations 
employed such as serum addition and culture on fibronectin and gelatin showed 
no effect on its expression. Although a number of MMP’s are expressed in the 
blastema (Vinarsky et al., 2005), the specific regulation of MMP9 by Prod1 may 
point to it having a role in regeneration associated with the mechanism through 
which  Prod1  directs  patterning  rather  than  a  more  gross  matrix  degrading 
function.   
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The fact that MMP9 is first induced in the migrating cells of the forming wound-
epidermis  and  that  expression  persists  past  the  time-point  observed  in  cells 
contributing to wound healing (Satoh et al., 2008) points to a role for it in the 
establishment of the different properties of wound epidermis compared to skin. 
Also,  the  dermis  is  known  to  posses properties  instructive  to  limb-patterning 
during regeneration (Namenwirth, 1974).These cells migrate into the blastema 
as it progresses through the regenerative process (Gardiner et al., 1986), and 
MMP9 may play a role in the regulation of this. 
 
3.3.4  Quantitative real time PCR for the analysis of the MMP9 regulatory 
pathway 
Compared  to  qRT-PCR,  zymography  is  a  less  quantitative  and  less  robust 
assay. MMP9 upregulation in response to Prod1 expression was an order of 
magnitude higher when assayed at the level of gene expression compared to 
secreted  enzyme  activity.  This  may  accurately  reflect  the  situation,  or  result 
from the experimental protocol employed to assay gelatinase activity. However, 
zymograms  were  not  overloaded  with  gelatinase  when  assaying  activity  in 
culture medium and showed good linearity, indicating that accurate detection 
and quantitation were not a limitation. It seems unlikely that the small difference 
in secreted enzyme activity between Prod1 and control expressing cells when 
compared to gene expression is due to MMP9 degradation or clearing from the 
medium as this would have to occur preferentially in Prod1 expressing cells, 
otherwise such an effect would affect absolute levels rather than the relative 
difference  in  levels.  It  was  observed  that  Prod1  expression  inhibited  the 
secretion  of  alkaline  phosphatase  (not  shown)  raising  the  possibility  that 
although Prod1 expression induces MMP9 gene expression, it somehow also 
inhibits its secretion by some general effect under the experimental conditions 
employed. Whatever the reason for the discrepancy between gene expression 
and  enzyme  secretion,  assaying  MMP9  by  qRT-PCR  was  shown  to  be 
significantly more sensitive to the effect of Prod1 expression, making it more 
suitable  for  further  analysis  of  the  specific  mechanism  through  which  Prod1 
acts. Once initial experiments with zymography had defined the presence of 
serum or ECM substrate as unnecessary in order to observe Prod1 stimulated  
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MMP9 secretion, as assaying in their absence was desirable in order to ease 
interpretation,  these  conditions  were  adopted  for  further,  more  accurate 
measurement  with  qRT-PCR,  which  confirmed  the  lack  of  a  requirement  for 
either. 
 
It has not been ruled out at this point that Prod1 regulates the processes of 
MMP9 gene expression and secretion through independent mechanisms. The 
possibility exists that despite the upregulation of MMP9 mRNA expression, no 
increase in MMP9 secretion directly results from this, instead being contingent 
on  a  second  mechanism  controlling  its  release.  Evidence  presented  in    
Chapter 4 makes this unlikely however.  
 
3.3.5  Issues of detection 
Overexpression  of  Prod1  in  B1H1  cells  by  transfection  results  in  a  level  of 
expression  in  cell  lysates  at  the  limit  of  detection  by  the  Western-blotting 
protocol  used.  Care  was  taken  to  guard  against  proteolysis  in  cell  lysates, 
however this has not been definitively ruled-out as the cause of the low signal. 
The transfection efficiency consistently averaged ~40% as indicated by nuclear 
GFP  (nGFP)  co-transfection  across  experiments  (not  shown),  a  level  not 
expected to give such low levels of protein expression in cell lysates. It was also 
observed that other salamander proteins, for example a transglutaminase-like 
protein  and  tissue  factor,  were  more  readily  detectable  by  Western-blotting 
when  expressed  in  B1H1  cells  by  lipofection  (not  shown).  In  order  to 
demonstrate by Western-blotting the expression of the Prod1 constructs used 
throughout the experiments described, electroporation with Anaxa nucleofector 
was  used  to  overexpress  transgenes,  as  the  technique  achieves  a  higher 
transfection efficiency and more reproducible detection, however this protocol 
was  only  established after  functional  data  had  been  collected.  Nucleofection 
delivers  vector  DNA  straight  to  the  nucleus  unlike  Lipofection,  which  simply 
allows  it  to  cross the  plasma  membrane. The  enhanced  reproducibility  seen 
with  nucleofection  may  therefore  reflect  a  difference  in  the  rate  or  level  of 
delivery of vector DNA to the nucleus.  
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Prod1 was detectable at the cell surface by immunofluorescence in a far higher 
proportion of transfected cells when engineered to contain the more active C-
terminal GPI anchor sequence from LFA-3 (not shown). The presumption is that 
the native Prod1 anchor sequence is only inefficiently recognised by the GPI 
anchor attachment machinery hence the GPI anchored protein is expressed at 
a  relatively  low  level  on  the  cell  surface.  It  was  observed  that  a  significant 
proportion of Prod1 with the native anchor attachment sequence was found in 
cell  culture  with  a  higher  molecular  weight  than  that  found  in  cell  lysates, 
possibly  representing  unanchored  protein  with  the  C-terminal  peptide  un-
cleaved. Conversely, Prod1 with the LFA3 anchor attachment sequence was 
not seen in culture medium (not shown). Perhaps the inefficient GPI anchor 
attachment  sequence  represents  a  form  of  regulation  involved  in  ensuring 
appropriate levels of Prod1 are expressed at the cell membrane. 
 
Despite the inability to readily detect the wild-type Prod1 protein by Western-
blotting or immunofluorescence under the experimental conditions used in the 
assays described, expression of wild-type Prod1 in B1H1 cells consistently led 
to  ERK1/2  pathway  activation  and MMP9  gene  induction  when  compared  to 
constructs of Prod1 rendered unable to be expressed on the cell membrane, 
inviting speculation that the molecule is highly biologically active and requires 
relatively low levels of cell-surface expression to bring about ERK1/2 pathway 
activation and MMP9 gene induction. 
 
As shown by their ERK1/2 response to EGF, B1H1 cells do express the EGFR. 
The ERK1/2 response is not particularly great, however B1H1 cells do exhibit a 
level of ERK1/2 background under the starvation conditions used which may 
make  it  difficult  to  detect  an  EGF  response  over  background.  This  will  be 
discussed further in Chapter 4. The possibility exists that nEGFR has a low 
affinity  to  human  recombinant  EGF  (hrEGF),  however  even  at  high 
concentrations of hrEGF the ERK1/2 response is still not large. The fact that a 
phosphotyrosine  antibody  could  not  detect  phosphorylation  of  the  EGFR  in 
response to EGF is perhaps the most telling point, as the EGFR was clearly 
being activated, revealed by ERK1/2 phosphorylation in response to EGF. The 
phosphotyrosine  epitope  recognised  by  the  antibody  cannot  exhibit  species  
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specificity as phosphorylated tyrosine residues are identical in all proteins and 
therefore the inability to detect it is likely to reflect a particularly low level of 
EGFR compared to other species. qRT-PCR of B1H1 cells also indicates a low 
level  of  EGFR  transcript  due  to  signal  emerging  at  a  relatively  high  cycle 
number  compared  to  other  genes,  however  as  no  absolute  quantitation  of 
transcript number was carried out it cannot be ruled out that this is due to a 
function of the annealing properties of the primers. 
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3.3.5.1  Supplementary Figure 1: Alignment of newt EGFR with human and 
mouse ErbB1  
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The newt EGFR protein sequence was first aligned against all non-redundant protein 
sequences at http://blast.ncbi.nlm.nih.gov/Blast.cgi. The top hit was ErbB1. Newt 
EGFR protein sequence was then aligned against human and mouse ErbB1 protein 
sequences using MacVector software. 
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4  Investigating  the  mechanism  of  Prod1 
signalling  
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4.1  Introduction 
 
In similarity to uPAR, Prod1 was shown in Chapter 3 to both activate signalling 
leading  to  ERK1/2  activation  and  induce  the  expression  of  MMP9.  The 
structurally similar proteins CD59 and uPAR (Garza-Garcia et al., 2009) have 
been  shown  to  interact  physically  with  the  EGFR  (Blagoev  et  al.,  2003) 
(Mazzieri  et  al.,  2006).  uPAR  has  also  been  shown  to  activate  ERK1/2 
signalling through it’s interaction with the EGFR in a ligand-independent manner 
(Liu et al., 2002). These similarities prompted investigation of whether Prod1 
also signals via the EGFR and ERK1/2 in order to induce MMP9 expression, 
and  whether  it  does  so  by physical  interaction  with  the  EGFR  leading  to  its 
ligand-independent  activation.  In  addition  to  its  interaction  with  the  EGFR, 
activation of downstream signalling by uPAR has been shown to be mediated 
by its interaction with β1 containing integrins (Ghosh et al., 2006) (Wei et al., 
2001) (Wei et al., 2007). β1 integrin was identified in a yeast-two-hybrid screen 
as  interacting  physically  with  Prod1  (P.  Gates,  unpublished),  prompting 
investigation of its possible physical interaction with Prod1 and participation in 
the mechanism leading to MMP9 induction. 
 
qRT-PCR  analysis  of  MMP9  induction  in  response  to  Prod1  expression 
provides a highly quantitative assay suitable for further characterisation of the 
specifics  of  the  molecular  mechanism  through  which  it  acts.  Considerable 
attention has been paid to the development of inhibitors for specific components 
of cellular signalling pathways, in particular those known to be involved in the 
oncogenic processes, which serve as targets for chemotherapy. These small 
molecules are in general analogues of ATP engineered to show a high degree 
of  specificity  for  the  ATP  binding  site  of  their  target,  thereby  acting  as 
competitive inhibitors at the active site of the kinase. Small molecule kinase 
inhibitors were employed to further investigate the mechanism through which 
Prod1 signals to induce MMP9 expression. Whether a link exists between the 
observed ERK1/2 activation and MMP9 induction was investigated through use 
of an ERK1/2 inhibitor. The roles of a number of other down-stream effectors of 
EGFR  signalling  were  also  investigated  using  specific  kinase  inhibitors  to  
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further characterise the intracellular signalling pathways through which Prod1 
acts. As inappropriate EGFR activity is known to be associated with a variety of 
cancers,  a  number  of  inhibitors  against  its  activity  have  been  developed.  In 
particular, inhibitors specific to ErbB1 or ErbB2 exist (Levitzki and Gazit, 1995), 
allowing investigation of the involvement of both isoforms in the mechanism of 
Prod1 signalling. 
 
The most notable similarity between the structure of Prod1 and the two most 
structurally similar members of the three-fingered family of proteins, uPAR and 
CD59, is that all three have an α-helical third finger. The role of this and other 
regions of the structure of Prod1 in the activation of ERK1/2, induction of MMP9 
and interaction with the EGFR were investigated in order to better understand 
the functional relationship between these structures, as well as to gain further 
insight  into  the  molecular  mechanism  through  which  Prod1  regulates  MMP9 
expression. 
 
4.2  Results 
 
4.2.1  Prod1 signalling pathway analysis 
In  order  to  investigate  the  role  of  the  EGFR  in  Prod1  activation  of  ERK1/2 
signalling,  the  EGFR  inhibitor  AG1478  was  employed.  The  minimum 
concentration of AG1478 required to completely inhibit EGF stimulated ERK1/2 
activation  was  first  established.  Cells  were  treated  with  increasing 
concentrations  of  AG1478  and  it  was  found  that  25uM  was  sufficient  to 
completely inhibit ERK1/2 phosphorylation in response to EGF (Fig. 4.1). Cells 
treated  with  AG1478  showed  inhibited  ERK1/2  phosphorylation  compared  to 
untreated starved cells indicating a background level of EGFR signalling occurs 
in B1H1 cells in the absence of serum. 
 
Prod1  and  GPI  GFP  expressing  cells  were  treated  with  AG1478  and  the 
ERK1/2 inhibitor U0126. U0126 completely inhibited ERK1/2 phosphorylation in 
Prod1 and GPI GFP expressing cell as expected, and inhibition of EGFR also 
inhibited ERK1/2 phosphorylation in both Prod1 and GPI GFP expressing cells 
(Fig. 4.2a). The subtraction of the pERK1/2 background levels seen in control  
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GPI GFP transfected cells from those in Prod1 expressing cells revealed the 
decreased  ERK1/2  phosphorylation  resulting  from  inhibition of  EGFR  was  of 
greater  magnitude  in  Prod1  expressing  cells  (Fig  4.2.b).  This  indicated  that 
there was a component of ERK1/2 activated by EGFR signalling above the level 
of background in these cells, which could only be attributed to the expression of 
Prod1. 
 
 
Figure 4.1 Optimising AG1478 concentration 
B1H1  cells  were  serum  starved  for  24hr,  then  treated  for  30min  with  indicated 
concentrations  of  AG1478  or  dimethylsulfoxide  (DMSO)  vehicle  control.  Cells  were 
stimulated for 20min with 100ng/ml EGF and cell lysates were subsequently Western-
blotted with anti-phospho ERK1/2 antibody 
 
Figure 4.2 Effect of EGFR inhibition on Prod1 induced ERK1/2 activation 
B1H1  cells  transfected  with  Prod1  (WT)  or  GPI  GFP  (GPI)  were  serum-starved  for 
24hrs, then treated with 5uM U0126 [U], 25uM AG1478 [A] or DMSO vehicle [D]. (A) 
Cell  lysates  were  Western-blotted  with  anti-phospho  ERK1/2  and  total  ERK1/2 
antibodies. (B) ERK1/2 phosphorylation was quantitated and normalised to the level 
seen  in  DMSO  treated  Prod1  expressing  cells.  GPI  GFP  ERK1/2  background  was 
subtracted  from  Prod1  ERK1/2  levels  for  each  treatment,  and  adjusted  ERK1/2 
phosphorylation was plotted.   
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Whether  inhibition  of  ERK1/2  or  EGFR  activity  affected  induction  of  MMP9 
expression  by  Prod1  was  investigated  by  zymography  and  qRT-PCR.  B1H1 
cells expressing Prod1 and GPI GFP were treated with the ERK1/2 inhibitor 
U0126  or  the  EGFR  inhibitor  AG1478.  Protein  secretion  was  analysed  by 
zymography  (Fig. 4.3 A) and quantitated (Fig. 4.3 B), and gene expression was 
assayed  by  qRT-PCR  (Fig.  4.3  C).  Assaying  by  qRT-PCR  indicated  an 
approximately  30%  inhibition  of  Prod1  induced  MMP9  expression  with  the 
EGFR inhibitor AG1478, and ~50% with the ERK1/2 inhibitor U0126. The EGFR 
inhibitor PD153035 showed a similar degree of inhibition as AG1478 (data not 
shown).  
 
Figure 4.3 Effect of ERK1/2 and EGFR inhibition on Prod1 induced MMP9 
expression. 
Prod1 (WT) and GPI GFP (GPI) expressing B1H1 cells were serum starved for 24hr 
then treated with U0126 [U], AG1478 [A] or DMSO [D] for 48hr. (A) MMP9 activity in 
culture  medium  conditioned  for  48hr  in  the  presence  of  inhibitors  was  analysed  by 
gelatin zymography, and (B) results of seven independent experiments were plotted on 
a histogram. (C) cDNA was prepared from cells and MMP9 expression was analysed 
by qRT-PCR. Results of nine independent experiments were plotted on a histogram.  
Values  in  each  experiment  are  normalised  to  that  seen  in  DMSO  treated  Prod1 
expressing cells. Bars represent SEM.  
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The duration of EGFR and ERK1/2 inhibition was extended (Fig. 4.4 A) and 
ERK1/2  inhibitor  concentration  was  raised  (Fig.  4.4  B),  showing  no  greater 
effect  on  MMP9  expression.  The  observation  that  ~30%  inhibition  of  MMP9 
induction  was  the  maximum  possible  with  the  EGFR  inhibitor  AG1478 
suggested that other transmembrane signal-transducers were involved in Prod1 
regulation  of  MMP9  expression.  The  role  of  ErbB2,  another  member  of  the 
EGFR  family  was  investigated  by  treating  Prod1  expressing  cells  with  the 
ErbB2 inhibitor AG879, resulting in ~40% inhibition of MMP9 induction (Fig. 4.4 
C).  No  greater  inhibition  was  observed  at  higher  concentrations  (data  not 
shown). Higher concentrations of AG879 were seen to be toxic to the cells, as 
seen by light microscopy (not shown). A combination of AG879 and AG1478 
was  unable  to  completely  inhibit  MMP9  induction  (Fig.  4.4  D),  despite 
exceptionally strong inhibition being observed with individual inhibitors in these 
experiments. Combined inhibition resulted in cytotoxicity however. 
 
As inhibition of ERK1/2 gave only 50% inhibition of MMP9 expression, the effect 
of inhibiting the other MAPKs, p38 and JNK, both of which are linked by MEKK 
(Lange-Carter et al., 1993) to EGFR signalling (Lange et al., 1998) (Minden et 
al., 1994) and have been shown to be involved in MMP9 regulation (Wang et 
al., 2009), was analysed. It was seen that inhibition of p38 showed no MMP9 
inhibition, even at high concentrations (Fig 4.5 A). Prod1 expression was seen 
to induce phosphorylation of JNK (Fig. 4.5 B) and inhibition of JNK activity with 
the  drug  SP600125  inhibited  Prod1  MMP9  induction  by  ~50%,  similar  to 
ERK1/2.  Inhibition  of  both  simultaneously  did  not  have an  additive  effect on 
Prod1 induced MMP9 transcription however, with no greater inhibition of MMP9 
transcription being seen than when they were inhibited singly (Fig. 4.5 C). It 
was  observed  that  ERK1/2  phosphorylation  was  inhibited  by  SP600125  and 
likewise,  that  JNK  phosphorylation  was  inhibited  by  U0126  (Fig.  4.5  D). 
SP600125 inhibited ERK1/2 phosphorylation by ~75% compared to ~95% seen 
with U0126 (Fig  4.5 E). Simultaneous inhibition of Prod1 expressing cells with 
SP600125 and AG1478 showed no greater inhibition of MMP9 induction than 
when JNK was inhibited singly (Fig. 4.5 F), indicating that JNK is downstream of 
EGFR signalling and not some other, as of yet unidentified, Prod1 interacting 
receptor.  
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Figure  4.4  Contribution  of  ERK1/2  and  EGFR  to  Prod1  induced  MMP9 
expression 
(A) B1H1 cells expressing Prod1 (WT) or GPI GFP (GPI) were serum starved for 24hr 
then treated with DMSO vehicle [D], 5uM U0126 [U5] or 25uM U0126 [U25] for 48hr. 
cDNA  was prepared from cells,  and  MMP9 expression  was analysed by  qRT-PCR. 
Histogram  represents  results  of  four  independent  experiments.  (B)  B1H1  cells 
expressing Prod1 were serum starved for 24hr then treated with 5uM U0126 or 25uM 
AG1478 for either 48 hr, or 48hr + 24hr with fresh inhibitor = 72hr. cDNA was prepared 
from cells and  MMP9 expression  was analysed  by qRT-PCR.  Histogram represents 
results of three independent experiments. (C) B1H1 cells expressing Prod1 (WT) or 
GPI GFP (GPI) were serum starved for 24hr then treated with DMSO vehicle [D], 5uM 
U0126 [U] or 5uM AG879 [A8] for 48hr. cDNA was prepared from cells and  MMP9 
expression  was  analysed  by  qRT-PCR.  Histogram  represents  results  of  six 
independent experiments. (D) B1H1 cells expressing Prod1 (WT) or GPI GFP (GPI) 
were serum starved for 24hr then treated with DMSO vehicle [D], 25uM AG1478 [A],  
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5uM AG879 [A8] or 25uM AG1478 + 5uM AG879 [A+A8] for 48hr. cDNA was prepared 
from cells and MMP9 expression was analysed by qRT-PCR. 
Values  in  each  experiment  are  normalised  to  that  seen  in  DMSO  treated  Prod1 
expressing cells. Bars represent SEM. 
---------------------------------------------------------------------------------------------------------- 
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Figure 4.5 Role of MAP kinases in Prod1 regulation of MMP9 expression  
(A) B1H1 cells transfected with Prod1 (WT) or GPI GFP (GPI) serum starved for 24hr 
then treated with 5uM U0126 [U], 15uM, 50uM or 150um P38 inhibitor [P15], [P50], 
[P150]  or  DMSO  vehicle  [D]  for  48hr.  cDNA  was  prepared  from  cells,  and  MMP9 
expression  was  analysed  by  qRT-PCR.  Histogram  represents  results  of  two 
independent  experiments  for  15uM  and  50uM  P38  inhibitor,  and  5  independent 
experiments for 150uM P38 inhibitor. (B) B1H1 cells were transfected with Prod1 (WT) 
Prod1 ΔN-terminal signal peptide (NS), Prod1 ΔC-terminal anchor attachment peptide 
(NA) and GPI anchored GFP (GPI). Cells were serum starved for 24hr and cell lysates 
were  Western-blotted  with  anti  phospho-JNK  antibodies.  (C)  B1H1  cells  transfected 
with  Prod1  (WT)  or  GPI  GFP  (GPI)  serum  starved  for  24hr  then  treated  with  5uM 
U0126  [U],  10uM  SP600125  [S],  5uM  U0126  +10uM  SP600125  [S+U]  or  DMSO 
vehicle control for 48hr [D]. cDNA was prepared from cells, and MMP9 expression was 
analysed by qRT-PCR. Histogram represents results of five independent experiments 
for SP600125 and four independent experiments for U0126+SP600125. (D) B1H1 cells 
transfected  with  Prod1  (WT)  or  GPI  GFP  (GPI)  were  serum-starved  for  24hr,  then 
treated  with  5uM  U0126,  10uM  SP600125,  or  DMSO  vehicle  for  30  minutes.  Cell 
lysates were Western-blotted with anti phospho-ERK1/2, anti phospho-JNK and total 
ERK1/2 antibodies, and results of three independent experiments were represented in 
a  histogram  (E).  B1H1  cells  transfected  with  Prod1  (WT)  or  GPI  GFP  (GPI)  serum 
starved  for  24hr  then  treated  with  25uM  AG1478  [A],  10uM  SP600125  [S],  25uM 
AG1478 + 10uM SP600125 [S+A] or DMSO vehicle [D] for 48hr. cDNA was prepared 
from cells, and MMP9 expression was analysed by qRT-PCR. Histogram represents 
results of four independent experiments for AG1478 + SP600125. Experimental values 
for SP600125 are as in (D). Values in each experiment are normalised to that seen in 
DMSO treated Prod1 expressing cells. Bars represent SEM. 
 
 
The inability to completely inhibit Prod1 induction of MMP9 with MAPK inhibitors 
indicated another distinct pathway may be involved. In addition to the MAPKs, 
the JAK/STAT pathway regulates transcription downstream of EGFR signalling. 
STATs are transcription factors which become phosphorylated either by JAKs 
activated by the EGFR (Andl et al., 2004) or by the EGFR itself (Silvennoinen et 
al., 1993), leading to their nuclear localisation. The MMP9 promoter has been 
shown to contain a STAT3 response element (Kim et al., 2008), therefore Prod1 
expressing cells were treated with the JAK2/STAT3 inhibitor AG490, resulting in 
~60% inhibition of MMP9 induction (Fig. 4.6). No greater inhibition was seen at 
higher inhibitor concentration (not shown). Whether JAK/STAT signalling was  
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regulating  MMP9  expression  independently  of  the  ERK1/2  pathway  was 
addressed by treating Prod1 expressing cells with both U0126 and AG490. The 
simultaneous  inhibition  of  both  pathways  showed  no  greater  effect  than 
inhibition of them singly (Fig. 4.6) indicating their interaction at some level in the 
regulation of MMP9 expression.  
  
 
Figure 4.6 Role of JAK/STAT pathway in Prod1 regulation of MMP9  
expression 
B1H1 cells transfected with Prod1 (WT) or GPI GFP (GPI) serum starved for 24hr then 
treated with 5uM U0126 [U], 20uM AG490 [A4], 5uM U0126 + 20uM AG490 [U+ A4] or 
DMSO  vehicle  control  [D]  for  48hr.  cDNA  was  prepared  from  cells,  and  MMP9 
expression  was  analysed  by  qRT-PCR.  Histogram  represents  results  of  five 
independent experiments. Values in each experiment are normalised to that seen in 
DMSO treated Prod1 expressing cells. Bars represent SEM. 
 
The inability to completely block MMP9 induction with combined inhibition of 
either ERK1/2 and JNK or ERK and JAK/STAT indicates that another pathway 
downstream of Prod1 is involved with the regulation of MMP9 expression. PI3K 
is  a  known  transducer  of  both  integrin  (Hruska  et  al.,  1995)  and  EGFR 
signalling,  in  particular  ErbB2  ErbB3  heterodimers  (Ram  and  Ethier,  1996). 
Reports  of  the  involvement  of  PI3K  co-operation  with  ERK1/2  in  MMP9 
regulation (Guo et al., 2007), and in MMP9 regulation by EGFR (Wang et al., 
2006) prompted investigation of its possible role in MMP9 regulation by Prod1. 
mTor  has  also  been  shown  to  interact  with  ERK1/2  signalling,  negatively 
regulating  MMP9  expression  in  response  to  lipopolysaccharide  in  a  manner  
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independent of PI3K (Mendes Sdos et al., 2009). Rather than inhibiting MMP9 
induction in Prod1 expressing cells, treatment with the PI3K inhibitor LY294002 
(Fig.3.7 A) lead to increased MMP9 expression in a dose-dependent manner. 
The mTor inhibitor rapamycin increased the induction of MMP9 seen to result 
from  Prod1  expression  (Fig.  4.7  B).  LY294002  treatment  also  raised  MMP9 
expression in GPI GFP control expressing cells (Fig. 4.7 C), as did rapamycin 
to a lesser extent (Fig. 4.7 D). 
 
4.2.2   Relating the structure of Prod1 to its function 
In order to identify structural elements of Prod1 relevant to its function, a series 
of  point-mutants  were  generated  by  site-directed  mutagenesis.  Amino-acids 
were  selected  for  mutation  based  on  computational  prediction,  which  was 
carried out by A. Garza-Garcia. See Materials and Methods for details of the 
mutation strategy.  
 
B1H1 cells were transfected with the series of point mutants, MMP9 expression 
was assayed by qRT-PCR and compared to the level seen for the wild-type 
Prod1 protein (Fig. 4.8 A). The point mutations either showed no effect, a mild 
effect or a complete inhibition of MMP9 induction. These three categories of 
mutation  were  represented  on  the  Prod1  tertiary  structure  (Fig.  4.8  B), 
indicating amino-acids glutamine 59 (Q59) and glutamate 66 (E66) on the α-
helix of finger three to be essential for MMP9 induction. Substitution of Q59 or 
E66 to alanine was also observed to abolish the ability of Prod1 to activate 
ERK1/2  signalling  (Fig.  4.8  C).  Expression  of  Q59A  and  E66A  on  the  cell 
membrane was confirmed by immunofluorescence (Fig. 4.8 D). 
 
4.2.3   Prod1 interacts physically with the EGFR 
As EGFR inhibition is observed to inhibit both ERK1/2 activation and MMP9 
induction, the possibility of a physical interaction between it and the EGFR was 
investigated. In order to further characterise the specific molecular interactions 
participating in the mechanism through which Prod1 activates ERK1/2 signalling 
and  induces  MMP9  expression,  the  effect  of  the  Q59A  mutation,  which 
completely  abolishes  these  activities,  was  investigated  in  the  context  of  the 
physical  interaction  between  Prod1  and  the  EGFR.  HEK  293T  cells  stably  
  120 
expressing Prod1-Flag or Prod1-Flag Q59A were transfected with Myc-tagged 
newt EGFR and proteins were immunoprecipitated from cell lysates with anti-
Flag antibody. Immunoprecipitated protein was Western-blotted with anti-Myc 
antibody  to  detect  Myc-tagged  EGFR  and  it  was  observed  that  EGFR 
specifically co-immunoprecipitated with both wild-type Prod1-Flag and Prod1-
Flag Q59A (Fig. 4.9 A). 
 
Figure 4.7 Role of PI3K and mTOR in Prod1 regulation of MMP9  
expression  
B1H1 cells transfected with Prod1 (WT) or GPI GFP (GPI) were serum starved for 24hr 
then treated  with LY294002 at a concentration  of 10uM [LY 10] and 50uM [LY 50], 
rapamycin [R] at a concentration of 0.1uM [R 0.1], 1uM [R 1] or 3uM [R 3], or DMSO 
vehicle control [D] for 48hr. cDNA was prepared from cells, and MMP9 expression was 
analysed  by  qRT-PCR.  Values  in  each  experiment  are  normalised  to  that  seen  in 
DMSO treated Prod1 expressing cells.  
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Figure 4.8 Identification of amino-acids key to Prod1 activity 
B1H1  cells  transfected  with  Prod1  constructs  with  single  point  mutations  to 
alanine/serine at the indicated amino-acid residues were serum-starved for 72hr.  (A) 
cDNA  was prepared from cells,  and  MMP9 expression  was analysed by  qRT-PCR. 
Amino-acids were categorised according to the severity of the effect of mutation, red 
being most severe, yellow being mild and green showing the same activity as wild-type  
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Prod1  (WT).  GPI  GFP  (GPI)  was  used  as  a  negative  control.  Values  in  each 
experiment  are  normalised  to  that  seen  in  wild-type  Prod1  expressing  cells.  Bars 
represent  SEM.  (B)  Amino-acids  were  colour  coded  on  the  structure  of  Prod1 
according to the convention described. Figure courtesy of A. Garza-Garcia (C) Protein 
from cell lysates collected for cDNA preparation from the point-mutants with the most 
severe  effect  on  MMP9  induction  was  Western-blotted  with  anti-ERK1/2  and  anti-
phospho ERK1/2 antibodies. Results shown are representative of three independent 
experiments.  (D)  Membrane  expression  of  the  point-mutants  with  the  most  severe 
effect on MMP9 induction was confirmed by immunofluorescence.  
 
In the light of the glutamine 59 mutation showing no disruption of the EGFR 
Prod1 physical association, the possibility that Prod1 interacts with the EGFR at 
another interface other than the α-helix was raised. Point mutations at a second 
surface remote from the α-helix showed an intermediate effect on Prod1 MMP9 
inducing  activity,  and  as  inhibition  of  EGFR  activity  also  showed  only  an 
intermediate effect on MMP9 induction, the role of this interface in the activation 
of EGFR signalling was investigated. If disruption of this interface perturbs the 
physical  interaction  between  Prod1 and  EGFR,  inhibition  of  EGFR  signalling 
should show no effect on the MMP9 inducing activity of these point-mutants, 
however cells transfected with Prod1 mutated at threonine 33 showed a degree 
of sensitivity to EGFR inhibition comparable to wild-type Prod1 (Fig. 4.9 B). 
 
4.2.4   Prod1 activation of the EGFR  
The EGFR is co-immunoprecipitated with Prod1 and inhibition of EGFR activity 
perturbs the ability of Prod1 to modulate downstream effects, though whether 
the EGFR is directly associated with Prod1 or is indirectly associated with a 
multi-protein  complex  including  Prod1  is  unclear.  Despite  experiments  being 
carried out under serum-free conditions, the possibility that the mechanism of 
Prod1  signal  transduction  through  the  EGFR  may  involve  EGFR  ligand  was 
assessed. Evidence from use of the EGFR inhibitor AG1478 that serum-starved 
B1H1  cells  have  a  constitutive  level  of  EGFR  signalling  (Fig.4.1)  raised  the 
possibility that the cells may produce their own EGFR ligand.  
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Figure 4.9 Physical interaction between Prod1 and EGFR 
(A) HEK-293T cells negative for Prod1 (-), expressing Prod1-Flag (WT) or Prod1-Flag 
Q59A  (Q59A)  were  transfected  with  EGFR-Myc.  Cells  lysates  were 
immunoprecipitated  with  anti-Flag  antibody  and  Western-blotted  with  anti-Myc 
antibody.  Expression  of EGFR-  Myc  and  Prod1-Flag  in cell lysates is shown in the 
bottom two panels. (B) B1H1 cells transfected with Prod1-Flag T33A (T33A) or GPI 
GFP (GPI) were serum starved for 24hr then treated with DMSO [D] or AG1479 [A] for 
48hr. cDNA was prepared from cells, and MMP9 expression was analysed by qRT-
PCR. Values in each experiment are normalised to that seen in DMSO treated Prod1 
expressing cells. Bars represent SEM. 
  
It was observed that serum-free conditioned medium collected from B1H1 cells 
contained  an  ERK1/2  stimulating  activity  that  was  inhibited  completely  by 
AG1478 (Fig. 4.10 A). Despite its physical interaction with the EGFR it had not 
been ruled-out that Prod1 may up-regulate the expression of EGF and thereby 
bring about EGFR dependent downstream effects. Conditioned medium from 
Prod1  expressing  cells  was  observed  to  contain  no  more  EGFR  stimulating 
activity than that produced by GPI GFP control expressing cells however (Fig. 
4.10 A) indicating that MMP9 induction by Prod1 activation of the EGFR is not a 
result of increased EGFR ligand production. The physical interaction between 
Prod1 and the EGFR may be modulating the response of the EGFR to EGF 
rather than directly activating it, however despite containing an EGFR ligand 
with  ERK1/2  stimulating  activity,  conditioned  medium  did  not  induce  further 
MMP9 expression in either Prod1 or GPI GFP control expressing cells, nor did 
ERK1/2 activation by serum stimulation (Fig. 4.10 B). Similarly, uPAR has been  
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shown to transactivate the EGFR in a ligand-independent manner (Monaghan-
Benson and McKeown-Longo, 2006) 
 
It has been suggested that uPAR participates in an interaction with integrins on 
neighbouring cells (Tarui et al., 2001) as well as on the same cell (Tarui et al., 
2003). It was therefore investigated whether the mechanism of MMP9 induction 
by Prod1 involves the participation of molecules on adjacent cells, or whether 
all necessary components are present on one cell membrane, by comparing the 
degree of Prod1 induced MMP9 expression seen in cells close to confluence to 
cells  plated  at  a  density  permitting  minimal  contact  between  membranes  of 
surrounding  cells.  It  was  observed  by  zymography  (Fig.  4.10  C)  that  the 
magnitude of MMP9 induction by Prod1 was not influenced by the degree of 
contact between membranes of adjacent cells. Similar results were observed 
with qRT PCR (not shown). 
 
The ability of Prod1 to activate mammalian EGFR signalling was investigated 
by transfecting HEK 293T cells with Prod1. It was observed however that in 
contrast to EGF stimulation, Prod1 expression did not lead to increased EGFR 
or ERK1/2 phosphorylation (Fig  4.11). 
 
4.2.5  The role of other Prod1 interacting molecules in the regulation of 
MMP9  
Taken together with the apparent maximum 35% decrease in MMP9 induction 
seen  with  EGFR  inhibition,  the  observation  that  mutation  of  Prod1  residue 
glutamine 59 does not affect its interaction with EGFR despite abolishing its 
MMP9  inducing  activity,  raised  the  possibility  of  the  involvement  of  another 
signal transducing protein that interacts with Prod1 at the α-helix. A previous 
yeast  two-hybrid  screen  aimed  at  identifying  Prod1  interacting  proteins 
indicated  a  potential  physical  interaction  between  Prod1  and  β1  integrin 
(P.Gates, unpublished). uPAR regulation of MMP9 involves fibronectin binding   
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Figure 4.10 Mode of EGFR activation by Prod1 
(A) B1H1 cells were serum starved for 8hr and stimulated with concentrated serum free 
culture medium (Med), concentrated serum free culture medium conditioned by B1H1 
(Cond),  GPI  GFP  expressing  (GPI)  or  Prod1  expressing  B1H1  cells  (WT),  in  the 
presence of AG1478 or  DMSO vehicle. Cell lysates were Western-blotted with anti-
phospho  ERK1/2  antibodies.  Results  shown  are  representative  of  four  independent 
experiments.  (B)  B1H1  cells  transfected  with  Prod1  (WT)  or  GPI  GFP  (GPI)  were 
incubated  for  72hr  in  the  presence  of  concentrated  cell  culture  medium  (Med), 
concentrated conditioned cell culture medium from B1H1 cells (Cond) or 10% serum 
(10%). cDNA was prepared from cells, and MMP9 expression was analysed by qRT-
PCR.  Results  shown  are  the  average  of  three  independent  experiments.  Values  in 
each experiment are normalised to that seen in DMSO treated Prod1 expressing cells. 
Bars represent SEM. (C) Equal numbers of Prod1 (WT) of GPI GFP (GPI) expressing 
cells  were  plated  on  surfaces  with  a  range  of  areas  in  equal  volumes  of  medium. 
MMP9 activity in serum free culture medium conditioned for 48hr in was analysed by 
gelatin  zymography.  Results  shown  are  representative  of  three  independent 
experiments. 
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induced α5β1 integrin signalling, leading to ERK1/2 activation (Wei et al., 2007), 
and  in  light  of  this  the  role  of  integrins  in  Prod1  regulation  of  MMP9  was 
investigated,  despite  the  apparent  lack  of  requirement  for  matrix-protein 
binding.  Prod1-Flag  and  Prod1-Flag  Q59A  expressing  HEK  293T  cells  were 
transfected  with  Myc-tagged  β1  integrin  and  cell  lysates  were 
immunoprecipitated with anti-Flag antibodies. β1 integrin was observed to co-
immunoprecipitate with both Prod1-Flag and Prod1-Flag Q59A however (Fig. 
4.12 A), indicating that the abolition of Prod1 MMP9 inducing activity resulting 
from  mutation  of  glutamine  59  is  also  not  attributable  to  a  disruption  of  its 
physical association with β1 integrin, as with the EGFR. 
  
 
 
 
 
Figure 4.11 Lack of activation of mammalian EGFR by Prod1 
HEK-239T cells were either stimulated with EGF, transfected with Prod1 (WT) or GPI 
GFP  (GPI).  Cell  lysates  were  Western-blotted  with  anti-phosphotyrosine  (pY),  anti-
phospho ERK1/2, total ERK1/2 or anti-Flag antibodies. Note that EGF treatment lead 
to  phosphorylation  of  a  170kD  band  corresponding  to  the  EGFR  and  ERK1/2 
activation, whereas Prod1 expression did not. 
 
Src  is  involved  in  the  activation  of  a  number  of  the  major  integrin  signal 
transducers,  reviewed  in  (Playford  and  Schaller,  2004),  and  is  specifically 
involved in regulating integrin mediated ERK1/2 activation (Zhao et al., 1998). 
uPAR  integrin  activation  of  ERK1/2  and  regulation  of  MMP9  requires  Src  
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activity (Wei et al., 2007), and integrin transactivation of EGFR has also been 
shown to be Src dependent (Moro et al., 2002). In order to investigate whether 
integrin activity plays a role in MMP9 regulation by Prod1, the Src inhibitor PP2 
was employed. Treatment of Prod1 expressing cells with the Src inhibitor PP2 
did not inhibit MMP9 induction however (Fig. 4.12 B), though an inhibition of 
ERK1/2 phosphorylation was observed (Fig. 4.12 C). 
 
 
 
Figure 4.12 Role of integrins in MMP9 induction 
(A) HEK-293T cells negative for Prod1 (-), expressing Prod1-Flag (WT) or Prod1-Flag 
Q59A  (Q59A)  were  transfected  with  β1  integrin-Myc.  Cell  lysates  were 
immunoprecipitated  with  anti-Flag  antibody  and  Western-blotted  with  anti-Myc 
antibody. Expression of β1 integrin-Myc and Prod1-Flag in cell lysates is shown in the 
bottom two panels. (B) B1H1 cells transfected with Prod1 (WT) or GPI GFP (GPI) were 
serum starved for 24hr then treated with DMSO [D] or 50uM PP2 [P] for 48hr. cDNA 
was prepared from cells, and MMP9 expression was analysed by qRT-PCR.  Results 
shown are the average of 4 independent experiments. Values in each experiment are 
normalised to that seen in DMSO treated Prod1 expressing cells. Bars represent SEM. 
(C) B1H1 cells transfected with Prod1 (WT) or GPI GFP (GPI) were serum starved for 
24hr then treated with DMSO [D], 5uM U0126 [U] or 15uM PP2 [P] for 30min. Cell 
lysates were Western-blotted. Results representative of two independent experiments. 
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4.3  Discussion 
 
4.3.1  Transmembrane-receptor mediated regulation of MMP9 expression 
by Prod1  
 
Inhibition  of  EGFR  activity  leads  to  both  diminished  ERK1/2  activation  and 
MMP9 gene induction in response to Prod1 expression. Similarly, inhibition of 
the activity of the EGFR family member ErbB2 diminishes Prod1 induced MMP9 
expression.  Prod1’s  ability  to  induce  MMP9  is  also  impaired  by  ERK1/2 
inhibition, and similarly, mutation of amino acids on the α-helix of Prod1 inhibit 
ERK1/2 activation and abolish MMP9 induction, indicating that the decrease in 
ERK1/2  activation  by  Prod1  seen  when  EGFR  signalling  is  inhibited  is 
mechanistically linked to the resulting decrease in MMP9 induction. Results of a 
single experiment (data not shown) in which ERK1/2 and either EGFR or ErbB2 
were  inhibited  simultaneously  showed  no  greater  effect  than  when  ERK1/2 
alone was inhibited, consistent with the proposal that ERK1/2 is downstream of 
EGFR.  Were  the  EGFR  to  be  signalling  primarily  through  another  pathway 
independent of ERK1/2, simultaneous inhibition should show an effect greater 
in magnitude than that seen with ERK1/2 inhibition alone.  
 
Prod1 was seen to interact physically with the EGFR, and the production of 
EGFR  ligand  was  not  stimulated by  Prod1 expression,  indicating  that  EGFR 
activation is not a result of increased autocrine signalling. Further to this, EGFR 
ligand  showed  no  stimulation  of  MMP9  induction  in  either  Prod1  or  control 
expressing  cells.  In  light  of  these  points,  it  is  proposed  that  Prod1  interacts 
physically with the EGFR, and in doing so, rather than modulating the effects of 
EGFR  ligand,  directly  activates  EGFR  signalling,  leading  to  activation  of 
ERK1/2  and  subsequently  resulting  in  induction  of  MMP9  gene  expression. 
Whether Prod1 makes direct contact with the EGFR or interacts with it via other 
components of a multi-protein complex has not been established however. As 
cell  density,  and  therefore  the  degree  of  contact  between  membranes  of 
adjacent cells, was not observed to influence MMP9 induction in response to 
Prod1 expression, it is proposed in addition that the interaction between Prod1  
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and EGFR family member occurs on the membrane of individual cells rather 
than between neighbouring cells.  
 
Mutation of residues on Prod1 revealed two classes of mutants. Those on the 
α-helix that showed a strong inhibition of MMP9 induction when mutated, and 
those  localised  to  a  second  surface  that  showed  a  mild  inhibition.  Cells 
expressing the second class of mutant Prod1, with an intermediate effect on 
MMP9 expression, were equally sensitive to EGFR inhibition as were wild-type 
Prod1 expressing cells, indicating that mutation at this interface does not disrupt 
EGFR  signalling. The  EGFR  is  also  observed  to  associate  with  Prod  Q59A, 
which  is  unable  either  to  activate  ERK1/2  signalling  or  induce  MMP9 
expression, raising the possibilities that the EGFR either associates with Prod 
Q59A  without  becoming  activated,  or  alternatively,  that  another  protein 
essential for any ERK1/2 activation or MMP9 induction requires this interface to 
associate  with  Prod1.  In  light  of  the  inability  to  completely  inhibit  Prod1 
induction  of  MMP9  with  EGFR  inhibitor  or  with  combined  EGFR  ErbB2 
inhibition,  it  seems  highly  likely  that  another  protein  able  to  induce  MMP9 
expression in the absence of EGFR ErbB2 signalling is also associated with 
Prod1, and it may be the interaction with this that is perturbed by mutation of 
Q59.  β1  integrin  was  thought  to  be  a  good  candidate  for  this  in  light  of 
experiments  with  uPAR  demonstrating  the  involvement  of  β1  integrins  in  its 
regulation of MMP9 (Mazzieri, D’Alessio 2006), and transactivation of the EGFR 
(Liu et al., 2002). However, β1 integrin was also observed to associate with both 
wild-type Prod1 and Prod1 Q59A. Attempts were made to inhibit integrin activity 
using the snake venom disintegrin echistatin, however results were too variable 
to make a reliable conclusion of whether it was able to inhibit MMP9 induction 
(not shown). Also, inhibition of Src kinase, a known mediator of both MMP9 
induction  (Wei  et  al.,  2007),  ERK1/2  activated  cell  migration  (Nguyen  et  al., 
2000) and EGFR transactivation by uPAR via integrins (Guerrero et al., 2004), 
had  no  effect  on  MMP9  induction.  Src  independent  activation  of  FAK,  a 
transducer of integrin signalling, and ERK1/2, have also been reported however 
(Tang et al., 1998). 
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Mutation of Q59 and EGFR inhibition both decrease ERK1/2 phosphorylation to 
the level seen in GPI GFP expressing control cells, however mutation of Q59 
has a much more drastic effect on MMP9 induction than EGFR inhibition. It 
seems unlikely therefore that it is only ERK1/2 signalling which is perturbed by 
Q59A  mutation,  indicating  the  role  of  another  signalling  pathway  originating 
from an as yet unidentified Prod1 interacting protein. Also, treatment of Prod1 
expressing cells with U0126 reduced ERK1/2 phosphorylation to a level greatly 
below that seen in GPI GFP control expressing cells, whilst the level of MMP9 
expression remained considerably higher than that seen in GPI GFP controls. 
In light of the inability to completely inhibit Prod1 induced ERK1/2 activation 
with concentrations of AG1478 shown to be sufficient to inhibit completely EGF 
induced ERK1/2 activation, it seems likely that this other protein, in addition to 
activating  the  hypothesised  ERK1/2  independent  pathway,  is  also  able  to 
transduce a signal to ERK1/2 independently of the EGFR. Further support for 
this comes from the observation that mutation of residues on the α-helix also 
inhibits ERK1/2 phosphorylation. It is proposed then that the ERK1/2 pathway 
contributes ~50% to Prod1 induced MMP9 expression, with components of this 
coming  from  EGFR  signalling  and  the  hypothesised  second  transmembrane 
signal transducer, and that this hypothesised transmembrane signal transducer 
also activates an ERK1/2 independent pathway contributing to 50% of Prod1 
induced MMP9 expression.  
 
Stimulation of the ERK1/2 pathway with either serum or EGFR ligand containing 
medium was not sufficient to induce MMP9 expression, suggesting that another 
pathway downstream of ERK1/2 must be activated simultaneously in order for 
ERK1/2  to  induce  any  MMP9  expression,  consistent  with  the  proposal  that 
mutation of Q59, which has a considerably greater effect than that of ERK1/2 
inhibition, disrupts the activation of an as yet unidentified pathway. The inability 
of EGFR ligand containing conditioned medium to stimulate MMP9 expression 
raises the possibility that Prod1 activates the EGFR in a manner distinct from 
that brought about by ligand. uPAR transactivation of EGFR in cooperation with 
integrins is shown to result in phosphorylation of EGFR residues distinct from 
those resulting from ligand binding (Monaghan-Benson and McKeown-Longo, 
2006), however this was also shown to be Src dependent. It is acknowledged  
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that  serum  or  conditioned  medium  may  contain  factors  inhibitory  to  MMP9 
expression, though this is none the less consistent with the involvement of a 
level of regulation able to supersede ERK1/2 activation.  
 
4.3.2  The role of PI3K, JNK and JAK STAT pathways in Prod1 regulation 
of MMP9 expression 
PI3K was a candidate for the second pathway (Guo et al., 2007) contributing to 
the  induction  of  MMP9  expression  by  Prod1,  however  the  PI3K  inhibitor 
LY294002  showed  no  inhibitory  effects  on  Prod1  induction  of  MMP9 
expression.  Instead,  inhibition  of  PI3K  showed  a  stimulation  of  MMP9 
expression  both  in  Prod1  and  GPI  GFP  expressing  cells,  indicating  that  it 
constitutively represses expression of MMP9 in B1H1 cells. To a lesser extent, 
the same was observed with mTor, a downstream component of PI3K signalling 
which  has  been  reported  previously  to  repress  MMP9  expression  (Mendes 
Sdos et al., 2009) through its repression of ERK1/2 activity. This previous report 
showed no effect of PI3K inhibition however. 
 
Prod1 expression was also observed to activate JNK, and similarly to ERK1/2 
inhibition  with  U0126,  its  inhibition  with  SP600125  diminished  induction  of 
MMP9 by Prod1 by ~50%. Simultaneous inhibition of ERK1/2 and JNK did not 
have additive effects on Prod1 induction of MMP9 however, indicating that they 
do  not  function  in  independent  pathways,  and  instead  converge  on  some 
common point. One possibility is that each kinase has a specific recognition site 
on  a  downstream  target,  with  phosphorylation  at  both  sites  simultaneously 
being  essential  for  its  activity.  It  was  observed  however  that  inhibitors  of 
ERK1/2 and JNK decrease the phosphorylation of each others targets to a level 
lower than that seen in control transfected cells. Were JNK or ERK1/2 required 
for  the  activation  of  each  other  specifically  in  response  to  Prod1  signalling, 
inhibition of either should merely prevent the activation of the other. However, 
as both ERK1/2 and JNK phosphorylation is lower than the background level 
seen in control transfected cells under the presence of either inhibitor, this does 
not appear to be the case. The inhibitors appear to have a general effect on the 
activation of their non-target kinase rather than being specific to the mediation  
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of Prod1 signalling, raising the possibility that JNK and ERK1/2 require each 
others activity for even the basal level of activation seen in control cells. The 
inhibitor  concentrations  used  were  within  the  range  of  conventional  usage, 
however  to  the  knowledge  of  the  author  the  specificity  of  each  for  their 
respective kinases in newt cells has not been confirmed, raising the possibility 
that they are directly acting on their non-target kinases. In giving consideration 
to  the  possible  non-specificity  of  either  inhibitor,  in  light  of  their  similarity  in 
molecular weight it must also be acknowledged that the antibodies used may 
not specifically detect the appropriate newt kinase. However, the observation 
that  subtle  differences  in the  level  of  phosphorylation are  seen  with  the  two 
antibodies after treatment with either inhibitor leads to the tentative suggestion 
that  the  antibodies  and  inhibitors  are  indeed  specific.  The  possibility  that 
ERK1/2 and JNK converge at some point in the pathway by phosphorylation of 
unique, equally essential targets is not ruled-out by the finding that both ERK1/2 
and  JNK  inhibitors  act  on  their  non-target  kinases,  however  it  does  prevent 
definitive interpretation of results. 
 
The  JAK/STAT  pathway  inhibitor  AG490  also  inhibited  MMP9  induction  in 
response  to  Prod1  expression,  however  simultaneous  treatment  with  U0126 
and AG490 was also not additive, again implying some degree of convergence 
of the targets of these compounds in the pathway and further indicating that 
another,  unidentified  pathway  also  contributes  to  Prod1  induced  MMP9 
expression. The JAK/STAT inhibitor used, AG490, inhibits JAK2 and STAT3. It 
has been shown that ERK1/2 (Chung et al., 1997) (Haq et al., 2002) and JNK 
(Turkson  et  al.,  1999)  phosphorylate  serine  residues  on  STAT3,  which  has 
been shown to enhance its activity (Wen et al., 1995), raising the possibility that 
the reduced MMP9 induction seen when ERK1/2 or JNK is inhibited may be 
due  to  a  lack  of  STAT3  activation,  providing  a  possible  explanation  for  the 
observed convergence of the two pathways. Reports of an inhibitory effect of 
STAT3 phosphorylation by ERK1/2 (Chung et al., 1997) and JNK (Lim and Cao, 
1999) also exist however. It is also known that JAK2 is able to phosphorylate 
ERK1/2  (Winston  and  Hunter,  1995),  raising  the  possibility  that  the effect of 
AG490 may be due to reduced ERK1/2 activation resulting from JAK2 inhibition, 
again  providing  a  possible  explanation  for  the  observed  convergence.  
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Stimulation of ERK1/2 phosphorylation in response to AG490 is also reported 
however (Kwak et al., 2008). Conflicting reports also exist as to whether AG490 
is able to inhibit EGFR autophosphorylation (Andl et al., 2004) (Osherov et al., 
1993).  In  some  experiments,  AG490  was  observed  to  mildly  inhibit  ERK1/2 
phosphorylation in GPI GFP transfected cells (not shown) raising the possibility 
that rather than affecting STAT3 activity, AG490 was actually acting by reducing 
ERK1/2  phosphorylation  either  by  JAK2  or  EGFR  kinase  inhibition.  The  Src 
inhibitor  PP2  also  showed  an  inhibition  of  ERK1/2  phosphorylation  without 
inhibiting  MMP9  expression  in  Prod1  expressing  cells  however.  In  order  to 
explain this lack of inhibition, a difference in the perdurance of ERK1/2 inhibition 
is posited compared to that resulting from U0126 treatment. 
 
A  model  is  proposed  in  which  ERK1/2  JNK  pathway  activation  by  EGFR 
signalling is placed in an ancillary role in the regulation of MMP9 expression by 
Prod1, requiring the cooperation of a second as yet unidentified transmembrane 
receptor (Fig.4.13), however serves to explain how Prod1 activation of EGFR is 
able to bring about effects not seen with ligand activation, adding complexity to 
the repertoire of the processes in which it participates. The model places Prod1 
in  the  role  of  an  adaptor  protein  able  to  guide  simultaneous  activation  of 
multiple signalling pathways through it’s participation in such a multi-receptor 
complex, facilitating a greater diversity of outcomes than would be possible with 
the activation of individual pathways. 
 
4.3.3  Future work 
In  order  to  fully  understand  the  mechanism  by  which  Prod1  induces  MMP9 
expression, the identity, or indeed existence of the hypothesised second signal 
transducer  should  be  determined.  A  strategy  based  upon  co-
immunoprecipitation  of  the  Prod1  signalling complex,  and  subsequent mass-
spectrometry to identify interacting proteins would seem the obvious approach, 
however  in  light  of  the  lack  of  an  annotated,  or  even  complete  genome 
sequence this is not a trivial exercise. uPAR is known also to interact with the 
GPCR FRPL-1 (Resnati et al., 2002), and this, or GPCRs in general, may serve 
as a potential target for future investigation.  
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Figure 4.13 A model for MMP9 induction by Prod1 
Prod1  activates  ErbB1  or  ErbB2  containing  EGFRs  by  a  ligand  independent 
mechanism through direct or indirect physical association, leading to ERK/JNK MAPK 
pathway activation. In order for ERK1/2/JNK activation to induce MMP9 expression, ‘X’ 
must  be  co-activated  by  a  signal  originating  from  another  Prod1  interacting 
transmembrane  receptor,  possibly  a  7TM  GPCR.  The  unidentified  transmembrane 
receptor also activates ERK/JNK signalling, which in total contributes to 50% of MMP9 
induction, with another independent unidentified pathway contributing the other 50%. 
PI3 Kinase and mTor negatively regulate MMP9 expression via a Prod1 independent 
mechanism. 
 
A  variety  of  reports,  reviewed  in  (Carpenter,  1999)  demonstrate  that  GPCR 
activation  can  lead  to  EGFR  phosphorylation.  This  may  represent  an 
explanation as to how EGFR activation by Prod1 leads to effects distinct from 
those seen with EGFR ligand stimulation, through phosphorylation of the EGFR 
at residues not promoted by ligand binding, however the requirement for Src 
activity is a general theme in this mode of EGFR activation (Andreev et al.,  
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2001). Reports of the requirement for the cooperation of EGFR and G-proteins 
in promoting cell migration (Schafer et al., 2004) are interesting to consider in 
light of this potentially being a process regulated by Prod1 (da Silva et al., 2002) 
(Echeverri  and  Tanaka,  2005).  A  common  approach  for  investigating  GPCR 
involvement in a process is through use of pertussis toxin, which inhibits the 
activation  of  some  classes  of  G-proteins  by  GPCRs.  GPCRs  are  able  to 
activate ERK1/2 and JNK signalling via activation of the adaptor protein Grb2 
(Luttrell et al., 1997) as proposed for the hypothesised second Prod1 interacting 
signal transducer, as well as a number of other signalling pathways including 
PLC  and  PKC  (Selvatici  et  al.,  2006),  which  may  represent  the  proposed 
second, ERK1/2 independent, MMP9 regulating signal transducer. PLA2 has 
been  shown  to  be  involved  in  MMP9  regulation  by  uPAR  (Menshikov  et  al., 
2006),  and  this  molecule  is  regulated  by  simultaneous  ERK1/2  and  PKC 
phosphorylation (Nemenoff et al., 1993). 
 
 Q59A was seen to inhibit ERK1/2 phosphorylation to the level seen in GPI GFP 
expressing cells, however under the experimental conditions used, serum was 
present. Whether Q59A prevents Prod1 EGFR activation of ERK1/2 must be 
addressed  using  EGFR  inhibitors  under  serum  free  conditions  in  order  to 
determine  whether  the  hypothesised  second  signal  transducer  also  acts  up-
stream  of  ERK1/2  to  inhibit  ERK1/2  activation  by  Prod1  stimulated  EGFR 
signalling when it is itself not activated.  
 
Whether AG490 results in inhibition of MMP9 induction through JAK2/STAT3 
signalling, or whether the effects are due to EGFR inhibition would ideally be 
confirmed with use of anti-phospho EGFR and anti-phospho STAT3 antibodies. 
Attempts  were  made  with  anti-phospho  human  EGFR  antibodies 
unsuccessfully, either due to the low level of EGFR thought to be present in 
B1H1  cells,  or  due  to  insufficient  identity  of  the  epitope  in  the  newt  EGFR. 
Whether anti-STAT3 antibodies would work is unclear. Ideally, knockdown or 
expression  of  dominant  negative  constructs  of  targets  identified  by  chemical 
inhibition in these studies would have followed. Each target would have to be 
cloned  from  the  newt  genome  however,  and  thus  far  technology  for  gene 
knockdown has not been well established in the newt.  
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5  Axolotl Prod1  
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5.1  Introduction 
 
In the previous chapters it has been shown that newt Prod1 is able to activate 
ERK1/2 signalling, leading to induction of MMP9 expression. These activities of 
Prod1 require it to be GPI anchored to the cell membrane. Axolotls are another 
species of salamander also studied as models of regeneration. Unlike newts, 
axolotls never become true adults, and instead reach sexual maturity without 
metamorphosing, a state termed paedomorphosis. Due to the retention of some 
embryonic  traits,  it  is  conceivable  that  axolotls  may  regenerate  in  a  manner 
closer to that exhibited by pre-metamorphic anurans (Dent, 1962) than other 
adult  salamanders.  It  is  important  therefore  to  establish  whether  limb 
regeneration  in  the  two  species  occurs  through  the  same  or  different 
mechanisms in order to be able to confidently interpret data collected in the 
different models. Newts and axolotls are both able to regenerate appropriately 
patterned limbs following amputation, and both express Prod1, indicating the 
likelihood of a conserved role for Prod1 in the two species. Indeed, the most 
compelling functional data for the role of Prod1 in limb patterning comes from 
the translocation of blastema cells along the proximodistal axis of the axolotl 
limb  observed  to  result  from  overexpression  of  newt  Prod1  (Echeverri  and 
Tanaka, 2005).  
 
Axolotl  Prod1  has  recently  been  isolated  by  P.  Gates  in  the  laboratory. 
Intriguingly,  in  contrast  to  newt  Prod1,  axolotl  Prod1  is  expressed  as  a 
precursor  lacking  the  C-terminal  signal  peptide  required  for  GPI  anchor 
attachment.  Extensive  screening  of  genomic  axolotl  libraries  consistently 
identified  the  same  Prod1  gene  without  the  C-terminal  anchor  attachment 
peptide, indicating that this is the only Prod1 molecule expressed by axolotls, 
and in Fig.5.1 B it can be seen that axolotl Prod1 migrates to the same position 
on a poly-acrylamide gel as newt Prod1 without the C-terminal anchor peptide. 
These observations raise the question of whether axolotl Prod1 is capable of 
carrying out the same functions as newt Prod1 without the requirement for GPI 
anchorage.  
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When compared to the genomes of other species, Prod1 seems most closely 
related to CD59 (Garza-Garcia et al., 2009), however the ongoing sequencing 
of  expressed  sequence  tags  (ESTs)  has  shown  that  the  axolotl  genome 
contains a three-fingered GPI anchored molecule more similar to CD59 in other 
species  than  it  is  to  Prod1  (http://salamander.uky.edu/ESTdb/).  Prod1 
therefore  seems  to  be  both  unique  to  salamanders  and  distinct  from  CD59. 
Prod1 has been show to interact with the EGFR, as CD59 has been shown to 
do (Blagoev et al., 2003), prompting investigation as to whether the similarities 
between Prod1 and CD59 extend to the induction of MMP9 expression. 
 
5.2  Results 
 
5.2.1  Characterising the axolotl Prod1 protein 
Axolotl Prod1 lacks the C-terminal peptide required for GPI anchor attachment 
(Fig.1A),  making  it  more  similar  to  the  inactive,  ΔC-terminal  Prod1  construct 
than the active, wild-type protein. Prod1 also lacks a C-terminal GPI anchor 
attachment sequence in a third salamander species more closely related to the 
axolotl than the newt, Ambystoma maculatum (Fig. 5.1 A).  
When  B1H1  cells  were  nucleofected  with  axolotl  Prod1,  Δ  C-terminal  newt 
Prod1 and wild-type newt Prod1, and the relative level of Prod1 released from 
the  cell  into  culture  medium  was  compared  to  that  retained  by  the  cell  by 
Western-blotting it could be seen that axolotl and ΔC-terminal newt Prod1 were 
indistinguishable in both their apparent molecular weights and in that a high 
proportion of protein was observed to be in the culture medium (Fig. 5.1B). As 
shown previously, wild-type newt Prod1 is also found in the culture medium as 
well as in cell lysate. Approximately 50% of wild-type Prod1 is GPI anchored 
and retained efficiently by the cell, however approximately 50% of the protein is 
not processed and is released into the culture medium as an unanchored form 
with  the  C-terminal  peptide  still  attached.  Due  to  this  inefficient  anchor 
attachment to wild-type newt Prod1, similar proportions of it are found released 
from the cell as in the cases of ΔC-terminal newt Prod1 and axolotl Prod1. 
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Figure 5.1 Comparison of newt and axolotl Prod1 proteins 
(A) Alignment of amino-acid sequences of newt Prod1, newt Prod1 ΔC-terminal axolotl 
Prod1 and Ambystoma maculatum Prod1. Amino-acid 59, shown to be essential for 
newt  Prod1  activity,  is  boxed.  Note  that  this  amino-acid  is  glutamate  in  the  axolotl, 
glutamine in the newt and lysine in A. maculatum. The point of GPI anchor attachment 
to  newt  Prod1  is  marked  with  an  arrowhead.  Note  that  in  the  axolotl  a  stop  codon 
marked * produces a protein without a C-terminal GPI anchor attachment sequence, 
and  that  A.  maculatum  Prod1  has  a  truncated  C-terminal  peptide.  (B)  Anti-Flag 
Western-blot of concentrated culture medium (M) and cell lysate (L) from B1H1 cells 
expressing Prod1 -Flag (-Flag), newt Prod1-Flag (WT), newt Prod1 ΔC-terminal-Flag 
(NA)  and  axolotl  Prod1-Flag  (Axo).  Equivalent  proportions  of  total  cell  lysate  and 
culture medium were loaded.  
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5.2.2  Characterising axolotl Prod1 activity 
Whether axolotl Prod1 was more similar to the anchored or unanchored newt 
Prod1 was first tested by transfecting B1H1 and axolotl AL1 cells with all three 
Prod1 constructs and the GPI GFP control. It was observed that axolotl Prod1 
induced MMP9 expression in both B1H1 (Fig. 5.2 A) and AL1 (Fig. 5.2 B) cells, 
and also activated ERK1/2 signalling (Fig. 5.2 C), similar to wild-type and in 
contrast with ΔC-terminal newt Prod1. 
 
 
Figure 5.2 Biological activity of axolotl Prod1 
(A) AL1 and (B) B1H1 cells expressing Newt Prod1 (WT), Axolotl Prod1 (Axo), newt 
Prod1 ΔC-terminal (NA) and GPI GFP (GPI) were serum starved for 72hr. cDNA was 
prepared from cells, and MMP9 expression was analysed by qRT-PCR. Results shown 
are  the  average  of  4  independent  experiments  in  (A)  and  3  in  (B).  Values  in  each 
experiment are normalised to that seen in newt Prod1 expressing cells. Bars represent 
SEM. (C) Protein from axolotl cell lysate collected for cDNA preparation was Western- 
blotted with anti-phospho ERK1/2 antibodies. Result is from a single experiment. 
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In order to address the question of whether secreted axolotl Prod1 has MMP9 
inducing activity when diffusing freely in the medium, cells expressing newt and 
axolotl  Prod1  were  cultured  on  porous  membranes,  sharing  culture  medium 
with untransfected cells. When compared to GPI GFP, both newt and axolotl 
Prod1 were seen to induce MMP9 expression in B1H1 cells as expected (Fig. 
5.3 A), however those cells sharing culture medium with Prod1 expressing cells 
showed no significant elevation of MMP9 expression when compared to GPI 
GFP control expressing cells (Fig. 5.3 B). Similar results were seen in axolotl 
cells (not shown).   
 
 
Figure 5.3 Lack of MMP9 induction by soluble Prod1 
(A) B1H1 cells expressing newt Prod1 (WT), axolotl Prod1 (Axo) and GPI GFP (GPI) 
were plated on a porous membrane, sharing medium with corresponding untransfected 
B1H1 cells in (B). Cells were serum starved for 72hr, cDNA was prepared and MMP9 
expression  was  analysed  by  qRT-PCR.  Results  shown  are  the  average  of  3 
independent experiments. Values in each experiment are normalised to that of cells 
sharing medium with Prod1 expressing cells. Note the difference in the Y axis between 
A and B due to non-specific MMP9 induction resulting from the transfection method. 
Bars represent SEM.  
 
5.2.3  Mutation of axolotl Prod1 activity 
Axolotl  Prod1  has  the  amino-acid  glutamate  at  residue  59  (Fig.  5.1  A),  the 
position on the structure of newt Prod1 shown previously to be essential for its 
MMP9 inducing activity. Newt Prod1 has a glutamine at this position, prompting 
investigation  of  whether  this  amino-acid  is  also  essential  for  axolotl  Prod1  
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activity. Glutamate 59 was substituted for either alanine or glutamine, and it was 
observed in newt cells transfected with these constructs that either substitution 
abolished both the ERK1/2 activating (Fig. 5.4 A) and MMP9 inducing (Fig. 5.4 
B)  activity  of  axolotl  Prod1.  These  substitutions  also  abolished  the  MMP9 
inducing (Fig. 5.4 C) activity of axolotl Prod1 in axolotl cells. The expression of 
both  axolotl  Prod1  mutants  was  confirmed  to  resemble  that  of  the  wild-type 
axolotl Prod1 by Western-blotting cell lysates and cell culture medium of B1H1 
cells transfected with the various Prod1 constructs (Fig. 5.4 D). 
 
5.2.4  Characterising axolotl CD59 activity 
CD59  is  another  GPI  anchored  member  of  the  three-fingered  protein 
superfamily. The three-fingered fold is adopted by proteins with diverse amino-
acid  sequences,  and  indeed  even  orthologs  may  share  only  limited  identity 
(Galat,  2008).  When  initially  identified,  Prod1  was  classified  as  the  newt 
ortholog of CD59 (da Silva et al., 2002) as this is the mammalian protein most 
closely  related  to  Prod1  based  upon  amino-acid  identity  and  alignment  of 
cysteine residues responsible for maintaining the integrity of the three-fingered 
fold (Fig. 5.5 A). Prod1 was also predicted to share structural motifs with CD59. 
Subsequent  identification  (http://salamander.uky.edu/ESTdb/)  and  cloning  (P. 
Gates,  unpublished)  of  an  axolotl  protein  more  similar  to  CD59  in  other 
genomes than it is to Prod1 cast doubt on this classification however, indicating 
that whereas axolotls, and possibly salamanders in general, express CD59 and 
Prod1,  other  species  express  only  CD59.  B1H1  cells  were  transfected  with 
axolotl CD59 and newt Prod1, and expression of MMP9 was compared to that 
seen in GPI GFP expressing cells. It was observed that expression of CD59 in 
B1H1  cells  was  unable  to  induce  MMP9  expression  (Fig.  5.5  B).  Protein 
expression of CD59 in B1H1 cells was confirmed by Western-blotting (Fig. 5.5 
C). 
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Figure 5.4 Mutation of axolotl Prod1 α-Helix 
(A)  B1H1  and  (C)  AL1  cells  expressing  axolotl  Prod1  (Axo),  axolotl  Prod1  E59A 
(E59A), axolotl Prod1 E59Q (E59Q) and Prod1 ΔC-terminal (NA) were serum starved 
for 72hr. cDNA was prepared from cells, and MMP9 expression was analysed by qRT-
PCR. Results shown are the average of 4 independent experiments in (A) and 3 in (C). 
Protein  from  B1H1  cell  lysates  collected  for  cDNA  preparation  was  Western-blotted 
with  anti-ERK1/2  antibodies  and  anti-phospho  ERK1/2  antibodies  (B).  (D)  Anti-Flag 
Western-blot of cell lysate and culture medium from untransfected (-), axolotl Prod1-
Flag  (Axo),  axolotl  Prod1-Flag  E59A  (E59A)  and  axolotl  Prod1-Flag  E59A  (E59Q) 
expressing B1H1 cells.  
  144 
 
Figure 5.5 Lack of MMP9 induction by CD59 
(A) Alignment of Prod1 and CD59 amino acid sequences. (B) B1H1 cells expressing 
newt Prod1 (WT), CD59 (CD59), and GPI GFP (GPI) were serum starved for 72hr. 
cDNA  was prepared from cells,  and  MMP9 expression  was analysed by  qRT-PCR. 
Results  shown  are  the  average  of  9  independent  experiments.  Values  in  each 
experiment  are  normalised  to  that  seen  in  Prod1  expressing  cells.  Bars  represent 
standard error of mean. (C) Anti-Flag Western-blot of cell lysate from untransfected 
and B1H1 cells expressing CD59-Flag.  
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5.3  Discussion 
 
5.3.1  Comparing Prod1 from newt and axolotl 
Axolotl Prod1 expression is seen to initiate ERK1/2 signalling and induce MMP9 
expression, as is seen with newt Prod1, however, distinct from newt Prod1, it 
does so without the requirement for GPI anchoring to the cell membrane. A 
significant proportion of axolotl Prod1 is released extracellularly, however this 
freely  diffusing  form  of  axolotl  Prod1  is  unable  to  induce  MMP9  expression. 
That it is inactive when freely diffusing is at first surprising, as the lack of an 
anchor  suggests  that  it  does  not  require  membrane  tethering  to  function. 
However, it is plausible that in order to activate ERK1/2 signalling and induce 
MMP9,  axolotl  Prod1  must  become  associated  with  another  membrane-
tethered protein prior to reaching the cell membrane. The presumption is that 
this  would  take  place  in  the  secretory  pathway,  and  that  unanchored  newt 
Prod1  is  unable  to  make  this  essential  association,  and  is  thus  unable  to 
become appropriately positioned at the cell membrane. In support of such a 
difference between unanchored newt and axolotl Prod1 is the observation that 
substitution of amino acid 59 on the α-helix of axolotl Prod1 from glutamate to 
glutamine, as seen in newt prod1, abolishes its activity, indicating that there is 
some  significance  to  the  difference  seen  between  the  α-helices  of  the  two 
orthologs. Such a line of argument suggests that the association between newt 
Prod1  and  the  essential  signal  transducing  protein  or  protein  complex  is 
significantly  weaker  than  that  of  axolotl  Prod1,  and  therefore  membrane 
tethering is required in order to decrease its degrees of freedom and promote 
their  encounter  and  association,  whereas  the  affinity  of  axolotl  Prod1  is 
sufficiently high as to occur to a significant extent without the requirement for 
restricted mobility.  
 
Domains  2  and  3  of  uPAR  are  actively  shed  from  the  cell  membrane  by 
regulated enzymatic cleavage by uPA, which activates downstream signalling 
via the G-protein coupled receptor FPRL, bringing about cellular effects distinct 
from those seen when it is tethered to the membrane (Mazzieri et al., 2006). 
Freely diffusing uPAR domains 2 and 3 act as a chemoattractant, promoting cell  
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migration through interaction with FPRL (Resnati et al., 2002), a function which 
Prod1  may  also  promote  in  light  of  evidence  from  blastema  confrontation 
assays  (da  Silva  et  al.,  2002)  and  Prod1  overexpression  in  blastema  cells 
(Echeverri and Tanaka, 2005). Significant proportions of newt and axolotl Prod1 
are also released from the cell, raising the question of whether these secreted 
forms of the protein do have some other function distinct from MMP9 regulation, 
or  whether  they  merely  represent  a  wholly inactive,  inappropriately  localised 
fraction of the total Prod1 expressed by the cell. 
 
In contrast to B1H1 cells, axolotl cells do express Prod1, as shown by qRT PCR 
(not shown). It would seem to be the case therefore that in the axolotl cells used 
in  the  experiments,  Prod1  signalling  is  not  at  its  maximal  level,  and  has 
significant potential for increasing in response to further Prod1 overexpression. 
Due to the method used to quantify the relative increase in MMP9 mRNA levels 
in response to Prod1 expression, the difference in the increase in the absolute 
level of transcripts between axolotl cells compared to newt cells which express 
no Prod1 cannot be stated. 
 
5.3.2  The evolution of Prod1 
The  axolotl  and  the  newt  diverged  as  salamander  species  approximately  95 
million years ago (Steinfartz et al., 2007),raising the possibility that newt and 
axolotl Prod1 may have independently evolved the capability to activate ERK1/2 
signalling and induce MMP9 expression after the divergence of the two species. 
The  belief  that  Prod1  is  critical  to  limb  regeneration,  coupled  with  the 
widespread ability of salamanders to regenerate limbs, indicates it to be more 
likely  that  the  properties  of  Prod1  seen  in  newt  and  axolotl  have  been 
maintained from those present in the common ancestral salamander however. 
Also, it was observed that in terms of ERK1/2 activation and MMP9 induction, 
both  newt  and  axolotl  Prod1  function  equivalently  in  newt  and  axolotl  cells, 
indicating a common mechanism of function for the protein. Prod1 has recently 
been  identified  in  the  salamander  Ambystoma  maculatum  (P.  Gates, 
unpublished),  further  indicating  its  presence  in  all  regenerating  salamanders  
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and origin in a common ancestor, however the activity of this molecule has not 
yet been investigated.  
 
Although it is unsurprising that the nucleotide sequence of Prod1 should show 
divergence between species, that the orthologs should differ in a property as 
significant as membrane anchorage, whilst retaining at least some of the same 
functions  is  intriguing.  The  most  plausible  explanation  for  the  lack  of  a 
requirement for a GPI anchor exhibited by axolotl Prod1 is that it acquired some 
change which released selective pressure for its direct attachment to the cell 
membrane in order to function, leading to acquisition of the non-sense mutation 
observed in the sequence 5’ of the C-terminal anchor attachment peptide. That 
axolotl Prod1 functions equivalently in both newt and axolotl cells indicates that 
it is indeed a change to the protein itself rather than a difference between the 
proteins with which it interacts with in the two species. The difference in amino-
acid  59/60  seen  between  the  two  orthologs,  shown  to  be  essential  for  the 
functioning of axolotl Prod1 without an anchor, indicates that it may be changes 
to the α-helical region of the protein that preceded the loss of the GPI anchor. 
Although the opposite is possible, that newt Prod1 acquired the property of GPI 
anchorage  by  addition  of  a  functional  anchor  attachment  peptide  at  the  C-
terminal, and subsequently altered in such a way as to be unable to function 
without it, evolutionarily this makes less sense. 
 
Ambystoma  maculatum  Prod1  is  more  similar  to  Prod1  found  in  the  axolotl 
Ambystoma mexicanum than to newt Prod1, which is unsurprising in light of 
their  common  genus,  however  there  are  a number of  interesting  differences 
between them. The stop codon resulting in a truncation of the C-terminal GPI 
anchor attachment peptide of the protein is in a different position, indicating that 
both Ambystoma species lost their GPI anchors at different points in evolution, 
subsequent  to  their  divergence  from  one  another.  The  degree  of  similarity 
between the α-helical region of the two Ambystoma Prod1 proteins, shown in 
the newt to be essential for MMP9 inducing activity, is greater than when either 
is compared individually to newt Prod1, which is again not highly surprising, 
however a number of amino-acids do differ, of particular note, amino-acid 59,  
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which  in  A.  maculatum,  rather  than  being  a  glutamine  as  in  the  newt  or  a 
glutamate  as  in  the  axolotl  is  instead  a  positively  charged  lysine.  This  is 
particularly interesting in light of the fact that the negatively charged glutamate 
has been shown to be essential for the function of unanchored axolotl Prod1, 
and  cannot  be  substituted  by  the  polar  glutamine  found  in  anchored  newt 
Prod1.  The  presumption  is  that  A.  maculatum  Prod1  is  functional  as  an 
unanchored protein, raising the question of how such a difference in charge at 
such an essential amino acid is tolerated. Both Ambystoma species seem to 
have lost their GPI anchors subsequent to their divergence which, based upon 
previous  reasoning,  suggests  that  prior  to  anchor  loss,  distinct  changes 
occurred after divergence permitting function without an anchor.  
 
5.3.3  The three-fingered family of proteins 
Being  largely  constrained  only  by  the  disulphide  bonding  between  cysteine 
residues  to  form  the  ‘palm’  of  the  three-fingered  domain,  the  secondary 
structures adopted by the fingers are flexible to evolve, facilitating the creation 
of diverse protein-protein interaction interfaces. Due to this, the three fingered 
proteins are a particularly diverse family at the sequence level (Galat, 2008) 
and  comparison  of  protein  structure  provides  a  more  informative  means  of 
categorisation of the members of the family. Such a structural categorisation 
indicates that uPAR domain 3 and CD59 are the most closely related domains 
found  in  species  other  than  salamanders,  (Garza-Garcia  et  al.,  2009)  all  of 
which exhibit an α-helix at finger 3. The GPI anchored domain 3 of uPAR has 
been shown to be responsible for the interaction with α5β1 integrin leading to 
ERK1/2 activation following fibronectin binding (Chaurasia et al., 2006) which 
has been shown to result in Src dependent MMP9 induction (Wei et al., 2007). 
Given the similarities in protein structure and downstream effects it is therefore 
surprising that Prod1 and uPAR do not seem to share integrin mediated Src 
activation in their mechanisms. 
 
The three-fingered protein family has been shown to have undergone a large 
expansion in salamanders (pers. com. R.Voss to J.Brockes) and based upon 
sequence,  Prod1  groups  most  closely  with  a  group  of  pheremone  proteins  
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named the plethodontid modulating factors (PMF) (Garza-Garcia et al., 2009), 
which are found only in lungless salamanders. The structures of these PMFs do 
not contain the α-helical region shared by Prod1, CD59 and uPAR shown to be 
essential for Prod1s MMP9 inducing activity however, and therefore structurally, 
and most likely functionally, Prod1 is more similar to CD59 and uPAR. Taken 
together with the absence of Prod1 from the genomes of all non-salamander 
species, these points indicate that Prod1 evolved after the divergence of the 
salamander  lineage  from  other  species,  and  that  it,  uPAR  and  CD59 
independently  evolved  the  structural  features  they  share,  and  their  ability  to 
interact  with  the  ‘older’,  evolutionarily  more  conserved  EGFR.  Results 
presented in Chapter 4 indicate however that it is not the shared α-helix that 
facilitates  Prod1  interaction  with  the  EGFR,  which  seems  a  strange  co-
incidence in light of these features being common to CD59, uPAR and Prod1.  
 
In this study Prod1 has been shown to regulate the expression of MMP9, as 
does uPAR, however CD59 was not observed to do so, despite reports that it 
interacts with the EGFR. It can be seen clearly from the amino-acid sequences 
of  the  two  proteins  that  there  are  significant  differences  between  Prod1 and 
CD59  however,  and  taken  in  light  of  the  evidence  in  Chapter  4  that  EGFR 
interaction alone is not sufficient even for Prod1 to induce MMP9, the inability of 
CD59 to induce MMP9 is likely to be due to its inability to interact with the full 
repertoire of proteins required to bring about this effect.  
 
5.3.4  Implications for the role of GPI anchors in cell-signalling 
An interesting point raised by the lack of requirement for the GPI anchor relates 
more generally to the broader field of GPI anchored protein biology. Reports 
exist that GPI anchoring plays a functional role in localising proteins to ‘lipid 
rafts’, reviewed in (Helms and Zurzolo, 2004) (Simons and Toomre, 2000) and 
that substitution of the lipid anchor for a proteinaceous anchor can disrupt their 
function (Robinson et al., 1989). It has also been suggested that NRTKs such 
as those of the Src family associate specifically with the inner leaflet of ‘lipid 
rafts’ (Simons and Toomre, 2000), and that they somehow transduce a signal 
initiated  by  clustering  of  GPI  anchored  proteins  in  the  outer  leaflet  of  the  
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membrane (Murray and Robbins, 1998), however as shown in Chapter 4, Src 
family kinases are not involved in the transduction of the Prod1 signal leading to 
induction of MMP9 expression. That axolotl Prod1 functions in the absence of a 
GPI  anchor  indicates  that  this  somewhat  mysterious  mode  of  coordinating 
signal  transduction  is  not  in  operation  and  that  axolotl  Prod1  at  least  is 
appropriately localised by a means other than through the association of lipids.    
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6  A primary culture model of MMP9 activity  
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6.1  Introduction 
 
In the preceding chapters Prod1 expression has been shown to regulate the 
expression of MMP9 in cultured limb cells, but the significance of this for the 
processes  occurring  in  the  blastema  during  limb  regeneration  remains  to  be 
addressed.  MMP9  is  known  to  be  upregulated  in  the  skin  and  the  wound 
epithelium  following  injury,  and  the  persistence  of  MMP9  expression  is  one 
characteristic of whether wound-healing or limb regeneration results (Satoh et 
al., 2008). Furthermore, the processes of wound healing and the formation of 
the  wound  epithelium  essential  for  blastema  formation  and  subsequent 
regeneration both involve the migration of epithelial cells. Prod1 is expressed at 
a significantly higher level in the dermis (A.Kumar, unpublished) compared to 
other  limb  tissue,  so  with  all  these  points  in  mind,  a  culture  model  to  study 
MMP9 regulation in the skin was developed. Although a large upregulation of 
MMP9 was observed in this model, it appeared not to depend on the pathways 
delineated earlier in this thesis. 
 
6.2  Results 
 
6.2.1  Locating the site of Prod1 and MMP9 expression in limb tissue 
It is known that RA both proximalises the regenerating limb and upregulates 
Prod1 in the blastema (da Silva et al., 2002). More recently, it has been shown 
that upregulation of Prod1 by RA is more pronounced in the dermis compared 
to the underlying blastemal tissue (Kumar et al., 2007a). Prod1 gene expression 
was  also  shown  to  be  markedly  higher  in  the  dermis  compared  to  in 
muscle/mesenchyme (Fig. 6.1 A) of intact limbs, although Prod1 expression in 
proximal dermis was not observed to be any higher than in distal dermis. Two 
independent  normalising  probes  were  used  when  comparing  skin  to 
mesenchyme  (for  a  detailed  discussion  of  normalisers,  see  Materials  and 
Methods). Immunofluorescence labelling also showed that the level of Prod1 
protein expression was markedly higher in the dermis of intact limbs compared 
to  other  tissues  (Fig.  6.1  B,  courtesy  of  A.  Kumar).  In  order  to  investigate 
whether induction of MMP9 gene expression correlated spatially with the high  
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Prod1 expression seen in the dermis, a protocol was developed to remove the 
epidermis from skin patches (see Materials and Methods). The structure of skin 
prior to treatment with trypsin clearly shows the epidermis and dermis (Fig. 6.1 
C.a, courtesy of A. Kumar). Subsequent to trypsin treatment, only the dermis 
remains (Fig. 6.1 C.b, courtesy of A. Kumar). Skin patches were explanted (see 
Materials and Methods), and the MMP9 expression in the dermis after 24hr of 
culture was compared to that seen in patches 1hr after removal from the limb 
(Fig. 6.1 D), and was observed to be highly upregulated following the culture 
period. MMP9 induction was observed in patches plated on collagen substrate, 
and to a lesser extent, patches cultured in suspension. MMP9 expression was 
also seen to be upregulated in a piece of skin with the epidermis removed prior 
to culture (Fig. 6.1 E), indicating that the dermis is necessary and sufficient for 
the response. 
 
6.2.2  Investigating the role of MMP9 in migrating skin cells 
Patches  of  limb  skin  were  explanted  into  culture  and  within  12hr  cells  were 
observed  to  migrate  out  from  patches,  a  process  that  proceeded  for 
approximately  96  hr,  after  which  migration  ceased.  The  identity  of  these 
migrating cells was analysed with antibodies against cytokeratin, a marker of 
epithelial cells (Fig. 6.2 A.a, courtesy of A. Kumar) and vimentin, a marker of 
mesenchymal cells (Fig. 6.2 A.b, courtesy of A. Kumar). The epithelial origin of 
a significant proportion of cells was indicated by their cytokeratin expression 
however all cells also expressed vimentin. MMP9 gene expression in migrating 
cells was observed at various time points after plating by in-situ hybridisation, 
as described in Materials and Methods. A representative sample is shown (Fig. 
6.2 B). In order to test whether MMPs are involved in this migration process, 
skin  patches  were  plated  in  the  presence  or  absence  of  GM6001,  a  broad 
spectrum  MMP  inhibitor  known  to  inhibit  limb  regeneration  (Vinarsky  et  al., 
2005).  Minimal  cell  migration  was  observed  in  the  presence  of  the  inhibitor 
compared to controls, and once the inhibitor was removed, migration proceeded 
as normal (Fig. 6.2 C).  
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Figure 6.1 Expression of Prod1 and MMP9 in limb skin 
(A) Expression of Prod1 in distal skin (DS), distal limb tissue (DT), proximal skin (PS) 
and  proximal  tissue  (PT)  was  determined  by  qRT-PCR.  cDNA  was  prepared  from 
pooled samples of skin or tissue from 6 limbs. Values are relative to that obtained for 
distal skin. Prod1 expression is normalised to EF1α in (Aa) and GAPDH in (Ab). (B) 
Sagittal section of newt limb stained with anti-Prod1 antibody. Epidermis is marked (E), 
dermis  (D).  Note  the  pronounced  Prod1  signal  in  the  dermis.  (C)  A  technique  for 
complete removal of the epidermis from the underlying dermis was developed (See 
Materials and Methods). Hematoxylin eosin stain shows the presence of the epidermis 
(E) and dermis (D) in (C.a) prior to processing, and the presence of only the dermal 
layer in (C.b) after processing. (D) Skin  was cultured for 1hr or 24hr in suspension 
culture  (S),  or  plated  on  collagen  (P).  Epidermis  was  subsequently  removed  and 
expression of MMP9 in the dermis was determined by qRT-PCR. Results shown are 
the average of two independent samples. (E) Skin (Sk) (i.e. dermis plus epidermis) was 
cultured for 1hr in suspension culture or 24hr plated on collagen, or dermis alone was 
cultured for 24hr plated on collagen (D). Epidermis was subsequently removed and the 
expression of MMP9 in the dermis was determined by qRT-PCR. Results shown are 
the average of two independent samples for Sk and from one sample for D. In (C) and 
(D) values are relative to that seen in one of the patches cultured for 1hr. GAPDH was 
used as a normalising gene. Bars represent SEM. 
 
 
6.2.3  Inhibiting Prod1 signalling in skin patches 
The inhibitors shown in Chapter 4 to be effective at inhibiting Prod1 induced 
MMP9  expression  in  B1H1  cells  were  used  to  investigate  the  role  of  the 
Prod1/EGFR/ERK1/2  pathway  in  the  regulation  of  MMP9  expression  in  skin 
patches.  Cells  were  treated  with  the  EGFR  inhibitor  PD153035  (Fig.  6.3  A), 
simultaneously  with  PD153035  and  the  ErbB2  inhibitor  AG879,  the  ERK1/2 
kinase inhibitor U0126, the JAK/STAT inhibitor AG490, and the Wnt pathway 
inhibitor  Dickkopf1  (Fig.  6.3  B),  and  simultaneously  with  U0126,  AG490, 
PD15305 and AG879 (Fig. 6.3 C). Wnt signalling was targeted as it is known to 
activated by skin injury and inhibition of this pathway by DKK has previously 
been  shown  to  inhibit  regeneration  in  axolotl,  Xenopus  and  zebrafish  by 
disrupting the formation of the apical ectodermal cap (Kawakami et al., 2006). 
Inhibition of EGFR signalling clearly showed no effect on MMP9 expression in 
the skin patches, neither did inhibition of Wnt signalling.  
  
  156 
 
Figure 6.2 MMP9 expression in migrating cells 
(A) Immunofluorescence showing cytokeratin (A.a) and vimentin  (A.b) expression in 
cells  migrating  from  an  explanted  skin  patch.  Nuclei  are  stained  blue  with  Hoechst 
stain.  (B)  MMP9  expression  in  cells  migrating  from  skin  patches  shown  by  in-situ 
hybridisation.  The  skin  explant  shown  was  fixed  48hr  after  culture  on  collagen 
substrate  and  is  representative  of  samples  fixed  after  24-96hr  in  culture.  Black 
arrowhead shows a migrating cell with perinuclear localisation of the anti-sense probe. 
(B) Skin explants were cultured for 48hr in the presence of DMSO (D) or GM6001 (G) 
and  photographed.  GM6001  was  then  substituted  for  DMSO  and  explants  were 
cultured for a further 48 hr (48hr+48hr=96hr) and photographed. The area of the sheet 
that had migrated out from the patch at 48hr or 96hr was compared to the area of the 
patch itself and expressed as a ratio. Bars represent SEM. Note that little migration 
occurs  in  the  presence  of  GM6001,  however  proceeds  at  the  normal  rate  after  its 
removal.  
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Surprisingly, there was some indication that treatment with AG490, and to a 
lesser extent with U0126, enhanced MMP9 induction in skin patches after 24hr, 
however  the  variability  between  results  observed  in  different  patches  makes 
interpretation difficult. A similar effect was observed following treatment with a 
combination of inhibitors including AG490 and U0126. 
 
 
Figure 6.3 Effect of signalling pathway inhibitors on MMP9 expression in 
the dermis of skin patches 
Skin (i.e. dermis plus epidermis)  was cultured for 1hr in suspension culture or 24hr 
plated on collagen in the presence of (A) DMSO [D] or PD153035 50uM [P], (B) DMSO 
[D], PD153035 25uM + AG879 10uM [P+A8], DKK1 4ug/ml [D], U0126 30uM [U] or 
AG490 50uM [A4] or (C) DMSO [D] or a combination of PD153035 25uM, AG879 5uM, 
U0126 10uM and AG490 20uM [C]. After the culture period, epidermis was removed 
and the expression of MMP9 in the dermis was determined by qRT-PCR. Values are 
relative to that seen in one of the patches cultured for one hour in the presence of 
DMSO.  
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A  peptide  of  sequence  VQQCAEVLEEVTAI,  representing  the  amino-acids 
constituting  the  α-helix  of  Prod1,  was  used  in  an  attempt  to  block  MMP9 
induction  by  Prod1  in  a  similar  approach  to  one  employed  to  disrupt  the 
interaction of uPAR and α3β1 integrins, thereby inhibiting downstream effects 
(Ghosh et al., 2006). It was hypothesised that as amino-acids on the α-helix of 
Prod1 had been shown to be essential for MMP9 induction by Prod1, such a 
peptide should compete with Prod1 for binding to its essential transmembrane 
signal  transducing  partner  protein  and  prevent  the  formation  of  a  functional 
signalling complex. The effect of the peptide on MMP9 induction resulting from 
Prod1 expression in B1H1 cells was investigated, but under the experimental 
conditions employed no effect of its inclusion in culture medium was observed 
(Fig. 6.4).  
 
 
 
Figure 6.4 Effect of Prod1 α-helix peptide on MMP9 expression 
B1H1 cells expressing either Prod1 (WT) or GPI GFP (GPI) were cultured in serum 
free medium containing 0.1% BSA in the presence of the indicated concentration of a 
polypeptide representing the amino-acid sequence of the α-helix of Prod1. After 72hr 
the expression of MMP9 was determined by qRT-PCR. Results shown are the average 
of three independent samples for 1uM and 10uM and two for 0.1uM. Bars represent 
SEM. Note that under the experimental conditions used, the peptide had no effect on 
MMP9 expression in either Prod1 or GPI GFP expressing cells.  
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6.2.4   Investigating the MMP9 inducing signal following injury 
In  the  response  to  injury,  the  behaviour  of  cells  at  the  wound  edge  can  be 
considered distinctive in view of their boundary location. In order to gain some 
insight  into  the  mechanism  initiating  the  induction  of  MMP9  following 
explantation  into  culture,  the  role  of  the  cells  at  the  edge  of  the  patch  with 
reduced lateral cell-cell association was investigated. Patches of skin were cut 
into quarters, doubling the length of the exposed edge and the number of cells 
not fully surrounded by others in the lateral plane, and MMP9 induction after 
24hr was compared to intact patches (Fig. 6.5 A). No significant difference in 
MMP9  induction  was  seen  to  result  from  this  doubling  of  the  edge  length 
however. Whether MMP9 induction in the dermis is unique to limb skin was 
addressed by explanting skin from newt head, a tissue known not to support 
limb regeneration following amputation when grafted in place of limb skin (Tank, 
1983). As with limb skin, 24hr in culture lead to a marked induction of MMP9 
expression in the dermis of head skin (Fig. 6.5 B).  
 
6.2.5  Investigating MMP9 expression in limb blastemas 
In order to determine if the level of Prod1 expressed by the cells of a blastema 
correlates with the level of MMP9 expressed by those cells, proximal and distal 
blastemas  were  compared  (Fig.  6.6  A)  as  well  as  RA  to  DMSO  treated 
blastemas (Fig. 6.6 B). On average, Prod1 expression was observed to be the 
expected 1.7 fold higher in cells harvested from proximal blastemas, however 
MMP9 expression was not observed to be higher proximally. RA treatment of 
animals  elevated  Prod1  expression  approximately  7.5  fold  in  blastema  cells 
compared  to  DMSO  controls,  and  in  two  out  of  three  experiments  MMP9 
expression was elevated in cells harvested from the blastemas of RA treated 
animals. 
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Figure  6.5  Initiation  of  MMP9  induction  in  the dermis  of  explanted skin 
patches 
(A) Patches of limb skin (dermis +epidermis) were either cultured whole [1/1] or cut into 
quarters [1/4] for 1hr in suspension or 24hr plated on collagen. After the culture period, 
epidermis was removed and the expression of MMP9 in the dermis was determined by 
qRT-PCR.  Results shown are the average of two independent samples in (Aa) and 
three independent samples in (Ab). (B) Patches of head skin (dermis +epidermis) were 
cultured  for  1hr  in  suspension  or  24hr  plated  on  collagen.  After  the  culture  period, 
epidermis was removed and the expression of MMP9 in the dermis was determined by 
qRT-PCR. Results shown are the average of two independent samples for 24hr and 
one sample for 1hr. In (A) and (B), bars represent SEM.  
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Figure 6.6 MMP9 expression in the blastema 
The  expression  of  MMP9  (A.a)  and  Prod1  (A.b)  in  distal  [Dist)  and  proximal  [Prox] 
blastemas was determined by qRT-PCR. Results shown are from three independent 
samples.  MMP9  and  Prod1  expression  is  shown  relative  to  that  seen  in  distal 
blastemas in each experiment. The expression of MMP9 (B.a) and Prod1 (B.b) in the 
blastemas of DMSO (DMSO) and retinoic acid [RA] injected animals was determined 
by qRT-PCR. Results shown are from three independent samples. MMP9 and Prod1 
expression is shown relative to that seen in blastemas from DMSO injected animals in 
each  experiment.  In  (A)  and  (B),  each  cDNA  sample  was  prepared  from  6  pooled 
blastemas.  
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6.3  Discussion 
 
6.3.1  Does  the  Prod1  EGFR  pathway  regulate  MMP9  expression  in  the 
dermis? 
It  has  been  shown  that  following  surgical  removal  from  the  limb,  MMP9 
expression becomes upregulated in the cells of the dermis. Prod1 is observed 
to be expressed most highly in the dermis of intact limbs, and following RA 
treatment,  which  proximalises  regenerating  limbs,  upregulation  of  Prod1 
expression is most marked in the dermis (Kumar et al., 2007a). Taken in light of 
the observed regulation of MMP9 expression by Prod1 in cultured limb cells, it 
is  tempting  to  speculate  that  the  induction of  MMP9  expression  seen  in  the 
dermis following surgical removal is regulated by the Prod1 expressed there.  
 
The  α-helix  of  Prod1  had  been  shown  previously  to  be  essential  for  the 
induction of MMP9, suggesting that a peptide with the amino-acid sequence of 
the α-helix of Prod1 may be able to block molecular interactions between Prod1 
and another protein essential for the induction of MMP9. The specific inhibition 
of  MMP9  induction  by  a  peptide  representing  the  α-helix  of  Prod1  in  skin 
patches  would  indicate  a  direct  relationship  between  Prod1  expression  and 
MMP9  induction,  however  the  approach  was  unsuccessful  at  blocking  the 
induction of MMP9 by Prod1 in the simpler B1H1 cell culture model and was not 
extended to skin patches. The possibility exists however that the peptide did not 
adopt  the  appropriate  α-helical  conformation  in  solution.  Work  is  currently 
underway in the group to develop a method to knock-down Prod1 expression in 
the regenerating limb using morpholinos, and should this be successful it will be 
interesting  to  see  whether  this  has  an  effect  on  the  regulation  of  MMP9 
expression in the dermis of these animals.  
 
The  inhibitors  of  EGFR,  ERK1/2  and  JAK/STAT  signalling  shown  to  inhibit 
MMP9 expression in cultured cells expressing Prod1 also proved unsuccessful 
in  establishing  a  link  between  the  process  characterised  in  the  cell-culture 
model and that occurring in the skin. The lack of efficacy of the compounds 
used,  even  when  used  at  concentrations  higher  than  when  treating  cultured  
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cells,  or  in  combination  to  target  each  level  of  the  pathway  simultaneously, 
raises  the  possibility  that  the  compounds  are  not  gaining  access  to  the 
appropriate cells in the dermis. When working with explanted skin patches in in-
situ hybridisation experiments, it was not possible to gain access to the dermis 
layer  with  an  oligonucleotide  probe,  even  after  enzymatic  digestion  of  the 
sample,  indicating  the  dermis  to  be  a  relatively  impenetrable  tissue.  The 
signalling  pathway  inhibitors  are  significantly  smaller  molecules  than 
oligonucleotides  however,  and  there  was  some  indication  that  AG490  in 
particular was instead able to stimulate MMP9 induction in skin patches. The 
number  of  experiments  carried  out  were  too  few  however,  in  light  of  the 
observed  variability  between  samples,  to  make  a  firm  conclusion  on  this. 
Should further experiments be conducted and confirm this result, it would be 
consistent with the conclusion of Chapter 4 that the EGFR ERK1/2 pathway is 
in fact secondary to some other as yet unidentified pathway. Also, as the skin 
has been completely removed from its normal location, dermal cells may be 
experiencing an overriding signal, either positive in nature or due to a release 
from  inhibition,  to  induce  MMP9  expression  which  would  occur  in  a  more 
regulated  manner  were  they  in  their  native environment.  These  experiments 
demonstrate the ability of dermal cells to rapidly upregulate MMP9 expression 
in response to removal from the limb, however further work will be required in 
order  to  establish  unequivocally  whether  this  process  occurs  in  the  dermis 
following limb amputation. 
 
6.3.2  The origin of migrating cells 
All migrating cells express the mesenchymal marker vimentin, however a sub-
population of these also express cytokeratin, indicative of their epithelial origin 
(Fuchs and Cleveland, 1998). It is unclear therefore whether all migrating cells 
are  undergoing  epithelial-to-mesenchymal  transition  (Zavadil  and  Bottinger, 
2005)  and  therefore  essentially  originate  from  the  epidermal  epithelium,  or 
whether  cells  originating  in  the  dermal  mesenchyme  also  migrate  out  from 
explanted  skin  patches.  A  population  of  these  cells  express  MMP9,  but  the 
identity of these migrating MMP9 expressing cells is not clear. Inhibition of MMP 
activity inhibits the migration of all cells however, indicating that its activity is 
required in order for any cells to exit the patch and spread across the substrate,  
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expressed either by themselves or by neighbouring cells. What is clear is that 
dermal cells that remain in the patch do markedly upregulate MMP9 expression. 
Cells  of  dermal  origin  are  known  to  begin  migrating  into  the  centre  of  the 
blastema at 5 days post injury in the axolotl (Gardiner et al., 1986) and they or 
their  progeny  translocate  distally  as  the  blastema  grows  becoming  widely 
distributed throughout it (Endo et al., 2004) and the subsequently regenerated 
structures (Kragl et al., 2009). In a 5 day blastema, MMP9 is expressed in a 
limited  number  of  cells,  however  at  15  days  its  expression  is  seen  to  be 
widespread  (Vinarsky  et  al.,  2005),  inviting  speculation  that  the  migrating 
dermal cells express MMP9 and thereby exit the dermis, allowing their progeny 
to  spread  through  the  blastema  as  it  grows.  Similarly,  Prod1  expression 
becomes more widespread throughout the blastema as regeneration proceeds 
(da Silva et al., 2002). Recent experiments in which GFP labelled dermis was 
grafted onto a wild-type axolotl prior to amputation showed that cells of dermal 
origin contribute to connective tissue, tendon and cartilage (Kragl et al., 2009). 
In these limbs, cartilage is the precursor to bone, indicating that dermal cells 
contribute to all of what could be considered the structural elements of the limb. 
As  the  limb  derives  its  complex  pattern  from  the  skeleton,  it  is  particularly 
interesting to observe such a high proportion of cells of dermal origin, believed 
to posses innate positional identity (Tank, 1981), in these structures following 
regeneration.    
 
6.3.3  MMP9 and cell adhesiveness 
It has been indicated by confronting proximal and distal blastemas that distal 
blastema cells may be more adhesive (Nardi and Stocum, 1983), and that this 
property is mediated through the level of Prod1 expressed on the cell surface 
(da Silva et al., 2002). The regulation of MMP9 expression by Prod1 in cultured 
cells allows interpretation of the lower adhesiveness of high Prod1 expressing 
cells in terms of their potentially higher MMP9 expression and matrix degrading 
activity.  Likewise,  that  distal  blastemas  translocate  along  the  limb  axis  by 
affinophoresis when grafted to the dorsal surface of a proximal amputation site 
whereas  proximal  blastema  do  not  (Crawford  and  Stocum,  1988a)  can  be 
interpreted as resulting from a higher affinity of distal blastemas for the ECM of 
the regenerating limb than proximal blastemas, which rather than being carried  
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along as the limb elongates instead remain at the site of grafting due to lack of 
adhesiveness.  The  proximal  translocation  of  distal  blastema  cells 
electroporated  with  Prod1  (Echeverri  and  Tanaka,  2005)  may  be  a  result  of 
them loosing contact with other distal cells due to their lower affinity for the 
ECM, and becoming re-located to more proximal regions of the limb.  
Rather  than  regulating adhesiveness,  higher  Prod1  expression  may  promote 
cell  migration.  Proximal  blastema  cells  may  tend  to  migrate  at  a  faster  rate 
around  distal  blastemas  due  to  less  constraint  from  the  ECM,  or  Prod1 
electroporated  distal  blastema  cells  may  actively  migrate  proximally.  The 
affinophoresis of distal blastemas grafted proximally is less easily explained in 
these terms unless it is supposed that proximal blastemas remain at the site of 
grafting  by  continually  migrating  proximally  to  counteract  the  effect  of  the 
outgrowth of the limb displacing it distally, whereas distal blastemas lack this 
ability and are unable to oppose the translocating effect of limb outgrowth.  
 
6.3.4  MMP9 regulation and proximodistal patterning 
Early in limb regeneration, HoxA13, a gene known to regulate patterning in the 
hand, is expressed, and as limb regeneration proceeds its localisation to distal 
cells becomes increasingly apparent, indicating that distal cells are specified to 
hand fates early in the process of regeneration (Gardiner et al., 1995). When 
distal blastemas are grafted onto proximal stumps, it is the cells from the stump 
that  regenerate  the  limb  structures  from  shoulder  to  wrist,  with  the  distal 
blastema only contributing to the hand (Pescitelli and Stocum, 1980). Similarly, 
electroporation of the most distal cells of a blastema with a GFP marker results 
in GFP localised only to hand structures (Echeverri and Tanaka, 2005). The 
cell-cycle length of cells found at more proximal locations in the blastema is 
significantly  shorter  than  more  distally  located  blastema  cells  (Connelly  and 
Bookstein, 1983) (Endo et al., 2004), indicating a greater contribution of these 
cells  to  the  regeneration  of  tissue.  In  light  of  the  fact  that  regeneration  will 
always  produce  the  same  hand  structure,  but  depending  upon  the  level  of 
amputation, the requirement for regeneration of more proximal structures varies 
across a range, it makes sense that the hand would follow a defined program in 
all cases, and that taken with the knowledge that distal regions of the blastema 
are  fated  early  to  form  the  hand  structures,  that  proximal  regions  of  the  
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blastema would be responsive to the requirement for the amount of other limb 
structures to regenerate. When labelled limb dermal cells are implanted into a 
blastema they are found distributed along the entire proximodistal axis of the 
blastema. In contrast, dermal cells from head skin, which do not support limb 
regeneration  are  not  (Satoh  et  al.,  2007). The  indication  of  this  is  that  cells 
originating from the dermis of the limb actively locate distally as the blastema 
elongates by migration or cell division. These cells have been shown to make a 
large contribution to the regenerated limb (Kragl et al., 2009), indicating that 
they are expanding in number by proliferation. A model has been developed to 
induce limb regeneration from wounds that would be expected to produce only 
skin regeneration, and this has been shown to require the encounter of dermal 
cells  with  positional  coordinates  from  around  the  circumference  of  the  limb, 
which stimulate the proliferation of blastema cells and maintains the process of 
regeneration  (Endo  et  al.,  2004).  The  evident  importance  of  dermal  cells  to 
drive  the  elongation  of  the  regenerating  limb  raises  the  question  of  whether 
Prod1 regulated MMP9 induction in dermal cells somehow mediates the limb 
structures regenerated by regulating their exit from the dermis and migration 
into the blastema. 
  
Regenerating limbs exposed to RA upregulate Prod1 expression in the dermis 
(Kumar  et  al.,  2007a)  and  produce  extra  proximal  limb  structures  (Maden, 
1982). It would be interesting to establish whether this leads to an increase in 
MMP9 expression by dermal cells, thereby enhancing their ability to migrate 
into the blastema and contribute to the regenerate. There was some indication 
of  a  mild  enhancement  of  MMP9  expression  in  blastema  cells  of  animals 
exposed  to  RA,  however  experiments  were  inconclusive.  There  was  no 
indication  of  higher  MMP9  expression  in  proximal  blastemas  than  in  distal 
blastemas, however as the difference in Prod1 expression is relatively small 
compared to the difference seen between RA and DMSO treated blastemas, 
presumably any difference in MMP9 expression would be accordingly smaller 
and more difficult to detect.  
 
Should the level of dermal Prod1 expression in normal intact limbs be the key 
regulator  of  the  extent  of  regeneration  of  proximal  structures,  it  would  be  
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expected to be expressed more highly in proximal dermis than distal dermis. 
The limited investigation of this documented here used dermis plus epidermis 
samples from a number of limbs pooled together and found no difference in 
Prod1  expression  in  proximal  skin  compared  to  distal  skin  however.  The 
gradient  of  Prod1  expression  previously  demonstrated  in  samples  prepared 
from all limb tissue is shallow but well established (Kumar et al., 2007a), making 
it somewhat puzzling as to why no gradient was detected in the skin. If the skin, 
particularly the dermis, is a major site of Prod1 expression, a gradient might be 
expected to be more pronounced in skin samples as the signal would not be 
‘diluted’ by normalisation for total mRNA taking account of all the mRNA from 
tissue which does not express Prod1. One possibility is that as 6 samples were 
pooled  rather  than  analysed  independently,  a  difference  may  have  been 
masked by variability in the overall level of Prod1 expressed in individual limbs, 
for which there has been some evidence gathered by P. Gates. This seems an 
unlikely explanation however, as paired proximal and distal samples were all 
taken from the same limb, so unless the variability in Prod1 expression was 
specifically only in either proximal or distal skin, pooling samples should not 
have resulted in such sampling error. Prod1 is expressed in cells other than 
those  found  in  the  dermis  however  (da  Silva  et  al.,  2002),  and  if  the 
proximodistal Prod1 gradient is truly not manifested by the cells of the dermis, 
the  indication  is  that  it  is  these  other  cells  that  express  Prod1  differentially 
according  to  their  position  along  the  limb  axis.  One  possibility  is  that  Prod1 
expressing cells associated with other tissues are distributed along the axis of 
the  limb  in  such  a  manner  that  there  are  either  more  of  them,  or  more 
expressing high levels of Prod1 proximally. 
 
Prod1 expression is generally higher in the cells of proximal blastemas and its 
expression is upregulated by RA (da Silva et al., 2002). Dedifferentiation is also 
observed  to  be  higher  in  RA  treated  blastemas  (Ju  and  Kim,  1994),  and 
proximal  blastemas  have  higher  RA  activity  (Scadding  and  Maden,  1994). 
Higher MMP9 expression has been observed in RA treated blastemas (Park 
and Kim, 1999) consistent with the possibility that higher expression of Prod1 
induced by higher RA activity in proximal blastemas increases de-differentiation 
through MMP9 regulation. Discussion in the Introduction of the role of MMPs in  
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patterning the regenerating limb leant towards a role for them in determining the 
size  of  the  regenerate  rather  than  establishing  the  number  of  limb 
compartments however. Should Prod1s function during limb regeneration be to 
regulate  the amount  of  stump  de-differentiation  according  to  the  PD  level  of 
amputation  via  MMP9,  the  indication  is  that  rather  than  being  a  primary 
determinant of PD patterning, Prod1 may instead act in a secondary capacity to 
ensure an appropriate quantity of precursor cells for the level of amputation. 
 
The  expression  of  Prod1  and  of  Meis  homeobox  protein  in  blastema  cells 
respecifies  them  to  more  proximal  identities  (Echeverri  and  Tanaka,  2005) 
(Mercader et al., 2005). The implication of this is that cells become relocated 
from a region of the blastema fated to form distal structures to a region with 
more proximal fate. It can be imagined that the overexpression of Prod1 may 
upregulate MMP9 expression and allow cells to migrate through the blastema to 
a more proximal region, however as Prod1 is expressed in a gradient along the 
limb axis (Kumar et al., 2007a) but Meis is not (Mercader et al., 2005), it is seen 
as being upstream of Meis in specifying the proximodistal identity of blastema 
cells. Should this be the case, if this relocation involves MMP9 it would imply 
that  it  is  regulated  by  Meis.  Alternatively,  Meis  may  upregulate  Prod1 
expression in proximal blastemas. It is conceivable that Meis may regulate both 
the  patterning  of  the  proximal  limb  compartments  and  the  extent  of  de-
differentiation via upregulation of MMP9 via Prod1, though it is also plausible 
that RA may independently regulate the level of Meis and Prod1 in the blastema 
as discussed in the Introduction. If either RA or Meis regulates the expression 
level  of  Prod1  in  the  blastema  however,  this  indicates  that  Prod1  is  not  a 
primary determinant of PD identity of blastema cells and that the PD gradient of 
Prod1 expression in the intact limb (da Silva et al., 2002) is misleading in its 
suggestion that the graded expression of a cell-surface determinant underlies 
the patterning process during limb regeneration 
 
6.3.5  A role for the Prod1 ligand nAG in the regulation of MMP9? 
Wounding  in  the  absence  of  a  nerve  supply  results  in  the  deposition  of  a 
collagenous matrix beginning around day 5 and becomes most evident at day 7 
(Endo et al., 2004), however if a nerve is deviated to the vicinity this matrix is  
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not formed. Regeneration of an amputated limb requires a threshold level of 
innervation, below which blastemas do not develop, possibly due in part to the 
accumulation  of  collagenous  matrix  associated  with  healing  which  interferes 
with  the  early  events  in  the  establishment  of  a  blastema.  nAG,  a  protein 
expressed  by  nerve  associated  Schwann  cells,  has  recently  been  shown  to 
rescue limb regeneration in the absence of the nerve, and evidence exists of a 
physical interaction between it and Prod1 (Kumar et al., 2007b). Whether nAG 
is involved in promoting the migration of Prod1 positive, MMP9 secreting cells 
from  the  dermis  that  degrade  this  collagen matrix,  and  thereby  facilitate  the 
appropriate environment for blastema development, is an interesting point for 
consideration. Although in some sense it may seem counterintuitive to suppose 
that  mesenchymal  cells  lay  down  collagen  only  for  it  to  be  simultaneously 
degraded,  when  taken  in  light  of  the  possibility  that  the  process  of  limb 
regeneration  may  have  evolved  subsequently  to  the  mechanisms  operating 
during  wound  healing  (Brockes  and  Kumar,  2008),  that  these  two  opposing 
processes are occurring during the early stages of blastema formation becomes 
more  plausible.  Collagen  degradation  occurs  during  the  process  of  wound 
healing  (Bullard  et  al.,  1999)  (Pilcher  et  al.,  1997)  and  the  mechanisms 
facilitating regeneration may have adapted the role of this process. Denervated 
blastemas  are  observed to  upregulate MMP9  expression  to  a  greater  extent 
than  innervated  blastemas  however  (Monaghan  et  al.,  2009),  making  a 
requirement  for  nAG  in  this  process  unlikely.  In  this  study  Prod1  has  been 
shown  to  regulate  the  expression  of  MMP9,  a  molecule  which  permits  cell 
migration through tissue, in cultured cells, however previous work indicates that 
its interaction with nAG promotes cell proliferation (Kumar et al., 2007b). Prod1 
may therefore play a role in the coordination of arguably the two most essential 
processes occurring during regeneration, one of which requires the participation 
of  nAG  and  one  of  which  does  not.  Denervated  limbs  rescued  by  nAG 
regenerate  the  skeleton  but  not  the  muscle  (Kumar  et  al.,  2007b)  which  is 
interesting when considered together with the fact that Prod1 expressing dermal 
cells contribute to the regeneration of skeletal and connective tissue but not 
muscle (Kragl et al., 2009).  
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6.3.6  Induction of dermal MMP9 expression following injury 
The mechanism initiating MMP9 expression in the cells of the limb dermis is of 
clear interest. MMP9 was seen to be upregulated in the dermis after 24hr both 
in samples cultured in suspension and plated on collagen, indicating it is not the 
interaction with collagen initiating the signal. Patches cut into quarters, thereby 
doubling the number of edge cells missing lateral cell-cell contact, showed no 
significant  increase  in  MMP9  induction  after  24hr,  indicating  that  the  loss  of 
these contacts are either not the source of the MMP9 initiating signal, or that 
the signal is propagated rapidly across all the cells of the dermis within 24hr. 
Perhaps it is in fact the loss of contact of dermal cells with signals from the 
underlying  ECM  that  induces  MMP9  expression  in  explanted  skin.  MMP9 
induction was also observed in a single sample of dermis plated in the absence 
of overlying epidermis. Should this be repeated it would indicate that dermal 
cells do not require signals from the epidermis in order to induce MMP9. 
 
MMP9 expression was induced in explanted head skin. Head skin is known to 
be inhibitory to limb regeneration (Tank, 1983) and dermal cells from head skin 
have  been  shown  to  remain  at  the  site  of  implantation  when  grafted  into  a 
regenerating blastema rather than becoming distributed along the axis of the 
regenerating limb (Satoh et al., 2007). The implication of this is that head skin 
dermal cells differ from limb skin cells in their ability to proliferate and migrate, 
however their ability to initiate dermal MMP9 expression in response to surgical 
removal indicates that this does not underlie their inability to contribute to the 
regenerating limb. Instead, they may have the capacity to migrate out from the 
dermis due to the expression of MMP9 but then fail to proliferate as they lack 
the required positional co-ordinates to do so. 
 
Induction of Wnt expression is known to result from injury to the skin (Fathke et 
al., 2006). The possibility that Wnt signalling may contribute to the initiation of 
MMP9 expression in the dermis was therefore explored using the Wnt pathway 
inhibitor DKK1 (Glinka et al., 1998). DKK1 showed no inhibitory effect on MMP9 
expression in the dermis however. This result does not rule out Wnt signalling 
as  an  initiation  signal,  however  the  possible  explanations  for  this  are  too 
numerous to be worthy of discussion.  
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7  Concluding comments  
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Prior to the work described in this thesis, direct molecular level details relating 
to the mechanism by which Prod1 regulates cellular processes had not been 
established. Prod1 has been shown through physical interaction with the EGFR 
to initiate signalling leading to activation of ERK1/2 and the induction of MMP9 
expression. ERK1/2 MAPK is known to modulate the activity of a wide variety of 
targets including transcription factors (Pearson et al., 2001), and due to this it is 
highly  likely  that  in  addition  to  MMP9  expression,  Prod1  participates  in  the 
regulation of other genes and cellular processes. The EGFR is known to feed 
into  numerous  downstream  effector  pathways  in  addition  to  ERK1/2  MAPK 
(Jorissen et al., 2003), which either act independently or via varying degrees of 
crosstalk,  providing  even  greater  potential  for  the  participation  of  Prod1  in 
diverse cellular processes. The cell-culture assay of the downstream effects of 
Prod1  expression  established  during  this  work  lends  itself  to  the  further 
investigation of genes regulated by Prod1. Although the lack of annotated newt 
genomic sequence hinders the application of micro-array technology in such an 
approach,  modern  sequencing  technology  may  prove  useful  in  conducting  a 
global analysis of the regulation of gene expression by Prod1. Prod1 expression 
shows the same downstream effects in axolotl cells as in newt cells, and as 
more extensive genomic resources exist for this species, analysis of this sort 
may be more suited to this system.  
 
As discussed in Chapter 4 there is some indication that the EGFR may not be 
the  only  transmembrane  signal  transducer  through  which  Prod1  acts,  and 
indeed the data can be interpreted in such a way as to suggest that regulation 
of MMP9 expression by EGFR signalling is dependent on some other signal 
originating from an independent Prod1 interacting transmembrane protein. It is 
therefore important to establish whether Prod1 activation of the EGFR is able to 
induce MMP9 expression, or even activate ERK1/2, independently of signalling 
from any other Prod1 interacting transmembrane protein. 
 
The  cooperation  of  integrins  and  the  EGFR  in  mediating  signalling  from  the 
Prod1  homolog  uPAR  has  been  shown  to  require  the  activity  of  Src  kinase 
(Monaghan-Benson and McKeown-Longo, 2006). Src kinase activity is required 
for EGFR activation upon integrin clustering by uPAR as integrins themselves  
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do not posses intrinsic kinase activity, however Prod1 initiated EGFR signalling 
leading to induction of MMP9 expression has been shown in this work not to 
require  Src  activity,  indicating  a  distinction  between  these  two  processes. 
Integrins can act via other kinases however (Giancotti and Ruoslahti, 1999), 
thus the lack of a requirement for Src in Prod1 regulation of MMP9 does not 
rule  out  the  involvement  of  integrins.  Due  to  its  demonstrated  physical 
association  with  Prod1,  β1  integrin  is  a  candidate  for  this  second 
transmembrane signalling partner, however the co-expression of Prod1 with a 
truncated β1 integrin supposed to act in a dominant negative manner did not 
indicate it to play a role in the regulation of MMP9. A similar result was seen 
with  a  dominant  negative  EGFR  construct  however.  As  the  expression  of 
neither construct could be detected in B1H1 cells by Western-blotting, this may 
be  due  to  technical  problems  with  achieving  sufficient  levels  of  protein 
expression  which  may  be  overcome  by  more  effective  over-expression 
techniques. Similarly, experiments with integrin inhibitors were inconclusive as 
to their involvement due to technical problems and warrant further work (data 
not shown).   
 
Uncertainties remain with respect to the involvement of some of the pathways 
investigated  with  kinase  inhibitors.  For  example  the  involvement  of  the 
JAK/STAT pathway remains uncertain due to the complexity of the crosstalk 
between signalling pathways, and the disputed specificity of the inhibitor used. 
It is also not clear how the ERK1/2 and JNK MAPK pathways interact in the 
regulation of MMP9. More information on the phosphorylation states of these 
proteins and their targets should help to further establish the details of Prod1 
regulation of MMP9 expression.  
 
The  EGFR  can  be  phosphorylated  on  a  variety  of  different  sites  depending 
upon  the  circumstances  of  its  activation  and  some  of  these  phosphorylation 
sites are indicative of the downstream pathways that will be activated (Jorissen 
et  al.,  2003).  Detailed  analysis  of  the  sites  phosphorylated  on  the  EGFR 
resulting  from  its  interaction  with  Prod1  should  therefore  prove  valuable  in 
further understanding the signalling pathways it feeds into. In this study, good  
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fortune permitted the use of commercially available anti-phospho ERK1/2 and 
anti-phospho  JNK  antibodies  in  the  analysis  conducted,  however  the  anti-
phospho human EGFR antibodies used did not react detectably with the newt 
EGFR, likely due to imperfect homology of their target epitopes. The use of 
commercially  available  antibodies  is  limited  when  analysing  newt  signal 
transduction therefore, and due to the large number of phosphorylation events 
that warrant investigation it is unreasonable to raise custom antibodies to all of 
these targets. As mass-spectrometry based proteomics becomes established in 
the  newt,  global  analysis  of  protein  phosphorylation  resulting  from  Prod1 
expression should provide further clarification of these questions and potentially 
identify  other  as  yet  unstudied  downstream  signalling  components. 
Alternatively, due to the more extensive genomic resources, axolotl cells may 
be a more suitable system for such analysis. Coupling global approaches such 
as transcriptome sequencing and proteomics with the use of kinase inhibitors 
such as those used in this study should provide even greater power to identify 
dissect  the  mechanism  through  which  signalling  pathways  are  activated, 
transcription factors are phosphorylated, and genes are regulated in response 
to Prod1.  
 
Site-directed  mutagenesis  has  revealed  that  amino-acids  on  the  α-helix  of 
Prod1  are  essential  for  its  MMP9  inducing  activity.  Mutation  of  an  α-helix 
residue with the greatest effect on the induction of MMP9 expression did not 
affect  the  physical  association  with  either the  EGFR or  β1  integrin  however. 
This  raises  the  possibility  that  rather  than  disrupting  the  physical  interaction 
between  Prod1  and  the  EGFR  or  β1  integrin,  mutation  of  α-helix  residues 
instead affect their activation. In order to address whether the α-helix mutation 
does indeed affect the activation of the EGFR upon engagement with Prod1, 
appropriate  antibodies  against  its  many  known  phosphorylation  sites  would 
have to be sought, or alternatively, a mass-spectrometry based approach could 
be  employed  in  order  to  asses  the  phosphorylation  state  of  the  protein. 
Alternatively  there  may  be  a  third  as  yet  unidentified  Prod1  interacting 
transmembrane adaptor. As discussed in Chapter 4, it is plausible that this may  
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be a G-protein coupled receptor, and the involvement of such proteins warrants 
investigation with appropriate inhibitors. 
 
It  had been  shown  previously that  the  level  of  cell-surface  expressed  Prod1 
influences  the  engulfment  of  blastemas  of  different  PD  origin  (Nardi  and 
Stocum, 1983) and that the overexpression of Prod1 in blastema cells causes 
them to become proximally re-located during limb regeneration (Echeverri and 
Tanaka, 2005), and this had been rationalised in terms of a direct function of 
Prod1 in regulating cell adhesivity. The demonstration that Prod1 regulates the 
enzyme  MMP9  raises  the  possibility  that  rather  than  directly  regulating  cell 
adhesivity  through  its  interaction  with  proteins  on  the  surface  of  other  cells, 
Prod1 may regulate the strength of association of cells within a tissue via the 
remodelling of the ECM. In particular, the involvement of MMPs in blastema 
engulfment could be addressed with relative technical simplicity through the use 
of  MMP  inhibitors  such  as  the  one  used to  inhibit  skin  cell migration  in  this 
thesis. 
 
 Experiments  with  explanted  skin  patches  have  shown  that  MMP  family 
enzymes  support  cell  migration  as  has  been  shown  in  other  experimental 
systems. In light of this it is possible to re-interpret blastema engulfment and 
proximal relocation  of blastema  cells  in terms  of  enhanced  cell  migration  by 
cells expressing high levels of Prod1. The difference between the regulation of 
adhesivity and migration is subtle at best, though the term migration in some 
ways implies a more active process than cell adhesivity. It is unclear though, 
given  the  available  experimental  systems,  how  to  distinguish  between  the 
involvement of MMPs in these two processes, if they are indeed distinct from 
one another. 
 
The  regulation  of  MMP9  by  Prod1  has  only  been  directly  demonstrated  in 
cultured  cells,  making  it  important  to  establish  categorically  whether  Prod1 
genuinely directly regulates the level of MMP9 in the blastema. The specific 
disruption  of  the  activity  of  Prod1  or  its  expression  in  either  explanted  skin 
patches or in regenerating blastemas should allow this relationship to be further 
investigated,  however  reliable  genetic  tools  to  address  this  question  are  
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currently unavailable. Should it become possible to knock-down gene activity it 
would  be  interesting  to  see  whether  Prod1 is  required  for  the expression  of 
MMP9  in  skin  cells  migrating  from  explanted  patches  or  in  the  cells  of  the 
blastema. Furthermore, it would be interesting to establish whether dermal cells 
migrating into the blastema or proximally relocating Prod1 overexpressing cells 
express MMP9 and whether its knockdown affects these processes. Progress is 
being  made  with  transgenic  technology  in  axolotls  making  this  system 
potentially  more  powerful  than  newts  when  investigating  questions  through 
genetic approaches. 
 
The  initial  focus  of  interest  in  Prod1  has  been  in  relation  to  its  potential 
involvement  in  the  regulation  of  proximodistal  patterning  during  limb 
regeneration.  The  controversial  suggestion  of  a  direct  role  of  MMP9  in  this 
process  through  the  regulation  of  stump  tissue  de-differentiation  has  been 
discussed  at  length  throughout  this  thesis.  A  difference  between  MMP9 
expression  in  proximal  and  distal  blastemas  was  undetectable,  however  a 
possible  upregulation  by  the  proximalising  molecule  RA  was  suggested.  It 
would  be  interesting  to  establish  whether  RA  does  indeed  regulate  MMP9 
expression, either via or independently of the upregulation of Prod1 expression, 
and whether manipulation of the level of expression of Prod1 and MMP9 affects 
de-differentiation as is seen with RA, and thereby regulates the number of limb 
compartments regenerated. Again, genetic tools to reliably manipulate the level 
of expression of these genes will be required in order to directly address these 
questions.  
 
Similar to Prod1, expression of the homeobox gene Meis has been shown to 
proximally relocate blastema cells. Furthermore, knockdown of Meis abolishes 
the  proximalising  effect  of  RA,  which  upregulates  both  Prod1  and  Meis 
expression in the blastema (Mercader et al., 2005). The relationship between 
Prod1 and Meis is unclear, though it has been assumed that Meis regulates the 
expression  of  Prod1.  Whether  proximal  relocation  of  blastema  cells  by  Meis 
involves MMP9 upregulation, as may be the case for Prod1, and if so, whether 
this is via Prod1 upregulation, should further clarify the role of MMP9 and Prod1 
in mechanism of PD patterning during limb regeneration.  
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An interesting revelation has come from the comparison of Prod1 of the axolotl 
to  that  of  the  newt.  Axolotl  Prod1  is  not  GPI  anchored,  yet  in  all  respects 
investigated it functions comparably to that of the newt, which is dependent on 
its GPI anchor in order to be functional. This finding has implications both for 
the evolution and mechanism of Prod1 and GPI anchored proteins in general, 
as it not only shows that the mechanism of Prod1 activity does not in essence 
require  it  to  be  GPI anchored, but  also  shows  that  orthologs  can diverge  in 
terms  of  this  characteristic  whilst  retaining  the  same activity.  A  controversial 
area  in  the  field of  membrane biology  is  the  existence  of  lipid  rafts  (Munro, 
2003), to which it has been proposed GPI anchored proteins require localisation 
in order to function. The clear demonstration of a difference in GPI anchored 
character between two orthologs with the same function shows that the GPI 
anchor does not necessarily participate directly in the molecular mechanism of 
a  protein,  despite  it  being  anchored  by  such  means  to  the  membrane.  The 
elegance  of  this  demonstration  lies  in  the  fact  that  in  the  case  of  previous 
investigations of the functional role of the GPI anchor based on experimentally 
engineered constructs (Walmsley et al., 2003) (Nicholson and Stanners, 2006) 
(Robinson et al., 1989), the results can arguably be attributed to the artificial 
nature of the resulting expressed proteins, whereas in this case the proteins 
under comparison exist naturally and have come about through evolution. As 
discussed in Chapter 5 the GPI anchor is likely to have been lost by Prod1 of 
the axolotl subsequent to the acquisition of a mutation rendering the GPI anchor 
superfluous, indicating that genetic drift can act to change a protein in a manner 
as seemingly drastic as the loss of direct membrane tethering without affecting 
its function. Clearly, whilst having implications for the role of GPI anchors in 
general, the ability of the axolotl Prod1 to function without a GPI anchor also 
suggests more specifically that the GPI anchor does not play the integral role in 
the  mechanism  of  Prod1  suggested  by  the  lipid  raft  model  in  localising  the 
protein to specific microdomains of the membrane, but rather that in the case of 
newt Prod1, it is required in order to ensure that the protein remains associated 
with  the  cell  in  order  to  be  able  to  form  the  appropriate  protein-protein 
interactions, without itself directly facilitating these interactions. 
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Prod1 and uPAR share structural similarities such as an α-helix at finger three 
of their structure (Garza-Garcia et al., 2009), and both associate physically with 
and  activate  the  EGFR  in  a  ligand  independent  manner.  Prod1  has evolved 
uniquely in salamander species (Garza-Garcia et al., 2009) indicating that it has 
independently  evolved  the  ability  to  interact  with  the  more  ancestral  EGFR. 
Comparison of these proteins may shed some light on the structural basis for 
ligand independent activation of the EGFR, which, in the case of uPAR, has 
implications during carcinogenesis (Inuzuka et al., 2000). Although mutation of 
an α-helical residue at finger three essential for MMP9 inducing activity does 
not appear to disrupt the interaction of Prod1 with the EGFR, the α-helix of 
uPAR may none the less be an interesting focus for the mechanism by which it 
can promote cancer via aberrant signalling. Induction of MMP9 expression by 
uPAR  is  known  to  promote  cell  migration,  which  can  be  linked  to  cancer 
metastasis, and contrary to the case of Prod1, this has been shown to require 
the activity of the oncogene Src (Wei et al., 2007). That Prod1 is able to induce 
MMP9  in  the  absence  of  Src  activity  may  again  have  implications  for  the 
signalling mechanism by which uPAR promotes cancer progression. 
 
In  summary,  the  work  presented  in  this  thesis  represents  a  step  forward  in 
understanding salamander limb regeneration through the first molecular level 
investigation  of  the  mechanism  of  Prod1,  providing  the  first  insight  into  the 
signal-transduction  pathways  through  which  it  operates  and  establishing  an 
assay  system  which  should  prove  useful  for  further  investigations  of  its 
biological  activity.  Results  obtained  may  provide  new  perspectives  on  the 
process  of  proximodistal  patterning  through  the  linking  of  two  previously 
unconnected molecules studied in the field of salamander limb regeneration, 
Prod1  and  MMP9.  Furthermore,  the  work  detailed  here  may  prove  to  be  of 
significance to fields of study outside the sphere of regeneration research, such 
as the cell-biology of GPI anchored proteins in general and to the study of the 
EGFR and uPAR in cancer. 
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9  Appendix- DNA  sequences of constructs 
used 
Newt Prod1-Flag 
Cloned EcoRI/Xba into PCI-Neo, then subcloned into EcoRI/NotI of peGFP-N2 
 
GAATTCCCGCCGCCACCATGATGCTTCTACCACTCTCCTTGTTTCTGGTGGCATG
CCTGCACTCAACTACAGCGTTAGACTACAAGGACGACGATGACAAGCTTAAATGC
TTCACCAGAAACGGAGACGACAGGACTGTGACCACCTGCGCCGAGGAACAGACT
CGATGCCTCTTCGTACAACTGCCATATTCTGAGATACAAGAATGCAAGACGGTGC
AACAGTGTGCTGAGGTGTTAGAGGAAGTCACTGCCATTGGATATCCAGCAAAGTG
CTGCTGCGAGGATCTCTGCAACCGGAGTGAGCAAGATTTTGAGACCACCACCCA
GACCACAACACTAGCATTCTTGGATGGACCACAGTGATCTAGA 
 
Newt Prod1-Flag ΔC-terminal anchor sequence 
Cloned NheI/EcoRI into PCI-Neo, then subcloned into NheI/NotI of peGFP-N2 
 
GCTAGCCCGCCGCCACCATGATGCTTCTACCACTCTCCTTGTTTCTGGTGGCATG
CCTGCACTCAACTACAGCGTTAGACTACAAGGACgACGATGACAAGCTTAAATGCT
TCACCAGAAACGGAGACGACAGGACTGTGACCACCTGCGCCGAGGAACAGACTC
GATGCCTCTTCGTACAACTGCCATATTCTGAGATACAAGAATGCAAGACGGTGCA
ACAGTGTGCTGAGGTGTTAGAGGAAGTCACTGCCATTGGATATCCAGCAAAGTGC
TGCTGCGAGGATCTCTGCAACCGGAGTGAGCAATGAGAATTC 
 
Newt Prod1-Flag ΔN-terminal secretory sequence 
Cloned NheI/EcoRI into PCI-Neo, then subcloned into NheI/NotI of peGFP-N2 
 
GCTAGCCCGCCGCCACCATGGACTACAAGGACGACGATGACAAGCTTAAATGCTT
CACCAGAAACGGAGACGACAGGACTGTGACCACCTGCGCCGAGGAACAGACTCG
ATGCCTCTTCGTACAACTGCCATATTCTGAGATACAAGAATGCAAGACGGTGCAAC
AGTGTGCTGAGGTGTTAGAGGAAGTCACTGCCATTGGATATCCAGCAAAGTGCTG
CTGCGAGGATCTCTGCAACCGGAGTGAGCAAGATTTTGAGACCACCACCCAGAC
CACAACACTAGCATTCTTGGATGGACCACAGTGACACGAATTC 
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Newt Prod1-Flag LFA anchor 
GFP sequence of GPI GFP replaced by Prod1 Flag (N and C terminal signal 
sequences of Prod removed) 
 
ATGGAGCTCTTTTGGAGTATAGTCTTTACTGTCCTCCTGAGTTTCTCCTGCCGGGG
GTCAGACTGGGAATCTCTGCAGTCGACGGTACCGCGGGCCCGGGATCCAGACTA
CAAGGACGACGATGACAAGCTTAAATGCTTCACCAGAAACGGAGACGACAGGACT
GTGACCACCTGCGCCGAGGAACAGACTCGATGCCTCTTCGTACAACTGCCATATT
CTGAGATACAAGAATGCAAGACGGTGCAACAGTGTGCTGAGGTGTTAGAGGAAGT
CACTGCCATTGGATATCCAGCAAAGTGCTGCTGCGAGGATCTCTGCAACCGGAGT
GAGGATCCGCGCCCAAGCAGCGGTCATTCTAGACACAGATATGCACTTATACCCA
TACCATTAGCAGTAATTACAACATGTATTGTGCTGTATATGAATGTTCTTTAAT 
 
Axolotl Prod1-Flag  
Cloned  HindIII/XbaI  into  bluescript  SK,  then  subcloned  into  EcoRI/Not  I  of 
peGFP-N2 
 
AAGCTTGATATCGAATTCCCGCCGCCACCATGAAGCTCGTCGGCGCCTCC
CTGTTTCTGGTGGCGTTCCTGTACTCAGCTGAAGCTCTGAAGCTTTACAAG
GACGACGATGACAAGGTATGCTATACCAGGAGCAGGGATAGCGAGAGCA
CTGTGACCACATGCAGTGCAGGCAGGACACACTGCCTCTACATACAGCTA
CCAAATACTCTGATACAGGAATGCCAAACCAAGGAAGGTTGTGAGGCGTT
GCGAGAAGAGGTCATGGCCATTGGCTATCCAGTAAAATGCTGTTCGGAGG
ATCTTTGCAACTACTAAGAATCGAAGGAGGATATCTACTAAAAAGGCAACA
AAATCGTTAGAAGGCAGAAAAGACTAAATCCGCAGATTCCCCAAATGGTCC
TGAGCACCCACTAGTTCTAGA 
 
Axolotl CD59-Flag 
Cloned EcoRI/Xba1 into PCI-Neo, then subcloned into NheI/NotI of pEGF- N2  
 
GAATTCCCGCCGCCACCATGAACCGGATCAGATGGAACGGTGGTCTATTGGCCG
TGGCAGCTGTGGTGCTGATGCTTTGTCAGTCTGGATATGCACTGAAGCTTGACTA
CAAGGACGACGATGACAAGTGCTACAACTGCTCCAATCTAAGTGATAAACCATGTT
TGAGCAATACAACTTGCCCTGCCTCAGAAGATGCCTGTCTACTGGTTGTATCTGGT
TCCCAAAAACTGACAAGCTGTTTCCCATACAACTCGTGCAACACGGAAGGTATTAC 
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AAaGAAATTTGGTGTCAACAGCTTCAGCTACTACTGTTGCCAAAAAGCACTCTGCA
ACAACAGTGTGATGGCCGTTGTCAATAAGACCGTTTTCAGCCTAGTCACAATGTTG
GCCCTCATGTGGATATGTTTCTGAAACGTCTAGA 
 
Newt EGFR-Myc  
Cloned EcoRI/NotI into PTL-1 
 
GAATTCGAGCTCGGTACCCCTAATACGACTCACTATAGGGCAAGCAGTGGTATCA
ACGCAGAGTACGCGGGGTGTCACGACCTGTGCCGGTAAACGTTTATATTGGATGC
TCCTGTGAAGCCCCATTACTCCTGCCCGGGCAGGACAGAAGCATGGGTTTGTACA
GCGTGAGCCCGGAGGAGAGACCGAGGAGCCGGGCTGAGGATTGAGGCTGAGTT
GTGAAGAAGCGGACAGCAGGACAGAAATCAGCTTTGGGAGATTCAAAGAGGGGA
TTTAGGACACAATACGTTCACAAAGTCTGCAATTGGGCGTCAGGAGCAGACACTG
TGGGACAGCGATAATGAACCGCCGGGCTGCGGTGCTGCTGGTGCTGTTTATCAT
CGGACGGAGCACCTTAGCCGATGAAGAGCAGAAAGTGTGCCACGGTTCAAACAA
TAAACTCAGCTTGATTGGCGATGAGAGTTCCCATTACACCAGCATGCAAAATATAT
ATAGCAACTGTGAAATCGTGCATGGGAGTTTGGAGATCACCTTTGTGCCACACAA
CAACAATACATCGTTCGTGAAGAACATAAAGGAGGTTGGAGGCTATGTCCTTATTG
CAATGAATGACGTGAAACAAATAACGCTAGAAAATCTACAGCTAATTCGAGGAAAC
TCACTTTATATTGACAAGTACGCTTTGGTAATTATAATGAATTTTCATGCAGCGATG
GATTCGGTTGGTCTGGAACAAGTATTAATGAATAATTTATTAGAAATTCTTAACGGC
GGCGTGAGAATAGAAAAGAACCCATTTCTCTGTAATATGGATGCAATCAAATGGGA
GGACATTGTGAATACAAACGATCCAAAAAATGAAATTCTAGTTGATAAAAGAACTC
CAAAGAACTGTCCAAAATGTGATTCAAGTTGCTATCACGGATCTTGCTGGGGACC
GGGTCCTGAAAATTGTCAACGTTTTACCAAGTTGATCTGTGCCCAGCAGTGTTCC
GGGCGCTGCAGAGGAAGGATGCCAGATGACTGCTGCCACAGCCACTGCGCATCT
GGCTGCACAGGACCTCGAGAAAGCGACTGCTTGACCTGTCGCCGGTTTCGTGAT
GGTAATACATGTAAGGAGAACTGTCCACCGTTGCTGTTGTATAACCCTAATACATA
TCAAATGGATGTAAACCCAGATGGAAAATATAGTTTCGGAGCCACTTGTTTAACAA
AATGTCCACACAATTATGTTGTAACGGATCATGGCTCCTGTGTTCGCACTTGTGAT
GATAAATCCTATGAAGTAGAAGAAAATGGTGTAAGAAAATGCAAAAAATGTGATGG
ACCGTGCAACAAAGTTTGCAGTGGACTACCTACTAATGAGCGTGTCCGTGCTGTA
AATCATTTCAATATTGAGAGATTTGCAAACTGCACCACGATCCAGGGAGATATTAT
AATCCTTCCTGTTACACTAGCTGGTGATGGCTTTGAAAAAATTCCGCCTTTGGACC
ACACTAAACTCGACTATTTTAAAAATGTAAAAGAAATAACAGGGTTTTTGGCAATTC
AGGCCTGGCCTGAAAATGCAACTCATCTCCATGCTTTTGAAAACCTGGAAGTTATC
CGCGGGAGATCAAAGACTTCTGGTCGTTTCTCTCTTGCTGTGATCCAAACAAGCA 
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TATCATCCCTTGGGTTCCGGTCCCTCCGTGAAATAAGTGATGGAGATGTGCTCCT
GAGAAGGAATGCTCAGCTCTGTTATACAGATATAATAAATTGGACAAGTGTCTTCA
GAACAAAGAATCAAAATATTACATCTGCTCTTAATAAACCTAAAGAGAGTTGTTTGG
CAGAAAACAAAATATGTGACCTCTTATGTTCTGACAATGGCTGCTGGGGCCCAGG
ACCTTTCAGCTGCCTGTCCTGCCGCTATTTCCTTCGAATGACAGAATGTGTGGAAA
CCTGCAACATTATGAAAGGGGAGCCAAGAGAGTATGTTAAAGACTCGAAGTGTTT
TCGATGCCATCCTGAATGCCTAATTCAGAACACAACTACGACTTGCACTGGACCG
GGCCCAGATAATTGTTTGGCCTGTGCCCACTTTAAGGATGGTCCTCATTGCGTAA
AATCCTGCCCAAGTGGAATAATGGGAGAGAATGACACATACATCTGGAAATACGC
AGATGAAAACAAAGTTTGCCAGCTGTGTCATGTTAATTGCACCGAAGGGTGCTTTG
GACCAGATTTGGAAGGCTGTCCGGATTCAGGATCAAGAATCCCATCCATTGCTGC
TGGAGTGTTTGGAGGCATCCTGTGTGTGGTCATTATAAGCTTATGTGTTGGATTTT
TCGTTCGCCGAATCCGTATACAGAGGAAACGCACTTCGCGGAGGTTACTCAATGA
AAAAACGTTAGTTGTGCCTTTAACTCCCAGCGGTGAAGCACCAAATCAAGCACTTC
TGAGAATCCTAAAAGAAACGGAAATAAAAAAAATCATGGTTCTTGGTTCAGGAGCT
TTTGGCACTGTATTTAAGGGATTGTGGCTTCCAGAAGGGGAACATGTAAAAATCCC
TGTAGCCATTAAGGAATTGAGAGAGGCTACATCCCCTAAAGCCAACAAGGAAATT
CTGGATGAGGCATATGTGATGGCCAGTGTGAACGATGCCCACGTCTGTCGTTTGC
TGGGTATCTGCCTTACCTCCACCGTCCAGCTGGTCACCCAACTCATGCCCTATGG
TTGTCTTCTTGACTACGTACGCGAGCACAAGGATAACATTGGCTCAAACCTTCTCC
TGAACTGGTGTGTTCAGATTGCAAAGGGAATGAATTACTTGGAAGAACGTCGACT
GGTACATCGTGACCTTGCAGCTAGAAATGTGCTTGTCCGAAATCCACAGCATGTC
AAGATCACAGATTTTGGACTTGCCAAACTGCTGGGTGCTGAGGAGAAAGAATACC
ATGCAGAGGGTGGCAAGGTGCCCATTAAATGGATGGCTTTAGAATCTATTCTTCAT
CGGATTTATACACACCAAAGTGATGTCTGGAGTTATGGTGTAACAGTTTGGGAGTT
GATGACTTTTGGCTCAAAACCTTATGATGCAATTCCTGCAGGTGAAATTCCAAATC
TTTTGGAACAAGGGGAACGCCTGCCACAGCCCCCCATCTGCACTATTGATGTTTA
TATGATCATGGTCAAATGCTGGATGATTGACGCAGACAGCCGTCCCAAATTCCGT
GAGCTGACTGCCGAATTCACCACAATGGCTCGTGATCCCCAGCGCTATTTGGTCA
TACAGAATGACGAGAGGATGGAGCTACCTAGTCCAGAAGACACCAAGTTTTATCG
CACCTTGATAGAGGAGGGTGAACTAGAGGAAGTAATTGATGCAGACGAGTATCTT
GTACCACACCAGGGCTTTTTCAACAGCCCGGCCACATCCCGCACTCCACTTCTCA
ACTCAGTGAGTACCACCAGTAATACTTCAGACATTGCCTTCATCAACAGAAACGGG
GGACCACCCACGAGAGAAGATAGCTTTGTTCAAAGGTACAGCTCGGATCCGACTG
TAATCCTGCAAGACGAAAACACCGATGATAGATTCCTGCCTGCACCAGAATACGT
GAACCAATTTATTTCCAAAAGGCCAAGTGAATCAAATGTACAGAATCCAGTCTACC
ACAATCTGGGACTTATTCTGTCTCCGACAACTTACCAGTACCAGAACTCCCAAAGC 
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ATGGCCGTGAACAACCCTGAGTACTTAAACACAGTTCATCCTTTCATGACGAATGG
CACTGGCACTGGTGAATTATGGGACCAGCAAGAGAACCACCAGATTAGTCTTGAC
AACCCAGACTACCAACAAGACTTCTTCCCCAAGGAATCTAAGACTAATGGCATTCT
GTTGCTTTCCATAGCAGAAAACCCTGAGTATTTGGAAGCGGGAGCACCCGAACAA
AAACTCATCTCAGAAGAGGATCTGTAGCGGC 
 
Newt β1 integrin-Myc  
Cloned EcoRI/NotI into pTL-1 
 
GAATTCCGCTGCCTGCCAAGATGGCTTACAAGCTGGCCTTCCTGGCAGTACTCTT
TTGTTCTGTTTCGAATGGACTTGCTCAACAAGGTGGCAGTGAGTGTCTAAAAGCG
AATGCAAAGTCGTGTGGAGAATGTATACAAGCAGGGCCAAACTGTGGATGGTGCA
CAAATTTGGACTTTTTACAAGAAGGAAAACCAACTTCAGCAAGATGTGATGATATA
GCAACGTTAAAGAGTAAGGGATGTAAAGAATCAGAAATTGAAAATCCCAGAGGTA
GCCAAAGAATGCGTGAAAATAAACCATTGACAAACCGCAGCAAAGACACTGCAGA
AAAACTGAAACCAGAGGACATCACTCAGATCCGCCCTCAAAAGATGGAATTAAAA
CTTCGATCAGGAGAACCACAAACTTTTACTTTAAAATTCAAGAGAGCTGAAGACTA
CCCAATTGATCTGTATTATCTGATGGACTTGTCCTTTTCAATGAAGGATGATTTAGA
GAATGTGAAAAGTCTTGGAACTGCTCTCATGAGTGAAATGAAGAAAATTACCTCCG
ATTTTAGAATTGGTTTCGGTTCTTTTGTGGAGAAAACAGTGATGCCTTACATCAGTA
CGACCCCTGCTAAGCTCCTGAACCCTTGCACTGGTGACCAAAACTGCACTAGCCC
CTTTAGCTACAAAAATGTGCTTAATCTTACGAGCGATGGCAGTCTATTCAATGAGC
TTGTAGGAAAACAGCACATTTCTGGCAATTTGGATTCTCCTGAAGGTGGATTTGAT
GCCATAATGCAGGTTGCTGTTTGTGGTGAACAAATCGGTTGGAGAAATGTTACTC
GTTTATTGGTATTTTCCACTGATGCTGGTTTTCATTTTGCTGGCGATGGTAAACTTG
GTGGAATCGTTTTACCAAATGATGGCAAATGTCACCTGGAAGACAATATGTACACA
ATGAGCCATTATTACGATTATCCTTCCATTGCTCATCTTGTGCAGAAGCTAAGTGA
AAACAATATTCAAACCATATTTGCCATTACAGAGGAATTTCAGCCTGTGTACAAGG
AGTTGAAAAATCTTATTCCAAAATCTGCTGTGGGAACGCTTTCATCAAATTCCAGC
AATGTGATTCATCTGATTATCGACTCTTATAATTCTTTATCTTCAGAGGTCATCTTG
GAAAACAGCAAGCTTCCGGAGGGTGTTACCATAAGCTACAAGTCCTTTTGTAAAAA
TGGTGTGAATGGTACTGGAGAAAACGGAAGAAAGTGTGCCAACATATCAATTGGA
GATTCGGTGCAATTTGAAATTAGTATCACTGCTCATAAGTGCCCAAAGAAAGGACA
AGATGAAACTATTAAAATCAAGCTGCTGGGATTCACTGAGGAAGTGGAGGTTGCA
CTTCAGTTCATTTGTGAATGTGACTGCCAAAATACAGGCATTCCAAATAGTGCAGA
CTGTTTCAATGGGAATGGAACATTTGAATGTGGAGCATGCAGATGCAATGAAGGA
CGTATTGGTAGAATCTGTGAATGCAGAACTGACGAAGTGAATAGTGACAATATGG 
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ATGCTTTCTGTAGAAAAGACAATGCTTCAGAAATTTGCAGTAATAATGGAGAGTGT
ATTTGTGGCCAATGTGTATGCAAAGAACGGGAAAATCCAAACGAAATCTACTCTGG
AAAGTTCTGTGAATGTGACAACTTTAACTGTGATAGATCGAACGGTTTGATTTGTG
GAGGAAATGGAATTTGTGATTGTCGAGTATGTAAGTGCTTCCCTAACTTCACTCGT
AGTGCCTGTGACTGTTCACTGGACACAACTAGTTGTGTTGCAACAAATGGCCAGA
TTTGTAATGGTCGTGGTACCTGTGATTGTGGACGGTGTAAATGCACAGATCCAAAA
TTCCAAGGAGCCACCTGCGAATTGTGTCAGACGTGTCCTGGTGTATGTGCTGAAC
ACAAGGAATGTGTGCAGTGCAAAGCTTTCAACAAAGGAGAAAAGAAAGATGTTTG
TGAACAGGAGTGCAAGCATTTCAACACTACAATTGTAGAAAGTCGGGACAAGTTA
CCACAGCCAGGCCAGGCTGATGCTCTGACGGTCTGTAAAGAGAAAGATGCTGAT
GACTGTTGGTTCTACTTCACATACTCTGTAAATGGAACCAATGAAGTTGTTGTCCA
CGTGGTAGACAAACCAGAGTGTCCCAGTGGTCCTGACATAATTCCCATTGTAGCT
GGTGTAGTTGCTGGAATTGTTCTCATTGGCCTTGCATTGCTGCTGATCTGGAAGCT
ACTAATGATCATTCATGACAGAAGAGAGTTTGCTAAGTTCGAAAAGGAGAAATCGA
ATGCCAAGTGGGACACAGGTGAAAATCCAATTTATAAAAGTGCGGTGACAACAGT
GGTGAATCCTAAATACGAGGGAAAAGAACAAAAACTTATTTCTGAAGAAGATCTGT
AGGGATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGA 
 
GFP anchored with LFA3 GPI anchor (GPI GFP) (Keller et al., 2001) 
 
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGA
GCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGG
GCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGC
TGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCT
TCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCC
CGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAA
GACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGC
TGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGT
ACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCAT
CAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGC
CGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGA
CAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCG
CGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCAT
GGACGAGCTGTACAAGTATGATCCGCGCCCAAGCAGCGGTCATTCTAGACACAG
ATATGCACTTATACCCATACCATTAGCAGTAATTACAACATGTATTGTGCTGTATAT
GAATGTTCTTTAA 
 